
<html lang="en"     class="pb-page"  data-request-id="e449e240-e043-4ae6-aa3d-64f8927ec1b8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b01713"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73" /></meta><meta name="dc.Creator" content="Joel W.  Beatty" /></meta><meta name="dc.Creator" content="Erick A.  Lindsey" /></meta><meta name="dc.Creator" content="Rhiannon  Thomas-Tran" /></meta><meta name="dc.Creator" content="Laurent  Debien" /></meta><meta name="dc.Creator" content="Debashis  Mandal" /></meta><meta name="dc.Creator" content="Jenna L.  Jeffrey" /></meta><meta name="dc.Creator" content="Anh T.  Tran" /></meta><meta name="dc.Creator" content="Jeremy  Fournier" /></meta><meta name="dc.Creator" content="Steven D.  Jacob" /></meta><meta name="dc.Creator" content="Xuelei  Yan" /></meta><meta name="dc.Creator" content="Samuel L.  Drew" /></meta><meta name="dc.Creator" content="Elaine  Ginn" /></meta><meta name="dc.Creator" content="Ada  Chen" /></meta><meta name="dc.Creator" content="Amber T.  Pham" /></meta><meta name="dc.Creator" content="Sharon  Zhao" /></meta><meta name="dc.Creator" content="Lixia  Jin" /></meta><meta name="dc.Creator" content="Stephen W.  Young" /></meta><meta name="dc.Creator" content="Nigel P.  Walker" /></meta><meta name="dc.Creator" content="Manmohan Reddy  Leleti" /></meta><meta name="dc.Creator" content="Susanne  Moschütz" /></meta><meta name="dc.Creator" content="Norbert  Sträter" /></meta><meta name="dc.Creator" content="Jay P.  Powers" /></meta><meta name="dc.Creator" content="Kenneth V.  Lawson" /></meta><meta name="dc.Description" content="CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of ad..." /></meta><meta name="Description" content="CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of ad..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 26, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01713" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01713" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01713" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01713" /></link>
        
    
    

<title>Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01713" /></meta><meta property="og:title" content="Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0015.jpeg" /></meta><meta property="og:description" content="CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of adenosine. Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme’s natural substrate, adenosine 5′-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported to date. These efforts have culminated in the discovery of 4-({5-[4-fluoro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (73, IC50 = 12 nM) and 4-({5-[4-chloro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (74, IC50 = 19 nM). Cocrystallization of 74 with human CD73 demonstrates a competitive binding mode. These compounds show promise for the improvement of drug-like character via the attenuation of the acidity and low membrane permeability inherent to known nucleoside inhibitors of CD73." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01713"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01713">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01713&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01713&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01713&amp;href=/doi/10.1021/acs.jmedchem.9b01713" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3935-3955</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01658" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01784" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Joel W. Beatty</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joel W. Beatty</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joel+W.++Beatty">Joel W. Beatty</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erick A. Lindsey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erick A. Lindsey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erick+A.++Lindsey">Erick A. Lindsey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rhiannon Thomas-Tran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rhiannon Thomas-Tran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rhiannon++Thomas-Tran">Rhiannon Thomas-Tran</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laurent Debien</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurent Debien</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurent++Debien">Laurent Debien</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debashis Mandal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debashis Mandal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debashis++Mandal">Debashis Mandal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenna L. Jeffrey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenna L. Jeffrey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenna+L.++Jeffrey">Jenna L. Jeffrey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anh T. Tran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anh T. Tran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anh+T.++Tran">Anh T. Tran</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremy Fournier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremy Fournier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy++Fournier">Jeremy Fournier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven D. Jacob</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven D. Jacob</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+D.++Jacob">Steven D. Jacob</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuelei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuelei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuelei++Yan">Xuelei Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samuel L. Drew</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel L. Drew</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel+L.++Drew">Samuel L. Drew</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elaine Ginn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elaine Ginn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elaine++Ginn">Elaine Ginn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ada Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ada Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ada++Chen">Ada Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amber T. Pham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amber T. Pham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amber+T.++Pham">Amber T. Pham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sharon Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharon Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharon++Zhao">Sharon Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lixia Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lixia Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lixia++Jin">Lixia Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen W. Young</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen W. Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+W.++Young">Stephen W. Young</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nigel P. Walker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nigel P. Walker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nigel+P.++Walker">Nigel P. Walker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manmohan Reddy Leleti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manmohan Reddy Leleti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manmohan+Reddy++Leleti">Manmohan Reddy Leleti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susanne Moschütz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susanne Moschütz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susanne++Mosch%C3%BCtz">Susanne Moschütz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Norbert Sträter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Norbert Sträter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Norbert++Str%C3%A4ter">Norbert Sträter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jay P. Powers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay P. Powers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay+P.++Powers">Jay P. Powers</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kenneth V. Lawson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth V. Lawson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e08b8c8197938f8ea0819283959382898fce838f8d"><span class="__cf_email__" data-cfemail="0b60676a7c7864654b6a79687e7869626425686466">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+V.++Lawson">Kenneth V. Lawson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5094-6337" title="Orcid link">http://orcid.org/0000-0001-5094-6337</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01713&amp;href=/doi/10.1021%2Facs.jmedchem.9b01713" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3935–3955</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 26, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 October 2019</li><li><span class="item_label"><b>Published</b> online</span>26 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01713" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01713</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3935%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJoel%2BW.%2BBeatty%252C%2BErick%2BA.%2BLindsey%252C%2BRhiannon%2BThomas-Tran%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D8%26contentID%3Dacs.jmedchem.9b01713%26title%3DDiscovery%2Bof%2BPotent%2Band%2BSelective%2BNon-Nucleotide%2BSmall%2BMolecule%2BInhibitors%2Bof%2BCD73%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3955%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01713"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2658</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01713" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;W. Beatty&quot;},{&quot;first_name&quot;:&quot;Erick&quot;,&quot;last_name&quot;:&quot;A. Lindsey&quot;},{&quot;first_name&quot;:&quot;Rhiannon&quot;,&quot;last_name&quot;:&quot;Thomas-Tran&quot;},{&quot;first_name&quot;:&quot;Laurent&quot;,&quot;last_name&quot;:&quot;Debien&quot;},{&quot;first_name&quot;:&quot;Debashis&quot;,&quot;last_name&quot;:&quot;Mandal&quot;},{&quot;first_name&quot;:&quot;Jenna&quot;,&quot;last_name&quot;:&quot;L. Jeffrey&quot;},{&quot;first_name&quot;:&quot;Anh&quot;,&quot;last_name&quot;:&quot;T. Tran&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;Fournier&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;D. Jacob&quot;},{&quot;first_name&quot;:&quot;Xuelei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;L. Drew&quot;},{&quot;first_name&quot;:&quot;Elaine&quot;,&quot;last_name&quot;:&quot;Ginn&quot;},{&quot;first_name&quot;:&quot;Ada&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Amber&quot;,&quot;last_name&quot;:&quot;T. Pham&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Lixia&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;W. Young&quot;},{&quot;first_name&quot;:&quot;Nigel&quot;,&quot;last_name&quot;:&quot;P. Walker&quot;},{&quot;first_name&quot;:&quot;Manmohan&quot;,&quot;last_name&quot;:&quot;Reddy Leleti&quot;},{&quot;first_name&quot;:&quot;Susanne&quot;,&quot;last_name&quot;:&quot;Moschütz&quot;},{&quot;first_name&quot;:&quot;Norbert&quot;,&quot;last_name&quot;:&quot;Sträter&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;P. Powers&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;V. Lawson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3935-3955&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01713&quot;},&quot;abstract&quot;:&quot;CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of adenosine. Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme’s natural substrate, adenosine 5′-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported to date. These efforts have culminated in the discovery of 4-({5-[4-fluoro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (73, IC50 = 12 nM) and 4-({5-[4-chloro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (74, IC50 = 19 nM). Cocrystallization of 74 with human CD73 demonstrates a competitive binding mode. These compounds show pro&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01713&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01713" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01713&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01713" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01713&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01713" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01713&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01713&amp;href=/doi/10.1021/acs.jmedchem.9b01713" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01713" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01713" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01713%26sid%3Dliteratum%253Aachs%26pmid%3D32212732%26genre%3Darticle%26aulast%3DBeatty%26date%3D2020%26atitle%3DDiscovery%2Bof%2BPotent%2Band%2BSelective%2BNon-Nucleotide%2BSmall%2BMolecule%2BInhibitors%2Bof%2BCD73%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D8%26spage%3D3935%26epage%3D3955%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=291465" title="Structure activity relationship">Structure activity relationship</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/jmcmar.2020.63.issue-8/20200423/jmcmar.2020.63.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of adenosine. Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme’s natural substrate, adenosine 5′-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported to date. These efforts have culminated in the discovery of 4-({5-[4-fluoro-1-(2<i>H</i>-indazol-6-yl)-1<i>H</i>-1,2,3-benzotriazol-6-yl]-1<i>H</i>-pyrazol-1-yl}methyl)benzonitrile (<b>73</b>, IC<sub>50</sub> = 12 nM) and 4-({5-[4-chloro-1-(2<i>H</i>-indazol-6-yl)-1<i>H</i>-1,2,3-benzotriazol-6-yl]-1<i>H</i>-pyrazol-1-yl}methyl)benzonitrile (<b>74</b>, IC<sub>50</sub> = 19 nM). Cocrystallization of <b>74</b> with human CD73 demonstrates a competitive binding mode. These compounds show promise for the improvement of drug-like character via the attenuation of the acidity and low membrane permeability inherent to known nucleoside inhibitors of CD73.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">High cellular turnover, immunogenic cell death due to chemotherapy, and a variety of nonlytic mechanisms contribute to a high extracellular concentration of adenosine triphosphate (ATP) in the tumor microenvironment (TME).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> ATP is rapidly converted to adenosine (ADO) through the sequential action of a number of extracellular nucleotidases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> CD73 (ecto-5′-nucleotidase, eN) is an ectonucleotidase responsible for the conversion of adenosine monophosphate (AMP) to adenosine (ADO)<a onclick="showRef(event, 'ref1 ref2 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref4 ref5">(1,2,4,5)</a> and has been found to be overexpressed in an array of tumor types.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Adenosine exerts a strong immunosuppressive response through the agonism of A<sub>2A</sub> and A<sub>2B</sub> adenosine receptors found on T cells, NK cells, and macrophages.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Overexpression of CD73 is consequently implicated in tumor immune-evasion, and inhibition of CD73 presents itself as an attractive node to reverse adenosine mediated immune suppression.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a></div><div class="NLM_p">Because of the therapeutic potential of CD73 blockade, considerable effort is underway to develop both small-molecule and monoclonal antibody (mAb)-based CD73 inhibitors. A hallmark approach in the pursuit of potent small molecule CD73 inhibitors has been the development of metabolically stable nucleotide analogues which do not undergo hydrolysis to adenosine.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> One such example is adenosine 5′-(α,β-methylene)diphosphate (AMPCP, <b>1</b>, <i>K</i><sub>i</sub> = 88.4 nM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which exhibits sub-micromolar potency against human CD73 (hCD73) and was first described in the literature in 1970.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Müller and co-workers have more recently reported the discovery of the structurally related PSB-12379 (<b>2</b>, <i>K</i><sub>i</sub> = 2.2 nM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as well as similar analogues.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Clinical compound AB680 (<b>3</b>, <i>K</i><sub>i</sub> = 5 pM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) also belongs to this class of phosphonate-based CD73 inhibitors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> While these compounds are highly potent and competitive inhibitors of CD73, efforts to develop less acidic, non-nucleotide small molecule CD73 inhibitors have been limited to a small group of structural families<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> including anthraquinones,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> sulfonamides,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and other flavonoids,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> all of which possess moderate potencies and/or potential metabolic liabilities. The discovery of an alternative chemotype for small molecule CD73 inhibition holds great promise to improve drug-like character via attenuation of the acidity and low membrane permeability inherent to known nucleotide inhibitors.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Described herein is the discovery and development of a novel class of potent, selective, and competitive non-nucleotide-based inhibitors of CD73 which forego the incorporation of a phosphonic acid moiety.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Potent nucleotide inhibitors of CD73 and the initial HTS hit A0001999.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We initiated our efforts with a high-throughput screening (HTS) campaign intended to identify a novel scaffold for further optimization. A library of more than 200 000 compounds was screened against overexpressed human CD73 in CHO cells using a malachite green assay for phosphate detection. These efforts resulted in a remarkably low number of validated hits, yielding only nine chemically distinct potential inhibitors exhibiting IC<sub>50</sub> values below a threshold of 30 μM. Compound <b>4</b> (hCD73 IC<sub>50</sub> = 15.6 μM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was selected as a candidate for further optimization.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationships (SAR)</h3><div class="NLM_p">Compound <b>4</b> exhibited poor metabolic and chemical stability <i>in vitro</i>, and the replacement of metabolically sensitive functional groups was consequently a primary goal in lieu of increasing potency against CD73.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Initial structure–activity relationships in the chemical space surrounding <b>4</b> were obtained through systematic replacement of each arene system, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. When potential heterocyclic core replacements were explored, rigorous requirements for heteroatom placement were encountered. Indeed, benzotriazole <b>13</b> was the sole modification that rendered improved potency over the original 1,2,4-triazolopyridine <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Exclusion of either nitrogen at positions 2 or 3 of the core resulted in significant loss of activity (compounds <b>6</b>–<b>11</b>), and inclusion of an H-bond donor at the 3-position was not tolerated (<b>5</b> and <b>8</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 5-6 Fused Core Replacement SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay CHO-CD73 IC<sub>50</sub> values were measured in the presence of 10% DMSO and are reported as an average of at least two measurements.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Estimated due to incomplete inhibition.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Phenol Replacement SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay CHO-CD73 IC<sub>50</sub> values were measured in the presence of 10% DMSO and are reported as an average of at least two measurements.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Furan Replacement SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0011.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay CHO-CD73 IC<sub>50</sub> values were measured in the presence of 10% DMSO and are reported as an average of at least two measurements.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Single measurement.</p></div></div><div></div></div><div class="NLM_p">The SAR encountered while exploring phenol replacement analogues was similarly steep (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Functionalization of various positions on the parent phenol ring with small groups such as fluorine was not tolerated (<b>14</b> and <b>15</b>), and strict requirements were found for heteroatom replacement, again suggesting the presence of a key hydrogen bonding interaction. Of the simple phenolic replacements investigated, only compound <b>23</b> with an unfunctionalized indazole, attached at the 6-position, provided an improved potency profile over <i>m</i>-phenol. Pyridine <b>18</b> and oxindole <b>22</b> were among the few additional analogues that retained minimal activity against CD73.</div><div class="NLM_p">In contrast to the limited number of viable core and phenolic replacement analogues, many five-membered heterocycles were tolerated in place of the furan ring (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). While the majority of compounds displayed moderate decreases in potency, a small number of examples were found to have similar or improved potency when compared to the parent scaffold (<b>25</b>, <b>26</b>, and <b>35</b>). 5-Substituted 1-methylpyrazole <b>26</b> was identified as the most promising of this class of compounds, and tolerance of <i>N</i>-alkylation suggested a potential space for further structural exploration.</div><div class="NLM_p">In further investigation of the benzotriazole core, we were able to improve potency substantially via incorporation of substituents at C4 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Incorporation of small hydrophobic groups such as Cl (<b>41</b>, IC<sub>50</sub> = 1.7 μM) and Me (<b>43</b>, IC<sub>50</sub> = 5.1 μM) provided enhanced potency, with chlorine providing a roughly 12-fold improvement over the unsubstituted core (<b>36</b>, IC<sub>50</sub> = 22.3 μM). Large hydrophobic groups such as benzylamine (<b>37</b>) and pyrrolidine (<b>38</b>) were not tolerated, while incorporation of a polar substituent such as 2-aminoethanol partially rescued this loss in activity (<b>39</b>, IC<sub>50</sub> = 49.0 μM). Further support for the small size requirements encountered at this position was evident through the comparison of vinyl (<b>44</b>, IC<sub>50</sub> = 14.2 μM) and ethyl incorporation (<b>45</b>, IC<sub>50</sub> = 140 μM), where the flat, less three-dimensional group was preferred.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Core C4 Substituent SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay CHO-CD73 IC<sub>50</sub> values were measured in the presence of 10% DMSO and are reported as an average of at least two measurements.</p></div></div><div></div></div><div class="NLM_p">Our initial investigation culminated in the synthesis of <b>46</b> (IC<sub>50</sub> = 9.2 μM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which combined each of the most promising arene replacements. Simultaneous investigation of the <i>N</i>-alkyl pyrrole moiety led to the discovery of multiple promising structural classes. Because of the steep SAR and dramatically decreased potency associated with the majority of phenol and core replacements, further efforts to improve compound potency centered on the <i>N</i>-alkyl pyrazole region. The addition of <i>N</i>-phenyl (<b>47</b>, IC<sub>50</sub> = 9.0 μM) and <i>N</i>-benzyl pyrazole (<b>48</b>, IC<sub>50</sub> = 1.1 μM) led to retained or improved potency, respectively, revealing positions for additional optimization.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>N</i>-Phenyl and <i>N</i>-benzyl pyrazoles identified as promising starting points for further optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Within the phenyl series (e.g., <b>47</b>), <i>ortho</i>-toluyl and <i>para</i>-toluyl substitution patterns (compounds <b>49</b> and <b>50</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) were not tolerated. In contrast, methylation at the meta position resulted in a significant improvement to sub-micromolar potency (<b>51</b>, IC<sub>50</sub> = 306 nM). This structure was rendered slightly more potent through the incorporation of Cl at the C4 position of the benzotriazole core (<b>53</b>, IC<sub>50</sub> = 220 nM), while fluorine incorporation offered no improvement (<b>52</b>, IC<sub>50</sub> = 333 nM). Substituents of size similar to Me, such as CN, CF<sub>3</sub>, OMe, OCF<sub>3</sub>, F, and Cl (<b>54</b>–<b>59</b>), were tolerated to varying degrees, but each displayed potency unimproved in relation to <b>51</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>N</i>-Aryl and <i>N</i>-benzyl pyrazole SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0013.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay CHO-CD73 IC<sub>50</sub> values were measured in the presence of 10% DMSO and are reported as an average of at least two measurements.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Single measurement.</p></div></div><div></div></div><div class="NLM_p">Another promising starting point for further SAR was the <i>N</i>-benzyl pyrazole <b>48</b> (IC<sub>50</sub> = 1.08 μM), which could be rendered more potent through the incorporation of groups at both the C2 and C4 positions of the benzyl arene. Para-substitution of the benzyl ring was most beneficial to improve potency, with chloro (<b>64</b>, IC<sub>50</sub> = 65 nM) and methyl (<b>66</b>, IC<sub>50</sub> = 78 nM) substituents providing large improvements. Incorporation of a cyano group (<b>72</b>, IC<sub>50</sub> = 21 nM) yielded a remarkable 51-fold improvement in potency over the unsubstituted analogue. Larger, more three-dimensional groups were not as well tolerated at the para-position of the benzyl ring (compounds <b>70</b>, <b>71</b>), and CN was found to be optimal for potency. Pyridyl incorporation (<b>67</b>–<b>69</b>, <b>75</b>–<b>78</b>) was found to improve physicochemical properties and metabolic stability <i>in vitro</i> but often resulted in reduced potency. It is worthwhile to note that while a single substituent at the <i>ortho</i>- or <i>para</i>-position generally improved potency in comparison to the unsubstituted benzyl group (e.g., <b>62</b>, IC<sub>50</sub> = 142 nM and <b>64</b>, IC<sub>50</sub> = 65 nM vs <b>48</b>, IC<sub>50</sub> = 1.08 μM), the combination of the two did not generally display a fully additive effect (<b>80</b>, IC<sub>50</sub> = 45 nM), and SAR trends became shallow with increasing arene substitution in this manner.</div><div class="NLM_p last">Given our previous findings that small substituents at C4 of the benzotriazole core resulted in better potency values (<i>vide supra</i>), we were optimistic to investigate C4 substituents on these more potent <i>N</i>-benzyl pyrazole scaffolds. The parent benzyl compound (<b>48</b>) was rendered roughly 8-fold more potent through chlorination at C4 (<b>61</b>, <i>R</i><sup>2</sup> = Cl, IC<sub>50</sub> = 141 nM), and fluorination of the same position gave roughly similar results (<b>60</b>, <i>R</i><sup>2</sup> = F, IC<sub>50</sub> = 210 nM). Unfortunately, this trend was not mimicked on the more potent <i>p</i>-cyanobenzyl series (<b>72</b>–<b>74</b>), where SAR remained relatively flat with respect to the C4 substituent. Similarly, no significant improvement was observed when the less-potent <i>m</i>-toluylpyrazole (<b>51</b>, IC<sub>50</sub> = 306 nM) was either fluorinated (<b>52</b>, <i>R</i><sup>2</sup> = F, IC<sub>50</sub> = 333 nM) or chlorinated (<b>53</b>, <i>R</i><sup>2</sup> = Cl, IC<sub>50</sub> = 220 nM), and the minor effects of halogenation at this position were generally unpredictable across scaffolds.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> X-ray Cocrystallization</h3><div class="NLM_p">Cocrystallization of <b>74</b> with human CD73 (1.94 Å resolution, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE">6XUE</a>) revealed that binding occurs at the active site of the enzyme, with the benzotriazole core sandwiched between F417 and F500 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). The inhibitor is well-defined by the electron density map with no indication of flexibility (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Figure S1A</a>). The active site of CD73 contains a dimetallic catalytic center, where the two Zn atoms are cradled by several polar residues of the <i>N</i>-terminal domain (residues 26–318) of the protein.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> CD73 exists in open and closed conformations, which differ in the orientation of the two domains of the enzyme by a ∼100° domain rotation. The closed enzyme state usually forms only in the presence of substrate analogues such as AMPCP (<b>1</b>). Interestingly, cocrystallization of CD73 with <b>74</b> also resulted in the closed enzyme state. In this conformation of the protein, the narrow channel leading from the catalytic center toward the protein’s surface is lined by a number of polar residues (N245, R354, R395, N390, D506) and is capped by two phenylalanine residues (F417, F500), which serve as an “adenine clamp” when binding the native substrate, AMP. The indazole portion of compound <b>74</b> reaches toward the dimetallic catalytic center and forms a key 2.96 Å hydrogen bond between the indazole N1 and D506. An additional 3.27 Å hydrogen bond is observed between N2 of the benzotriazole core and N<sub>δ2</sub> of N390. N2 of the indazole and N3 of the benzotriazole form hydrogen bonds to well-defined water molecules, which are part of a hydrogen-bonding network. Toward the surface of the protein, the benzyl pyrazole conforms to the solvent-exposed lip of the binding cleft, while N2 of the pyrazole ring has no donor positioned to satisfy its H-bond acceptor function. F500 is aligned edge-to-face with the six-membered arene. A cocrystal structure of CD73 with <b>53</b> (shown in yellow, 2.09 Å resolution, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>) reveals close alignment in the binding of the two analogues <b>74</b> and <b>53</b>, with slight differences in pyrazole orientation conspiring to orient the respective arene substituents (CN or Me) into the same surface groove. In this structure, the electron density also reveals a water molecule positioned for a hydrogen-bonding interaction to N2 of the pyrazole ring.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structures of inhibitors bound to recombinant human CD73. (A) Cocrystal structure of compound <b>73</b> (green, 1.94 Å resolution, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE">6XUE</a>). (B) Overlay of <b>74</b> (green) with the cocrystal structure of compound <b>53</b> (2.09 Å resolution, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>). (C) Published cocrystal structure of AMPCP <b>1</b> (cyan, 2 Å resolution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H2I">4H2I</a>). (D) Overlay of the two cocrystal structures of <b>74</b> (green) and AMPCP <b>1</b> (cyan, superimposed based on the C-terminal domain) shows close alignment of hydrogen bonding motifs. See the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a> for further details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The previously published cocrystal structure of AMPCP (<b>1</b>) with CD73<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> displays several similar binding interactions and serves as an important comparison to the non-nucleotide binding mode (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Superimposition of bound structures <b>1</b> and <b>74</b> reveals a close overlap of the key hydrogen bonding moieties (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). The adenine core of AMPCP is situated between F417 and F500, while the terminal phosphonate group bonds directly to the di-Zn catalytic site. Conversely, in place of this phosphonate binding event, the crystal structures of <b>53</b> and <b>74</b> reveal a phosphate ion bound to both zinc ions. Phosphate ions were not added to the protein stock solution or the crystallization buffer for determination of the cocrystal structure with <b>74</b>. Thus, phosphate was copurified with the enzyme and probably binds with high affinity in the presence of the compounds studied here, as phosphate binding has not been observed for crystal structures of unliganded CD73 in the open state. Binding of the phosphate ion is probably necessary to neutralize the positive charge of R354, R395, and the two Zn<sup>2+</sup> ions in the presence of the neutral, partially hydrophobic inhibitor, which replaces many active site water molecules that shield the positive charges in the unliganded enzyme. For subsequent cocrystal structures such as <b>53</b>, phosphate ions were added during crystallization.</div><div class="NLM_p last">As noted in the introduction, the binding affinity of nucleotide CD73 inhibitors is greatly improved by the introduction of hydrophobic substituents at the N<sup>6</sup> position of the nucleobase and a chloro substituent at the C2-position, such as for compounds <b>2</b>, <b>3a</b>, and <b>3b</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Interestingly, a superimposition of the CD73 cocrystal structures of <b>53</b> and <b>3b</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>) shows that the improved affinity of these more functionalized nucleotides is partially achieved by binding interactions which resemble those of compounds <b>53</b> and <b>74</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Figure S1B</a>). Specifically, the aryl chloride substituents of <b>53</b> and <b>74</b> bind at the entrance of the “C2-pocket” and the hydrophobic substituents interact with the region 184–186 of the N-terminal domain. The latter interaction is formed by the N6-substituents at the adenine ring of <b>3b</b> and by the pyrazole ring of <b>53</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Selectivity Profile</h3><div class="NLM_p">Promisingly, compound <b>74</b> displayed high selectivity for CD73, with no observed potency against CD39 (IC<sub>50</sub> > 20 μM) or related NTPDases 2, 3, and 8 (IC<sub>50</sub> > 20 μM, targets overexpressed in CHO cells); however, further development of this series was hampered by early evidence of time-dependent CYP inhibition (CYP TDI), potent direct CYP inhibition, and poor hepatocyte stability. Guided by our improved understanding of the binding mode of our lead inhibitors, a large number of compounds were synthesized and tested in order to overcome these poor properties, including the incorporation of an array of polar functionalities (e.g., carboxylic acids, amides, and various potential Zn binding motifs) at logical positions on the scaffold. Most of these structural alterations were met with a significant or complete loss of potency; however, replacement of the indazole ring system with a benzimidazolone scaffold resulted in a series of improvements across several metrics (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). For example, replacement of the indazole ring system of <b>73</b> with benzimidazolone resulted in a 3.7-fold loss of potency (<b>83</b>, IC<sub>50</sub> = 113 nM), but simultaneously rendered a dramatic improvement in the <i>in vitro</i> pharmacokinetic profile. Compound <b>73</b> displays a 4.7 min half-life in human hepatocytes, with a Cl<sub>int</sub> of 146 μL/min/10<sup>6</sup> cells. These measures of <i>in vitro</i> metabolic stability were both improved by an order of magnitude through benzimidazolone incorporation (<b>83</b>, hCl<sub>int</sub> = 14.2 μL/min/10<sup>6</sup> cells, <i>T</i><sub>1/2</sub> = 48.7 min). The direct CYP inhibition profile of the indazole series was also problematic, particularly against CYP1A2, CYP2C9, and CYP2C19. Again, the benzimidazolone alleviated a large portion of these issues. Comparing compounds <b>82</b> and <b>86</b>, the CYP inhibition profile improves dramatically, especially against CYP1A2, where the IC<sub>50</sub> changes over 700-fold (<b>81</b>, CYP1A2 IC<sub>50</sub> < 55 nM, <b>86</b> CYP1A2 IC<sub>50</sub> > 40 μM). Accordingly, the inclusion of the benzimidazolone moiety onto the inhibitor scaffold results in a generally favorable trade-off, wherein a minor loss in potency results in improvement across a range of <i>in vitro</i> metrics and is a promising step toward further compound development.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Hepatocyte Stability and CYP Inhibition</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Cellular assay IC<sub>50</sub> values reported as an average of at least two measurements unless otherwise stated. The assay was run in the presence of 2% DMSO. IC<sub>50</sub> values obtained in the presence of 10% DMSO are denoted in parentheses and were generally about 2-fold higher than those obtained in 2% DMSO.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>int</sub> and <i>T</i><sub>1/2</sub> refer to single in vitro human hepatocyte stability measurements.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">CYP inhibition values refer to single experiment IC<sub>50</sub> determinations and are color-coded across the assay window according to potency from red (<0.055 μM) to green (>40 μM).</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">No data obtained in the presence of 10% DMSO.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">No data obtained in the presence of 2% DMSO.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthetic Chemistry</h3><div class="NLM_p">Synthesis of A0001999 and its subsequent phenol and furan replacement analogues commenced with 4-bromo-2-hydrazinylpyridine (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Oxidative cyclization with 3-hydroxybenzaldehyde served to form the brominated 1,2,4-triazolopyridine core <b>89</b>, which could be subsequently cross-coupled with furan-3-boronic acid or a variety of alternative cross-coupling partners. Structural diversity could likewise be achieved in place of the phenolic ring through cyclization of 4-bromo-2-hydrazinylpyridine with triethylorthoformate, followed by chlorination to provide the dihalogenated core <b>90</b>. This material was then cross-coupled with furan-3-boronic acid and could be used to synthesize various phenol replacement analogues. Synthesis of the benzotriazole core commenced with S<sub>N</sub>Ar of <i>m</i>-aminophenol into 4-bromo-2-fluoro-1-nitrobenzene, followed by reduction of the nitro group. The resulting 1,2-diaminoarene was treated with NaNO<sub>2</sub> (or alternatively isoamylnitrite) to form the benzotriazole <b>93</b>, and a final cross-coupling with furan-3-boronic acid afforded compound <b>13</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of A0001999 Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) two steps (i) 3-hydroxybenzaldehyde, EtOH, reflux. (ii) PIDA, CH<sub>2</sub>Cl<sub>2</sub>, 21%, 2 steps. (b) for compounds <b>4</b>, <b>25</b>–<b>27</b>, <b>30</b>–<b>31</b>, <b>33</b>–<b>35</b>, aryl boronate, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF or dioxane, 75–100 °C. (c) for compound <b>28</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2-(tri-<i>n</i>-butyl stannyl)oxazole, toluene, 90 °C. (d) for compound <b>29</b>, (i) trimethylsilylacetylene, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Et<sub>3</sub>N, DMF, 80 °C, 35%. (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, 36%. (iii) NaN<sub>3</sub>, HCHO, AcOH, CuSO<sub>4</sub>, Na Ascorbate, THF. (e) For compound <b>32</b>, CuI, pyrazole, <i>N</i>,<i>N</i>′-dimethylethylenediamine, K<sub>2</sub>CO<sub>3</sub>, DMF (f) two steps (i) triethyl orthoformate, <i>p</i>TsOH, 80 °C, 79%. (ii) NCS, DMF, 50 °C, 60%. (g) furan-3-boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, 75 °C, 61%. (h) for compounds <b>14</b>–<b>24</b>, aryl boronate, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, or dioxane, 75–100 °C. (i) 3-Aminophenol, <i>N,N</i>-diisopropylethylamine, NMP, 100 °C, 60%. (j) AcOH, EtOH, Fe powder, 60 °C. (k) AcOH, 5 N HCl, NaNO<sub>2</sub>, 0 °C, 9%. (l) Furan-3-boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, 75 °C, 71%.</p></p></figure><div class="NLM_p">Subsequent investigations into substitution at the 4-position of the core involved a similar initial series of steps, where the chlorinated analogue <b>41</b> was readily delivered from 5-bromo-1-chloro-3-fluoro-2-nitrobenzene <b>94a</b> in four steps (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Amination of the aryl chloride was realized through palladium-mediated chemistry, and vinyl- and ethyl-substituted analogues <b>44</b> and <b>45</b> were obtained through cross-coupling followed by hydrogenation. Compounds with simple substituents such as H (<b>36</b>) and methyl (<b>43</b>) could be accessed from the corresponding nitroarenes through an identical sequence.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Early C4-Substituted Analogues<sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-aminophenol, <i>N,N</i>-diisopropylethylamine, NMP, 100 °C. (b) SnCl<sub>2</sub>, EtOH, EtOAc, 70 °C. (c) Isoamyl nitrite, acetonitrile. (d) 1-Methylpyrazole-5-boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 68%. (aq.), THF, 75 °C. (e) For compounds <b>37</b>–<b>39</b>, Pd-BrettPhos-G3, BrettPhos, amine, LiHMDS, THF, 70 °C. (f) For compound <b>40</b>, Pd-BrettPhos-G3, BrettPhos, NaOMe, MeOH, THF, 70 °C, 33%. (g) For compound <b>42</b>, Zn(CN)<sub>2</sub>, Pd-BrettPhos-G3, BrettPhos, THF, 70 °C, 58%. (h) For compounds <b>44</b> and <b>45</b>: (i) Vinylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), dioxane, 110 °C, 82%. (ii) For compound <b>45</b>, Pd/C, H<sub>2</sub> (1 atm), MeOH, 68%.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compounds <b>36</b> and <b>43</b> were synthesized in an analogous fashion from 4-bromo-2-fluoro-1-nitro benzene and 5-bromo-1-fluoro-3-methyl-2-nitrobenzene, respectively.</p></p></figure><div class="NLM_p">The synthesis of the majority of <i>N</i>-phenyl and <i>N</i>-benzyl pyrazole analogues was accomplished through a similar S<sub>N</sub>Ar sequence, wherein the benzotriazole core was constructed from the corresponding 2-fluoro-1-nitroarene (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Analogues unsubstituted at the 4-position of the core were constructed from the resulting bromo-benzotriazole <b>96</b>. Subjection of <b>96</b> to Heck-type conditions resulted in an intermediate acetylated core, which was then treated with DMF-DMA at high temperatures to furnish the vinylogous amide <b>97</b>. This intermediate could then be converted to both <i>N</i>-phenyl and <i>N</i>-benzyl analogues (compounds <b>47</b>–<b>51</b>, <b>54</b>–<b>59</b>, <b>62</b>–<b>72</b>, <b>75</b>–<b>80</b>) through condensation with various monosubstituted hydrazines. Syntheses of the corresponding C4-halogenated compounds (<b>52</b>, <b>53</b>, <b>60</b>, <b>61</b>, <b>73</b>, <b>74</b>) were accomplished through analogous sequences (see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a>). <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> depicts a representative synthesis of 4-halogenated analogues (<b>83</b>, <b>86</b>, and <b>87</b>) in the benzimidazolone series, which differs from the indazole synthetic route primarily in protecting group strategy. Syntheses of analogues in the 5-<i>aza</i>-series (<b>84</b> and <b>85</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) begin with the corresponding nitropyridine (see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Vinylogous Amide Synthesis and Pyrazole Formation in the Indazole Series<sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 6-aminoindazole, Et<sub>3</sub>N, DMSO, 65 °C, 75%. (b) SnCl<sub>2</sub>, EtOAc, EtOH, 70 °C; (c) isoamyl nitrite, MeCN, 65 °C, 60%, 2 steps. (d) butyl vinyl ether, Pd(OAc)<sub>2</sub>, dppf, ethylene glycol, Et<sub>3</sub>N; then HCl, 82%. (e) DMF-DMA, 100 °C, 45%. (f) Aryl or benzyl hydrazine hydrochloride, EtOH, 80 °C.</p><p class="last"><span class="fn-label"><sup>b</sup></span>C4-halogenated compounds were derived through a similar sequence. See the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a>.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Vinylogous Amide Synthesis and Pyrazole Formation in the Benzimidazolone Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-aminobenzimidazolone, Et<sub>3</sub>N, DMSO, 90 °C. (b) SnCl<sub>2</sub>, EtOAc, EtOH, 80 °C. (c) isoamyl nitrite, MeCN, 60 °C. (d) SEM-Cl, methyl dicyclohexylamine, THF, 24%, 4 steps (X = Cl). (e) PdCl<sub>2</sub>(dppf), isopropenyl boronic acid pinacol ester, 100 °C, 87% (X = Cl). (f) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, 2,6-lutidine, THF, H<sub>2</sub>O. (g) DMF-DMA, 100 °C, 70%, 2 steps (X = Cl). (h) benzyl hydrazine dihydrochloride, EtOH, 80 °C (i) TFA, H<sub>2</sub>O, then DMEDA, MeOH, 45 °C.</p></p></figure><div class="NLM_p">Compound <b>81</b> was synthesized in six steps from commercially available 6-bromo-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>), beginning with global Boc protection and proceeding through vinylogous amide <b>103</b>. This sequence involved an early stage pyrazole formation and was capped by a final <i>N</i>-1 arylation of the indazole core with THP-protected 6-iodoindazole, which directly furnished <b>81</b>.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0008.jpeg" id="GRAPHIC-d7e1857-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Indazole <b>81</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, MeCN, 60 °C, 99%. (b) Isopropenylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), dioxane, 100 °C, 35%. (c) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 2,6-lutidine, THF, H<sub>2</sub>O. (d) DMF-DMA, 100 °C, 3%, 2 steps. (e) [(2,4-Dichlorophenyl)methyl]-hydrazine hydrochloride, EtOH, 80 °C, 54%. (f) CuI, DMEDA, 6-iodo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole, DMF, 110 °C, 4%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, systematic optimization of an initial HTS hit (A0001999, <b>4</b>, IC<sub>50</sub> = 15.6 μM) has identified a novel series of highly potent non-nucleoside 5′-ectonucleotidase inhibitors that feature a benzotriazole core and inhibit hCD73 with cellular potency as low as 12 nM (<b>73</b>). Further optimization within this series of inhibitors may be guided by a comparison of the cocrystal structures of <b>74</b> and AMPCP <b>1</b>, where several polar interactions (e.g., with N390, D506) and nonpolar interactions (e.g., with F417, F500) are conserved in the binding of both classes of competitive CD73 inhibitors. The binding pocket of CD73 presents a daunting challenge to the development of suitable small-molecule therapeutics, and the SAR encountered during the development of this class of CD73 inhibitors was unforgiving and steep. Furthermore, compounds in this class which exhibit potent inhibitory effects on CD73 simultaneously span a sector of chemical space that is fraught by CYP inhibition and metabolic instability. Substantial progress has been made in this regard through the incorporation of a benzimidazolone ring system into the parent scaffold, which serves to dramatically improve the CYP inhibition profile as well as the metabolic stability of these compounds in human hepatocytes. This chemical series represents the most potent class of non-nucleotide inhibitors of CD73 disclosed to date; the nonphosphonate nature of this chemical class is of particular significance, as the low oral bioavailability and poor membrane permeability associated with some nucleotide phosphonates could impede their clinical development. Because of the therapeutic promise of targeting CD73 for immunooncology, further work in this compound class is merited, and this work represents significant progress toward the discovery of a potent, non-nucleotide inhibitor of CD73.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Chemistry</h3><div class="NLM_p">All reactions were performed using a Teflon-coated magnetic stir bar at the indicated temperature and were conducted under an inert atmosphere when stated. All chemicals were used as received. Reactions were monitored by TLC (silica gel 60 with fluorescence F254, visualized with a short wave/long wave UV lamp) and/or LCMS (Agilent 1100 series LCMS with UV detection at 254 nm using a binary solvent system [0.1% TFA in MeCN/0.1% TFA in H<sub>2</sub>O] using either of the following columns: Agilent Eclipse Plus C18 [3.5 μm, 4.6 mm i.d. × 100 mm], Aeris Widepore C4 [3.6 μm, 2.1 mm i.d. × 50 mm]). Flash chromatography was conducted on silica gel using an automated system (CombiFlash RF+ manufactured by Teledyne ISCO), with detection wavelengths of 254 and 280 nm. Reverse phase preparative HPLC was conducted on an Agilent 1260 Infinity seriese HPLC. Samples were eluted using a binary solvent system (0.1% TFA in MeCN/0.1% TFA in H<sub>2</sub>O) with gradient elution on a Gemini C18 110 Å column (21.2 mm i.d. × 250 mm) with detection at 254 nm. Final compounds obtained through preparative HPLC were concentrated through lyophilization. All reported yields are isolated yields. All assayed compounds were purified to ≥95% purity as determined by LCMS (Agilent 1100 series LCMS with UV detection at 254 nm using a binary solvent system [0.1% TFA in MeCN/0.1% TFA in H<sub>2</sub>O] using either of the following columns: Agilent Eclipse Plus C18 column [3.5 μm, 4.6 mm i.d. × 100 mm], Aeris Widepore C4 column [3.6 μm, 2.1 mm i.d. x 50 mm]). <sup>1</sup>H NMR spectra were recorded on a Varian 400 MHz NMR spectrometer equipped with an Oxford AS400 magnet. Chemical shifts (δ) are reported as parts per million (ppm) relative to residual undeuterated solvent as an internal reference. The abbreviations s, br. s, d, t, q, dd, dt, ddd, and m stand for singlet, broad singlet, doublet, triplet, quartet, doublet of doublets, doublet of triplets, doublet of doublet of doublets, and multiplet, respectively.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Compound Synthesis. 3-(6-(Furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl) (<b>4</b>)</h4><div class="NLM_p">A solution of 3-hydroxybenzaldehyde (1.0 g, 8.2 mmol) and 5-bromo-2-hydrazinylpyridine (1.54 g, 8.2 mmol) in ethanol (40 mL) was heated to 80 °C for 30 min. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure. The mixture was reconstituted in dichloromethane (40 mL), and (diacetoxyiodo)benzene (2.64 g, 8.2 mmol) was added in four equal portions over 15 min. After 1 h, the reaction was diluted with DCM and washed with saturated NaHCO<sub>3</sub>, water and brine. The organics were dried over MgSO<sub>4</sub> and concentrated. Column chromatography (SiO<sub>2</sub>, 0–10% MeOH/DCM) afforded 3-(6-bromo-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol <b>89</b> as an off-white solid (500 mg, 21%). ESI MS [M + H]<sup>+</sup> for C<sub>12</sub>H<sub>8</sub>BrN<sub>3</sub>O calcd 290.0, found 290.0.</div><div class="NLM_p last">To a degassed solution of 3-(6-bromo-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>89</b>, 281 mg, 0.97 mmol), furan-2-boronic acid (163 mg, 1.45 mmol), and Na<sub>2</sub>CO<sub>3</sub> (1.0 M/H<sub>2</sub>O, 3.9 mL, 3.84 mmol in THF (9.7 mmol) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (112 mg, 0.097 mmol). The reaction was sealed and heated to 65 °C for 4 h. After cooling to room temperature, the mixture was diluted with EtOAc and washed with water and brine. The organics were dried over MgSO<sub>4</sub> and concentrated. Column chromatography (SiO<sub>2</sub>, 0–15% MeOH/DCM) afforded 3-(6-(furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl) <b>4</b> as an off-white solid (172 mg, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.85 (s, 1H), 8.56 (d, <i>J</i> = 1.3 Hz, 1H), 8.36 (d, <i>J</i> = 1.2 Hz, 1H), 7.89 (dd, <i>J</i> = 9.5, 1.1 Hz, 1H), 7.78 (t, <i>J</i> = 1.7 Hz, 1H), 7.71 (dd, <i>J</i> = 9.5, 1.5 Hz, 1H), 7.42 (dd, <i>J</i> = 8.6, 7.1 Hz, 1H), 7.38–7.33 (m, 1H), 7.30–7.27 (m, 1H), 7.12–7.06 (m, 1H), 7.01–6.94 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> calcd 278.1, found 278.2.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-(5-(Furan-3-yl)-1<i>H</i>-indazol-3-yl)phenol (<b>5</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 9.39 (s, 1H), 8.54 (d, <i>J</i> = 2.1 Hz, 1H), 8.33 (d, <i>J</i> = 2.2 Hz, 1H), 8.24 (s, 1H), 7.77 (d, <i>J</i> = 7.2 Hz, 1H), 7.26–7.19 (m, 1H), 7.18–7.11 (m, 2H), 7.07 (d, <i>J</i> = 2.5 Hz, 1H), 6.65 (dd, <i>J</i> = 8.0, 2.7 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> calcd 277.1, found 277.2.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3-[6-(Furan-3-yl)-1<i>H</i>-indazol-1-yl]phenol (<b>6</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.85 (s, 1H), 8.34–8.27 (m, 2H), 7.91 (s, 1H), 7.86 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (m, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (t, <i>J</i> = 8.0 Hz, 1H), 7.24 (m, 1H), 7.18 (m, 1H), 7.07 (m, 1H), 6.79 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> calcd 277.1, found 277.1.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 3-(6-(Furan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenol (<b>7</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.49 (s, 1H), 8.20 (s, 1H), 7.77–7.70 (m, 3H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (dd, <i>J</i> = 8.2, 8.2 Hz, 1H), 7.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.06–7.03 (m, 1H), 7.01–6.98 (m, 1H), 6.89 (d, <i>J</i> = 8.2 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>, calcd. 277.1, found 277.1.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3-(5-(Furan-3-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenol (<b>8</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 9.38 (s, 1H), 8.54 (d, <i>J</i> = 2.1 Hz, 1H), 8.33 (s, 1H), 8.24 (s, 1H), 7.77 (dd, <i>J</i> = 5.5, 3.6 Hz, 2H), 7.26–7.19 (m, 1H), 7.17–7.11 (m, 2H), 7.06 (s, 1H), 6.65 (d, <i>J</i> = 8.0 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> calcd 277.1, found 277.2.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3-(6-(Furan-3-yl)imidazo[1,2-<i>b</i>]pyridazin-3-yl)phenol (<b>9</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 8.64 (s, 1H), 8.28–8.13 (m, 2H), 7.90 (d, <i>J</i> = 1.8 Hz, 1H), 7.78 (d, <i>J</i> = 2.1 Hz, 1H), 7.67 (d, <i>J</i> = 9.5 Hz, 1H), 7.55 (d, <i>J</i> = 7.7 Hz, 1H), 7.30 (t, <i>J</i> = 7.9 Hz, 1H), 7.19 (s, 1H), 6.77 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> calcd 278.1, found 278.2.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-(6-(Furan-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)phenol (<b>10</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69 (s, 1H), 8.60 (s, 1H), 8.27 (s, 1H), 7.77 (s, 1H), 7.73–7.64 (m, 2H), 7.57 (dd, <i>J</i> = 9.3, 1.7 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (s, 1H), 6.99 (s, 1H), 6.83 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> calcd 277.1, found 277.1.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-(2-(Furan-3-yl)-9<i>H</i>-purin-9-yl)phenol (<b>11</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 9.23 (d, <i>J</i> = 3.4 Hz, 0H), 8.97 (d, <i>J</i> = 3.3 Hz, 1H), 8.44 (s, 1H), 7.86–7.70 (m, 1H), 7.54 (d, <i>J</i> = 2.2 Hz, 1H), 7.47–7.29 (m, 2H), 7.14–7.03 (m, 1H), 6.92–6.82 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub> calcd 279.1, found 279.2.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-(5-(Furan-3-yl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)phenol (<b>12</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.14 (s, 1H), 9.81 (s, 1H), 8.64 (s, 1H), 7.97–7.85 (m, 1H), 7.79 (t, <i>J</i> = 2.3 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.48 (t, <i>J</i> = 8.2 Hz, 2H), 7.21 (s, 1H), 6.93 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H). ESI MS [M-H]<sup>−</sup> for C<sub>14</sub>H<sub>9</sub>N<sub>5</sub>O<sub>2</sub> calcd 278.1, found 278.1.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(6-(Furan-3-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>13</b>)</h4><div class="NLM_p">A solution of 4-bromo-2-fluoro-1-nitrobenzene (<b>92</b>, 8.0 g, 36.4 mmol), 3-aminophenol (4.76 g, 43.6 mmol), and <i>N,N</i>-diisopropylethylamine (9.5 mL, 54.6 mmol) in NMP (40 mL) was heated to 100 °C. This temperature led to the formation of observable byproducts, so the reaction temperature was lowered to 55 °C, and the reaction was heated overnight. The resulting solution was partitioned between EtOAc and water, and the aqueous layer was extracted ×1 with ethyl acetate. The resulting organic layers were combined, washed with water (x2), brine (×1), dried over sodium sulfate, and concentrated. The crude residue was purified by column chromatography (5–10% EtOAc/hexanes) to yield 3-((5-bromo-2-nitrophenyl)amino)phenol (6.72 g, 60% yield). ESI MS [M-H]<sup>−</sup> for C<sub>12</sub>H<sub>9</sub>BrN<sub>2</sub>O<sub>3</sub>, calcd 307.0, found 307.0.</div><div class="NLM_p">3-((5-Bromo-2-nitrophenyl)amino)phenol (6.72 g, 21.7 mmol) and acetic acid (8.7 mL, 152.2 mmol) were combined in EtOH (220 mL) and heated to 60 °C. Iron powder (3.64 g, 65.1 mmol) was added portion wise, and the reaction was heated to reflux. Upon completion, the reaction was filtered through a bed of Celite, which was subsequently washed with two portions of hot methanol. The solution was concentrated, treated with 20 mL of 2 N HCl, and extracted with EtOAc (×3). The combined organics were washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to a crude residue, which was taken on without further purification.</div><div class="NLM_p">This crude residue was dissolved in a 1:1 solution of AcOH and 5 N HCl (49 mL) and cooled to 0 °C. NaNO<sub>2</sub> (1.53 g, 22.2 mmol) in water (25 mL) was added slowly to the resulting solution, and the mixture was warmed to room temperature and stirred for 3 h. The solution was the neutralized to pH with saturated NaHCO<sub>3</sub> and extracted with EtOAc. The combined organics were concentrated to a crude residue, which was purified by column chromatography (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to yield 3-(6-bromo-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>93</b>, 310 mg, 9% yield) as an orange solid. ESI MS [M + H]<sup>+</sup> for C<sub>12</sub>H<sub>8</sub>BrN<sub>3</sub>O, calcd 290.0, found 290.0.</div><div class="NLM_p last">3-(6-Bromo-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>93</b>, 49 mg, 0.17 mmol), furan-3-boronic acid (20 mg, 0.18 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (19.6 mg, 0.017 mmol) and Na<sub>2</sub>CO<sub>3</sub> (1 M aq., 0.5 mL, 0.5 mmol) were combined in dioxane (1 mL) and heated to 75 °C. Upon completion the reaction was concentrated, and the crude residue was purified by column chromatography (20% EtOAc/hexanes) to yield 3-(6-(furan-3-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>13</b> (35 mg, 71% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.42 (s, 1H), 7.88 (d, <i>J</i> = 9.6 Hz, 1H), 7.82–7.77 (m, 2H), 7.64–7.49 (m, 4H), 7.23 (s, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>, calcd 278.1, found 278.1.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Fluoro-3-(6-(furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>14</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.44–8.31 (m, 2H), 7.98–7.87 (m, 1H), 7.77 (m, 2H), 7.28–7.06 (m, 4H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>11</sub>FN<sub>3</sub>O<sub>2</sub> calcd 296.0, found 296.1</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Fluoro-5-(6-(furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>15</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (q, <i>J</i> = 1.4 Hz, 1H), 8.39 (t, <i>J</i> = 1.2 Hz, 1H), 7.93 (dt, <i>J</i> = 9.5, 1.2 Hz, 1H), 7.81 (q, <i>J</i> = 1.6 Hz, 1H), 7.76 (dt, <i>J</i> = 9.6, 1.5 Hz, 1H), 7.23 (ddt, <i>J</i> = 9.3, 2.3, 1.3 Hz, 1H), 7.15 (ddt, <i>J</i> = 10.0, 1.9, 1.2 Hz, 2H), 6.84–6.76 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>11</sub>FN<sub>3</sub>O<sub>2</sub> calcd 296.0, found 296.1.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 6-(Furan-3-yl)-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>16</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64–8.53 (m, 1H), 8.36 (dt, <i>J</i> = 1.5, 0.7 Hz, 1H), 7.90 (dt, <i>J</i> = 9.5, 0.8 Hz, 1H), 7.79–7.76 (m, 1H), 7.73 (ddd, <i>J</i> = 9.5, 1.6, 0.6 Hz, 1H), 7.58–7.42 (m, 3H), 7.18–7.13 (m, 1H), 7.12 (dq, <i>J</i> = 1.8, 0.8 Hz, 1H), 3.97–3.68 (m, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> calcd 292.1, found 292.1.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 6-(Furan-3-yl)-3-phenyl-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>17</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61–8.53 (m, 1H), 8.40–8.31 (m, 1H), 7.99–7.87 (m, 3H), 7.83–7.69 (m, 2H), 7.67–7.53 (m, 3H), 7.12 (dq, <i>J</i> = 1.9, 0.9 Hz, 1H). ESI MS [M + H]+ for C<sub>16</sub>H<sub>12</sub>N<sub>3</sub>O calcd 262.1, found 262.1</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-(Furan-3-yl)-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.11 (s, 1H), 8.80 (d, <i>J</i> = 4.7 Hz, 1H), 8.29 (s, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (d, <i>J</i> = 9.5 Hz, 1H), 7.78 (d, <i>J</i> = 1.4 Hz, 1H), 7.63–7.50 (m, 2H), 7.47 (d, <i>J</i> = 9.5, 1H), 7.26 (d, <i>J</i> = 1.1 Hz, 1H), 6.64 (s, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>11</sub>N<sub>4</sub>O calcd 263.1, found 263.1</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-[6-(Furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]benzoic acid (<b>19</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.32 (s, 1H), 8.64 (d, <i>J</i> = 1.4 Hz, 1H), 8.49–8.31 (m, 2H), 8.27–8.09 (m, 2H), 8.04–7.88 (m, 1H), 7.87–7.64 (m, 3H), 7.14–7.11 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>O<sub>3</sub> calcd 306.1, found 306.1.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-(Furan-3-yl)-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>20</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 8.61 (s, 1H), 8.36 (s, 1H), 7.92 (d, <i>J</i> = 9.6 Hz, 1H), 7.83–7.72 (m, 3H), 7.69 (d, <i>J</i> = 7.8 Hz, 1H), 7.59 (dd, <i>J</i> = 7.9, 7.9 Hz, 1H), 7.4 (d, <i>J</i> = 7.9 Hz, 1H), 7.08 (s, 1H), 3.30 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>S, calcd. 355.1, found 355.1</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-(Furan-3-yl)-3-(1<i>H</i>-indol-6-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>21</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.41 (s, 1H), 8.63 (s, 1H), 8.35 (s, 1H), 7.96–7.85 (m, 2H), 7.81–7.71 (m, 2H), 7.70 (d, <i>J</i> = 9.5 Hz, 1H), 7.56–7.45 (m, 2H), 7.08 (s, 1H), 6.56 (s, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>12</sub>N<sub>4</sub>O, calcd. 301.1, found 301.1.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-(6-(Furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)indolin-2-one (<b>22</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.57 (s, 1H), 8.57 (s, 1H), 8.36 (s, 1H), 7.89 (d, <i>J</i> = 9.5 Hz, 1H), 7.78 (s, 1H), 7.72 (d, <i>J</i> = 9.5 Hz, 1H), 7.53–7.41 (m, 2H), 7.28 (s, 1H), 7.1 (s, 1H), 3.60 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>12</sub>N<sub>4</sub>O<sub>2</sub>, calcd. 317.1, found 317.2.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-(Furan-3-yl)-3-(1<i>H</i>-indazol-6-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>23</b>)</h4><div class="NLM_p">A solution of 5-bromo-2-hydrazineylidene-1,2-dihydropyridine (<b>88</b>, 10.0 g, 53.2 mmol) and <i>p</i>-toluenesulfonic acid monohydrate (1.0 g, 5.8 mmol) in triethyl orthoformate (100 mL) was heated to 80 °C for 15 h. The reaction mixture was concentrated to an orange solid, which was purified by column chromatography (SiO<sub>2</sub>, 0–5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 6-bromo-1,2,4-triazolo[4,3-<i>a</i>]pyridine (8.27 g, 79% yield). ESI MS [M + H]<sup>+</sup> for C<sub>6</sub>H<sub>4</sub>BrN<sub>3</sub>, calcd. 198.0, found 198.1.</div><div class="NLM_p"><i>N</i>-Chlorosuccinimide (7.94 g, 59.5 mmol) was added to a solution of 6-bromo-1,2,4-triazolo[4,3-<i>a</i>]pyridine (7.81 g, 39.7 mmol) in DMF (80 mL), and the resulting mixture was heated to 50 °C for 2 h. The reaction was diluted with water and extracted with ethyl acetate, and the resulting organic layer was washed with water (×3), brine (×1), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield 6-bromo-3-chloro-[1,2,4]triazolo[4,3-<i>a</i>]pyridine <b>90</b> as a red oil (5.47 g, 60% yield). ESI MS [M + H]<sup>+</sup> for C<sub>6</sub>H<sub>3</sub>BrClN<sub>3</sub>, calcd. 231.9, found 231.9.</div><div class="NLM_p">To a solution of 6-bromo-3-chloro-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>90</b>, 5.47 g, 23.7 mmol) in THF (140 mL) was added furan-3-boronic acid (2.92 g, 26.1 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (2.7 g, 2.57 mmol), and Na<sub>2</sub>CO<sub>3</sub> (1 M aq., 71.0 mL, 71.0 mmol). The resulting mixture was heated overnight at 75 °C. Upon completion, the reaction was filtered through a plug of Celite, concentrated, and purified by column chromatography [10% (6% NH<sub>4</sub>OH in MeOH)/CH<sub>2</sub>Cl<sub>2</sub>] to yield 3-chloro-6-(furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine <b>91</b> (3.17 g, 61% yield) as a white solid. ESI MS [M + H]<sup>+</sup> for C<sub>10</sub>H<sub>6</sub>ClN<sub>3</sub>O, calcd. 220.0, found 220.0.</div><div class="NLM_p last">3-Chloro-6-(furan-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>91</b>, 50.0 mg, 0.23 mmol), indazole-6-boronic acid (74.5 mg, 0.46 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (23.1 mg, 0.02 mmol), and Na<sub>2</sub>CO<sub>3</sub> (1 M aq., 690 μL, 0.69 mmol) were combined in dioxane (1.4 mL) and heated to 100 °C for 20 h. The reaction mixture was filtered through a plug of Celite, concentrated, and purified by column chromatography [0–50% (6% NH<sub>4</sub>OH in MeOH)/CH<sub>2</sub>Cl<sub>2</sub>] to yield 6-(furan-3-yl)-3-(1<i>H</i>-indazol-6-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine <b>23</b> as a pale yellow solid (42.2 mg, 61% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.35 (s, 1H), 8.69 (s, 1H), 8.36 (s, 1H), 8.21 (s, 1H), 8.08 (s, 1H), 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.92 (d, <i>J</i> = 9.6 Hz, 1H), 7.79–7.71 (m, 2H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>11</sub>N<sub>5</sub>O, calcd. 302.1, found 302.1.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-(Furan-3-yl)-3-(5-methyl-1<i>H</i>-indazol-6-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>24</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>23</b> from intermediate <b>91</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.24 (s, 1H), 8.34 (s, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.94 (d, <i>J</i> = 10.3 Hz, 1H), 7.84 (s, 1H), 7.79 (s, 1H), 7.76 (d, <i>J</i> = 9.6, 1H), 7.73 (d, <i>J</i> = 4.2 Hz, 1H), 7.08 (d, <i>J</i> = 2.8 Hz, 1H), 2.22 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>14</sub>N<sub>8</sub>O, calcd 317.1, found 317.3.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3-(6-(2-Methylfuran-3-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>25</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.87 (s, 1H), 8.41–8.30 (m, 1H), 7.95–7.89 (m, 1H), 7.64 (d, <i>J</i> = 2.0 Hz, 1H), 7.57 (dd, <i>J</i> = 9.5, 1.6 Hz, 1H), 7.46–7.35 (m, 2H), 7.33–7.27 (m, 1H), 7.00–6.95 (m, 1H), 6.83 (d, <i>J</i> = 2.1 Hz, 1H), 2.45 (s, 3H). ESI MS [M + H]+ for C<sub>17</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> calcd 292.1, found 292.1.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-[6-(1-Methyl-1<i>H</i>-pyrazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>26</b>)</h4><div class="NLM_p last">A solution of 6-bromo-3-chloro-[1,2,4]triazolo[4,3-<i>a</i>]pyridine (<b>90</b>, 0.15 g, 0.5 mmol, 1.0 equiv), (1-methyl-1<i>H</i>-pyrrol-2-yl)boronic acid (0.098 g, 0.7 mmol, 1.5 equiv), and 2.0 M aqueous Na<sub>2</sub>CO<sub>3</sub> (0.67 mL, 1.4 mmol, 2.6 equiv) in 2.6 mL of 1,4-dioxane (0.2 M) was sparged with N<sub>2</sub> for 10 min. Pd(dppf)Cl<sub>2</sub> (38 mg, 0.05 mmol, 0.1 equiv) was then added, and the reaction was heated to 110 °C under N<sub>2</sub> atmosphere for 2.5 h. Upon completion, the organic phase of the biphasic reaction mixture was separated, filtered through Celite (washed with 3 × 10 mL CH<sub>2</sub>Cl<sub>2</sub>), and concentrated in vacuo. The resulting residue was purified by column chromatography (gradient 0–20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-[6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol <b>26</b> (0.083 g, 68% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.87 (s, 1H), 8.55 (s, 1H), 7.97 (d, <i>J</i> = 9.5 Hz, 1H), 7.60 (d, <i>J</i> = 9.5 Hz, 1H), 7.52 (d, <i>J</i> = 1.9 Hz, 1H), 7.46–7.36 (m, 2H), 7.32 (s, 1H), 6.98 (d, <i>J</i> = 10.3 Hz, 1H), 6.57 (d, <i>J</i> = 1.9 Hz, 1H), 3.89 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O, calcd 291.3, found 291.3.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-[6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared in a  manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.86 (s, 1H), 8.55 (t, <i>J</i> = 1.4 Hz, 1H), 8.36–8.22 (m, 1H), 8.08–7.94 (m, 1H), 7.94–7.84 (m, 1H), 7.73–7.64 (m, 1H), 7.44 (dd, <i>J</i> = 8.7, 7.0 Hz, 1H), 7.38–7.33 (m, 1H), 7.29 (dd, <i>J</i> = 2.5, 1.6 Hz, 1H), 7.02–6.92 (m, 1H), 3.87 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>14</sub>N<sub>5</sub>O calcd 292.1, found 292.1.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-(6-(Oxazol-2-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>28</b>)</h4><div class="NLM_p last">A solution of 3-(6-bromo-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)-phenol (<b>89</b>, 307 mg, 1.05 mmol, 1.0 equiv) and 2-(tri-<i>n</i>-butylstannyl)oxazole (658 mg, 1.84 mmol, 1.75 equiv) in toluene (10.5 mL, 0.08M) was sparged with nitrogen for 10 min, followed by the addition of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.105 mmol, 10 mol %). The solution was heated overnight at 90 °C. The solution was concentrated and purified by reverse phase HPLC to yield 33-(6-(oxazol-2-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol <b>28</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (s, 1H), 8.85 (s, 1H), 8.30 (m, 1H), 7.99 (d, <i>J</i> = 9.6 Hz, 1H), 7.90 (d, <i>J</i> = 9.6 Hz, 1H), 7.49–7.42 (m, 2H), 7.35 (m, 1H), 7.29 (m, 1H), 7.05–6.98 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub> calcd 279.1, found 279.1.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-[6-(1<i>H</i>-1,2,3-Triazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>29</b>)</h4><div class="NLM_p">To a solution of 3-(6-bromo-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)-phenol (<b>89</b>, 200 mg, 0.689 mmol, 1.0 equiv) in a 1:1 solution of DMF/Et<sub>3</sub>N (1.4 mL, 0.5M) was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (48.4 mg, 0.069 mmol, 10 mol %) and CuI (13.1 mg, 0.069 mmol, 10 mol %). The solution was sparged with nitrogen for 5 min before the addition of TMS acetylene (491 μL, 3.45 mmol, 5.0 equiv), and the reaction was heated to 90 °C. Upon completion, the reaction was cooled to room temperature, partitioned between H<sub>2</sub>O and EtOAc, and extracted with EtOAc (×3), dried over sodium sulfate, and concentrated onto Celite. The crude material was purified by flash chromatography (gradient 0–10% [6% NH<sub>4</sub>OH in MeOH] in CH<sub>2</sub>Cl<sub>2</sub>) to yield 3-(6-((trimethylsilyl)ethynyl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (74 mg, 35% yield). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>OSi calcd 308.1, found 308.1.</div><div class="NLM_p">A solution of 3-(6-((trimethylsilyl)ethynyl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (135 mg, 0.438 mmol, 1.0 equiv) and K<sub>2</sub>CO<sub>3</sub> (182 mg, 1.32 mmol, 3.0 equiv) in methanol (2.2 mL, 0.2 M) was stirred at room temperature for 4 h. Upon completion, the reaction was diluted with EtOAc and H<sub>2</sub>O. The organics were collected, and the aqueous phase was extracted ×3 with EtOAc. The combined organics were washed with 1:1 H<sub>2</sub>O/brine, dried over MgSO<sub>4</sub>, and concentrated to provide 3-(6-ethynyl-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (37 mg, 36% yield). ESI MS [M + H]<sup>+</sup> for C<sub>14</sub>H<sub>9</sub>N<sub>3</sub>O calcd 236.1, found 236.1.</div><div class="NLM_p last">A solution of acetic acid (14 μL, 0.235 mmol, 1.5 equiv) and HCOH (37% aq., 1.56 mmol, 10 equiv) in THF (312 μL) was stirred for 15 min at room temperature. Sodium azide (15.3 mg, 0.235 mmol, 1.5 equiv) and 3-(6-ethynyl-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (37 mg, 0.16 mmol, 1.0 equiv) were added, and the reaction was stirred for an additional 10 min before the addition of sodium ascorbate (6.2 mg, 0.031 mmol, 0.2 equiv) and CuSO<sub>4</sub> (10 μL of a 200 mg/mL soln, 0.008 mmol, 5 mol %). The reaction was stirred at room temperature overnight. Upon completion, the reaction was concentrated and purified by HPLC to yield the desired 3-[6-(1<i>H</i>-1,2,3-triazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol <b>29</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H), 8.85 (s, 1H), 8.52 (s, 1H), 8.13–7.70 (m, 2H), 7.48–7.44 (m, 1H), 7.38–728 (m, 2H), 7.14–6.76 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>14</sub>H<sub>11</sub>N<sub>6</sub>O calcd 279.1, found 279.1.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(6-(1<i>H</i>-Pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>30</b>)</h4><div class="NLM_p last">The title compound was prepared in a  manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.09 (s, 1H), 9.84 (s, 1H), 8.58 (s, 1H), 8.36 (s, 1H), 8.04 (s, 1H), 7.87 (d, <i>J</i> = 9.5 Hz, 1H), 7.73 (d, <i>J</i> = 9.6 Hz, 1H), 7.42 (t, <i>J</i> = 7.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.29 (s, 1H), 6.96 (d, <i>J</i> = 8.0 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>11</sub>N<sub>5</sub>O calcd 278.1, found 278.2.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(6-(Isoxazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>31</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.89 (s, 1H), 8.27–7.97 (m, 2H), 7.84 (t, <i>J</i> = 9.9 Hz, 1H), 7.63–7.48 (m, 1H), 7.46–7.37 (m, 1H), 7.34–7.15 (m, 2H), 6.96 (dd, <i>J</i> = 8.1, 3.2 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub> calcd 279.1, found 279.2.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3-[6-(1<i>H</i>-Pyrazol-1-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>32</b>)</h4><div class="NLM_p last">To a solution of 3-(6-bromo-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)-phenol (<b>89</b>, 418 mg, 1.44 mmol, 1.0 equiv) and pyrazole (98 mg, 1.44 mmol, 1.0 equiv) in DMF (1.5 mL, 1 M) was added CuI (14 mg, 0.07 mmol, 5 mol %), DMEDA (16 μL, 0.144 mmol, 10 mol %), and K<sub>2</sub>CO<sub>3</sub> (40 mg, 0.28 mmol, 20 mol %). The reaction was heated to 130 °C overnight. Upon completion, the reaction was diluted with EtOAc and H<sub>2</sub>O. The organics were collected, and the aqueous phase was extracted ×3 with EtOAc. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated onto Celite. The crude material was purified by flash chromatography (gradient 2–10% [6% NH<sub>4</sub>OH in MeOH] in CH<sub>2</sub>Cl<sub>2</sub>) followed by further purification by reverse phase HPLC to yield 3-[6-(1<i>H</i>-pyrazol-1-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol <b>32</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.92 (s, 1H), 8.80 (t, <i>J</i> = 1.5 Hz, 1H), 8.62 (dd, <i>J</i> = 2.6, 0.6 Hz, 1H), 8.02 (s, 1H), 8.01 (s, 1H), 7.79 (d, <i>J</i> = 1.8 Hz, 1H), 7.43 (dd, <i>J</i> = 7.8, 7.8 Hz, 1H), 7.32 (m, 1H), 7.27 (dd, <i>J</i> = 2.4, 1.6 Hz, 1H), 6.97 (ddd, <i>J</i> = 8.1, 2.5, 1.0 Hz, 1H), 6.58 (dd, <i>J</i> = 2.5, 1.8 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>12</sub>N<sub>5</sub>O calcd 278.1, found 278.1.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 3-[6-(1<i>H</i>-Pyrazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>33</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.81 (s, 1H), 7.98 (d, <i>J</i> = 12 Hz, 1H), 7.86 (d, <i>J</i> = 8.0 Hz, 1H), 7.75 (s, 1H), 7.49 (dd, <i>J</i> = 8.0, 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 12.0 Hz, 1H), 7.30 (s, 1H), 7.06 (d, <i>J</i> = 8.0 Hz, 1H), 6.80 (d, <i>J</i> = 2.3 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>12</sub>N<sub>5</sub>O, calcd 278.1, found 278.2</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-[6-(1<i>H</i>-Pyrrol-2-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl]phenol (<b>34</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 1H), 9.89 (s, 1H), 8.66 (s, 1H), 7.84 (dd, <i>J</i> = 9.6, 1.0 Hz, 1H), 7.76 (dd, <i>J</i> = 9.6, 1.6 Hz, 1H), 7.45 (dd, <i>J</i> = 7.8, 7.8 Hz, 1H), 7.35 (d, <i>J</i> = 8.1 Hz, 1H), 7.31–7.29 (m, 1H), 7.00 (d, <i>J</i> = 9.6 Hz, 1H), 6.93 (d, <i>J</i> = 6.8 Hz, 1H), 6.67 (d, <i>J</i> = 7.5 Hz, 1H), 6.16 (d, <i>J</i> = 8.3 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>13</sub>N<sub>4</sub>O, calcd 277.1, found 277.1.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 3-(6-(Isothiazol-5-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)phenol (<b>35</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>26</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.90 (s, 1H), 9.16 (s, 1H), 8.61 (s, 1H), 8.44 (s, 1H), 7.95 (d, <i>J</i> = 9.6 Hz, 1H), 7.77 (dd, <i>J</i> = 9.6, 1.7 Hz, 1H), 7.43 (t, <i>J</i> = 7.8 Hz, 1H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 7.30 (t, <i>J</i> = 2.1 Hz, 1H), 6.98 (dd, <i>J</i> = 7.9, 2.5 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>OS calcd 295.1, found 295.2.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-(6-(1-Methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>36</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>93</b> in a similar manner to compound <b>13</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.10 (s, 1H), 8.29 (d, <i>J</i> = 8.7 Hz, 1H), 7.97 (s, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (d, <i>J</i> = 1.7 Hz, 1H), 7.48 (dd, <i>J</i> = 8.2, 8.2 Hz, 1H), 7.36 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (dd, <i>J</i> = 2.0, 2.0 Hz, 1H), 6.98 (d, <i>J</i> = 10.8 Hz, 1H), 6.58 (d, <i>J</i> = 1.7 Hz, 1H), 3.91 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>14</sub>N<sub>5</sub>O, calcd 292.11, found 292.3.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 3-(4-(Benzylamino)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>37</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>39</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.02 (s, 1H), 7.79 (t, <i>J</i> = 6.3 Hz, 1H), 7.49–7.37 (m, 4H), 7.35–7.23 (m, 3H), 7.20 (dd, <i>J</i> = 4.6, 2.3 Hz, 2H), 6.99–6.81 (m, 2H), 6.31 (d, <i>J</i> = 11.7 Hz, 2H), 4.62 (d, <i>J</i> = 6.2 Hz, 2H), 3.57 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>20</sub>N<sub>6</sub>O calcd 397.2, found 397.3.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-(6-(1-Methyl-1<i>H</i>-pyrazol-5-yl)-4-(pyrrolidin-1-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>38</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to compound <b>39</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 7.48 (s, 1H), 7.47–7.41 (m, 1H), 7.27 (d, <i>J</i> = 10.7 Hz, 1H), 7.22 (d, <i>J</i> = 4.1 Hz, 1H), 6.94 (s, 1H), 6.92 (d, <i>J</i> = 3.4 Hz, 1H), 6.49–6.44 (m, 1H), 6.34 (s, 1H), 3.88 (s, 3H), 3.84 (s, 4H), 2.05 (s, 4H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>14</sub>N<sub>5</sub>O, calcd 362.17, found 362.3.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 3-(4-((2-Hydroxyethyl)amino)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>39</b>)</h4><div class="NLM_p last">A flask charged with 3-(4-chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>41</b>, 50 mg, 0.15 mmol), Pd-BrettPhos-G3 (14 mg, 0.015 mmol), and BrettPhos (8 mg, 0.015 mmol) was evacuated and backfilled with nitrogen three times. Degassed THF (1.5 mL) was added followed by ethanolamine (14 uL, 0.23 mmoL) and LiHMDS (1.0 M/THF, 460 uL, 0.46 mmol). The mixture was heated to 70 °C for 4 h. After cooling to room temperature, the reaction was diluted with EtOAc and washed with 10% citric acid. The organics were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. HPLC purification (C18, MeCN/H<sub>2</sub>O, 0.1% TFA) afforded 3-(4-((2-hydroxyethyl)amino)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>39</b> (24 mg, 45% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.03 (s, 1H), 7.52–7.37 (m, 2H), 7.27 (d, <i>J</i> = 7.8 Hz, 1H), 7.22 (s, 1H), 7.03–6.87 (m, 2H), 6.81 (t, <i>J</i> = 5.8 Hz, 1H), 6.51 (s, 1H), 6.44 (d, <i>J</i> = 1.9 Hz, 1H), 4.83 (t, <i>J</i> = 5.6 Hz, 1H), 3.65 (q, <i>J</i> = 5.8 Hz, 2H), 3.45 (q, <i>J</i> = 6.0 Hz, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub> calcd 351.2, found 351.3.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-(4-Methoxy-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>40</b>)</h4><div class="NLM_p last">A flask charged with 3-(4-chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>41</b>, 50 mg, 0.15 mmol) Pd-BrettPhos-G3 (14 mg, 0.015 mmol, 10 mol %), and BrettPhos (8 mg, 0.015 mmol, 10 mol %) was evacuated and backfilled with nitrogen. Degassed THF (1.5 mL, 0.1 M) was added followed by NaOMe (25 wt % in MeOH, 0.17 mL). The mixture was heated to 70 °C for 1 h. After cooling to room temperature, the reaction was diluted with EtOAc and washed with 10% citric acid. The organic layer was collected, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC (MeCN/H<sub>2</sub>O) to provide 3-(4-methoxy-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>40</b> (16 mg, 33% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 7.51–7.40 (m, 3H), 7.29 (dd, <i>J</i> = 7.8, 2.2 Hz, 1H), 7.26–7.21 (m, 1H), 7.05 (t, <i>J</i> = 1.6 Hz, 1H), 6.94 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 6.55 (d, <i>J</i> = 2.0 Hz, 1H), 4.10 (s, 3H), 3.89 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub> calcd 322.1, found 322.2.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-(4-Chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>41</b>)</h4><div class="NLM_p last">A flask charged with 3-(6-bromo-4-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (333 mg, 1.02 mmol), 1-methyl-1<i>H</i>-pyrazol-5-yl-5-boronic acid (142 mg, 1.13 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (116 mg, 0.10 mmol) was evacuated and backfilled with nitrogen three times. Degassed THF (10 mL) and 1.0 M Na<sub>2</sub>CO<sub>3</sub> (4 mL) were added. The reaction vessel was sealed and heated to 65 °C for 3 h. After cooling to room temperature, the reaction was diluted with EtOAc and washed with 10% citric acid. The organics were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Column chromatography (SiO<sub>2</sub>, 0 to 50% EtOAc/DCM) afforded 3-(4-chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>41</b> (226 mg, 68% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.12 (s, 1H), 7.91 (s, 1H), 7.81 (s, 1H), 7.54–7.42 (m, 2H), 7.32 (d, <i>J</i> = 7.9 Hz, 1H), 7.25 (t, <i>J</i> = 2.4 Hz, 1H), 6.97 (dd, <i>J</i> = 8.1, 2.6 Hz, 1H), 6.70–6.53 (m, 1H), 3.89 (d, <i>J</i> = 2.7 Hz, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>12</sub>ClN<sub>5</sub>O calcd 326.1, found 326.2.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-(3-Hydroxyphenyl)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole-4-carbonitrile (<b>42</b>)</h4><div class="NLM_p last">A screw-top vial charged with 3-(4-chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>41</b>, 50 mg, 0.15 mmol), zinc cyanide (27 mg, 0.23 mmol), Pd-BrettPhos-G3 (14 mg, 0.015 mmol), and BrettPhos (8 mg, 0.015 mmol) was evacuated and backfilled with nitrogen. Degassed THF (1.5 mL) was added, and the reaction was heated to 70 °C for 4 h. After cooling to room temperature, the reaction was diluted with EtOAc and washed with water and brine. The organics were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC (C18, MeCN/H<sub>2</sub>O) to provide 1-(3-hydroxyphenyl)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole-4-carbonitrile <b>42</b> (28 mg, 58% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 7.62–7.42 (m, 2H), 7.35 (dd, <i>J</i> = 7.9, 2.0 Hz, 1H), 7.27 (s, 1H), 7.00 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 6.66 (d, <i>J</i> = 2.0 Hz, 1H), 3.90 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>12</sub>N<sub>6</sub>O calcd 317.1, found 317.2.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-(4-Methyl-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>43</b>)</h4><div class="NLM_p last">The title compound was prepared from 5-bromo-1-fluoro-3-methyl-2-nitrobenzene in a manner similar to compound <b>41</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 7.74 (s, 1H), 7.49 (d, <i>J</i> = 1.9 Hz, 1H), 7.47–7.43 (m, overlap, 2H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.26–7.25 (m, 1H), 6.94 (d, <i>J</i> = 8.1 Hz, 1H), 6.52 (d, <i>J</i> = 1.9 Hz, 1H), 3. 87 (s, 3H), 2.79 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>O, calcd 306.3, found 306.2.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 3-(6-(1-Methyl-1<i>H</i>-pyrazol-5-yl)-4-vinyl-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>44</b>)</h4><div class="NLM_p last">A solution of 3-(4-chloro-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>41</b>, 0.15 g, 0.46 mmol, 1.0 equiv), vinyl boronic acid pinacol ester (0.107 g, 0.7 mmol, 1.5 equiv), and 2.0 M aqueous Na<sub>2</sub>CO<sub>3</sub> (0.67 mL, 1.4 mmol, 2.6 equiv) in 2.3 mL 1,4-dioxane (0.2 M) was sparged with N<sub>2</sub> for 10 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (53 mg, 0.05 mmol, 0.1 equiv) was then added, and the reaction heated to 110 °C under N<sub>2</sub> atmosphere for 18 h. Upon completion, the organic phase of the biphasic reaction mixture was separated, filtered through Celite (washed with 3 × 10 mL CH<sub>2</sub>Cl<sub>2</sub>), and concentrated in vacuo. The resulting residue was purified by column chromatography (gradient, 100% CH<sub>2</sub>Cl<sub>2</sub> to 70% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-4-vinyl-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>44</b> (0.12 g, 82% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 7.84 (d, <i>J</i> = 1.3 Hz, 1H), 7.73 (s, 1H), 7.53 (d, <i>J</i> = 1.9 Hz, 1H), 7.48 (dd, <i>J</i> = 8.0, 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 4.6 Hz, 1H), 7.26 (d, <i>J</i> = 10.9 Hz, 1H), 6.99 (d, <i>J</i> = 7.4 Hz, 1H), 6.89 (d, <i>J</i> = 19.2 Hz, 1H), 6.59 (d, <i>J</i> = 1.9 Hz, 1H), 5.79 (d, <i>J</i> = 11.2 Hz, 1H), 3.91 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O, calcd 318.13, found 318.3.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3-(4-Ethyl-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>45</b>)</h4><div class="NLM_p last">To a solution of 3-(6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-4-vinyl-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol (<b>44</b>, 0.09 g, 0.28 mmol, 1.0 equiv) in 1.4 mL of methanol (0.2 M) was added 10% Pd/C (0.006 g, 0.05 mmol, 0.2 equiv) under N<sub>2</sub> atmosphere. The reaction mixture was then purged with H<sub>2</sub> and a vacuum was applied. This purging cycle of H<sub>2</sub> and a vacuum was repeated three times. Then the reaction mixture was stirred under H<sub>2</sub> atmosphere for 4 h. Upon completion, the reaction mixture was filtered through a pad of Celite, and the resulting filtrate was concentrated in vacuo to give 3-(4-ethyl-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)phenol <b>45</b> (0.61 g, 68% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 1H), 7.51 (dd, <i>J</i> = 1.7, 1.7 Hz, 1H), 7.48–7.46 (m, 1H), 7.44 (ddd, <i>J</i> = 8.3, 8.3, 1.4 Hz, 1H), 7.27 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (d, <i>J</i> = 3.0 Hz, 1H), 6.97–6.90 (m, 1H), 6.55 (dd, <i>J</i> = 1.7, 1.7 Hz, 1H), 3.90 (s, 3H), 3.22 (q, <i>J</i> = 7.6 Hz, 2H), 1.42 (t, <i>J</i> = 7.6 Hz, 3H). ESI MS [M + 2H]<sup>+</sup> for C<sub>18</sub>H<sub>17</sub>N<sub>5</sub>O, calcd 320.1, found 320.3.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>E</i>)-1-(1-(1<i>H</i>-Indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-3-(dimethylamino)prop-2-en-1-one (<b>97</b>)</h4><div class="NLM_p">2-Fluoro-4-bromonitrobenzene (<b>92</b>, 7 g, 32 mmol) was dissolved in 8 mL of DMSO. 6-Aminoindazole (4.7 g, 35 mmol) was then added, followed by 8 mL of triethylamine. The mixture was warmed to 65 °C and allowed to stir overnight. The mixture was then cooled to room temperature, diluted with ethyl acetate, and washed with water. The organic layer was dried using anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The solid was washed with MTBE and the resulting crude (5-bromo-2-nitrophenyl)-1<i>H</i>-indazol-6-ylamine <b>96</b> was taken on without further purification (8.0 g, 75%). ESI MS [M-H]<sup>+</sup> for C<sub>13</sub>H<sub>8</sub>BrN<sub>4</sub>O<sub>2</sub>, calcd 330.98, found 331.0.</div><div class="NLM_p">(5-Bromo-2-nitrophenyl)-1<i>H</i>-indazol-6-ylamine (<b>95</b>, 8.0 g, crude) was dissolved in 100 mL of ethyl acetate and 70 mL of ethanol. The slurry was then warmed to 70 °C and SnCl<sub>2</sub> (16.2 g, 73 mmol) was added in portions. The mixture was then stirred at 70 °C overnight. The mixture was cooled to room temperature, and 200 mL of saturated Na<sub>2</sub>CO<sub>3</sub> was added. The slurry was then filtered over Celite and washed with ethyl acetate; the filtrate was dried using anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude material was purified using column chromatography to yield 4-bromo-2-(1<i>H</i>-indazol-6-ylamino)aniline (7.5 g, 100%) ESI MS [M + H]<sup>+</sup> for C<sub>13</sub>H<sub>12</sub>BrN<sub>4</sub>, calcd 303.0, found 303.2.</div><div class="NLM_p">4-Bromo-2-(1<i>H</i>-indazol-6-ylamino)aniline (5.3 g, 17.5 mmol) was dissolved in 180 mL of acetonitrile, and isoamyl nitrite (3.5 mL, 26.3 mmol) was added dropwise. The mixture was then warmed to 65 °C and stirred for 4 h. The mixture was cooled to room temperature, concentrated, and purified using column chromatography to yield 6-bromo-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazole <b>96</b> (3.31 g, 60%) ESI MS [M + H]<sup>+</sup> for C<sub>13</sub>H<sub>9</sub>BrN<sub>5</sub>, calcd 314.0, found 314.0.</div><div class="NLM_p">6-Bromo-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>96</b>, 5.0 g, 15.9 mmol, 1.0 equiv) and triethylamine (4.4 mL, 31.8 mmol, 2.0 equiv) in 32 mL of ethylene glycol (0.5 M) was sparged with N<sub>2</sub> for 10 min. Pd(OAc)<sub>2</sub> (107 mg, 0.5 mmol, 0.1 equiv), 1,1′-bis(diphenylphosphino)ferrocene (554 mg, 1.0 mmol, 0.2 equiv), and <i>n</i>-butyl vinyl ether (4.1 mL 31.8 mmol, 2.0 equiv) were then added, and the reaction was heated to 140 °C under N<sub>2</sub> atmosphere for 14 h. Additional triethylamine (4.4 mL, 31.8 mmol, 2.0 equiv), Pd(OAc)<sub>2</sub> (107 mg, 0.5 mmol, 0.1 equiv), 1,1′-bis(diphenylphosphino)ferrocene (554 mg, 1.0 mmol, 0.2 equiv), and <i>n</i>-butyl vinyl ether (4.1 mL 31.8 mmol, 2.0 equiv) were added at this time, and the reaction was continued at 140 °C for an additional 6 h. The reaction was then cooled to room temperature, and diluted with 64 mL dioxane, and 1 N aqueous HCl (32 mL) was added. The biphasic mixture was stirred until the reaction was complete by TLC analysis and then diluted with water (200 mL) and EtOAc (200 mL). The organic phase was collected, and the aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The resulting residue was purified by column chromatography (gradient, 100% CH<sub>2</sub>Cl<sub>2</sub> to 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to yield 1-(1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)ethan-1-one (3.6 g, 82% yield). ESI MS [M + H]<sup>+</sup> for C<sub>15</sub>H<sub>11</sub>N<sub>5</sub>O, calcd 278.3, found 278.3.</div><div class="NLM_p last">1-(1-(1<i>H</i>-Indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)ethan-1-one (3.6 g, 12.9 mmol) was taken up in 26 mL of DMF-DMA (0.5 M), and the reaction was heated to 100 °C for 2.5 h. Upon completion, the reaction mixture was cooled to room temperature and concentrated in vacuo. The resulting residue was purified by column chromatography (gradient, 100% CH<sub>2</sub>Cl<sub>2</sub> to 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give (<i>E</i>)-1-(1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-3-(dimethylamino)prop-2-en-1-one <b>97</b> as a pale yellow solid (1.9 g, 45% yield). ESI MS [M + H]<sup>+</sup> for C<sub>18</sub>H<sub>16</sub>N<sub>6</sub>O, calcd 333.4, found 333.3.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> General Procedure A: Hydrazine Condensation with Vinylogous Amide <b>97</b></h4><div class="NLM_p last">A solution of (<i>E</i>)-1-(1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-3-(dimethylamino)prop-2-en-1-one (<b>97</b>, 1 equiv) and benzyl or aryl hydrazine HCl salt (1.2–2.5 equiv) in EtOH (0.18 M) was heated to 80 °C in a sealed vial. Upon complete pyrazole formation as judged by LCMS, the reaction mixture was cooled to room temperature and concentrated in vacuo, and the resulting residue was purified by reversed-phase column chromatography (C18, MeCN/H<sub>2</sub>O/0.1% TFA).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>46</b>)</h4><div class="NLM_p last">The title compound was prepared from compound <b>96</b> via cross-coupling in a manner similar to compound <b>41</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.38 (s, 1H), 8.30 (d, <i>J</i> = 8.6 Hz, 1H), 8.24 (s, 1H), 8.09–8.01 (m, 3H), 7.67 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 7.64 (dd, <i>J</i> = 8.7, 1.8 Hz, 1H), 7.50 (d, <i>J</i> = 2.0 Hz, 1H), 6.55 (d, <i>J</i> = 2.0 Hz, 1H), 3.89 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>17</sub>H<sub>13</sub>N<sub>7</sub> calcd 316.1, found 316.2.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-phenyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>47</b>)</h4><div class="NLM_p last">The title compound was prepared from compound <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 13.41 (s, 1H), 8.27 (s, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 8.00 (d, <i>J</i> = 8.7 Hz 1H), 7.95 (s, 1H), 7.86–7.79 (m, 1H), 7.78–7.70 (m, 1H), 7.50–7.40 (m, 3H), 7.40–7.28 (m, 4H), 6.93–6.85 (m, 1H).ppm. ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>16</sub>N<sub>7</sub> calcd 378.1, found 378.3.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(1-Benzyl-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>48</b>)</h4><div class="NLM_p">6-Bromo-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>96</b>, 16.7 g, 53 mmol) was combined with triethylamine (11.0 mL, 80 mmol, 1.5 equiv) and DMAP (1.3 g, 11 mmol, 0.2 equiv) in dichloromethane (300 mL, 0.18 M). Di-<i>tert</i>-butyl dicarbonate (14.0 g, 64 mmol, 1.2 equiv) was added, and the resulting solution was stirred at room temperature. Upon completion, the reaction was diluted with dichloromethane and washed with 10% aq. Ccitric acid, followed by brine. The resulting organics were dried over magnesium sulfate and concentrated to a crude residue, which was used without further purification.</div><div class="NLM_p last">A flask charged with <i>tert</i>-butyl 6-(6-bromo-1,2,3-benzotriazol-1-yl)-1<i>H</i>-indazole-1-carboxylate (100 mg, 0.25 mmol) and PdCl<sub>2</sub>(dppf) (22 mg, 0.03 mmol) was evacuated and backfilled with N<sub>2</sub> (3×). Degassed dioxane (2 mL), 1.0 M Na<sub>2</sub>CO<sub>3</sub> (1 mL), and 1-benzyl-1<i>H</i>-pyrazole-5-boronic acid pinacol ester (142 mg, 0.5 mmol) was subsequently added. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, the reaction was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by column chromatography which afforded 6-(1-benzyl-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole <b>48</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.38 (s, 1H), 8.30–8.20 (m, 2H), 7.98 (d, <i>J</i> = 8.6 Hz, 1H), 7.93 (d, <i>J</i> = 1.8 Hz, 1H), 7.76–7.69 (m, 1H), 7.64 (dd, <i>J</i> = 1.8, 0.7 Hz, 1H), 7.59–7.53 (m, 1H), 7.45 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 7.11 (q, <i>J</i> = 8.2, 7.3 Hz, 3H), 7.01–6.89 (m, 2H), 6.63 (dd, <i>J</i> = 1.9, 0.7 Hz, 1H), 5.42 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>18</sub>N<sub>7</sub> calcd, 392.2, found 392.2.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(<i>o</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>49</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.25 (s, 1H), 8.14 (d, <i>J</i> = 8.7 Hz, 1H), 7.98 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (d, <i>J</i> = 2.0 Hz, 2H), 7.48 (dd, <i>J</i> = 8.6, 1.6 Hz, 1H), 7.46 (s, 1H), 7.44–7.34 (m, 2H), 7.30 (q, <i>J</i> = 4.9, 4.1 Hz, 2H), 7.06 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 6.96 (d, <i>J</i> = 2.0 Hz, 1H), 1.86 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>14</sub>ClN<sub>7</sub> calcd 392.4, found 392.1.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>50</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.28 (s, 1H), 8.20–8.11 (m, 1H), 8.04–7.96 (m, 2H), 7.81–7.73 (m, 2H), 7.39–7.28 (m, 2H), 7.26–7.16 (m, 4H), 6.88–6.86 (m, 1H), 2.27 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>18</sub>N<sub>7</sub> calcd 392.2, found 392.3.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(<i>m</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>51</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.41 (s, 1H), 8.27 (q, <i>J</i> = 1.2 Hz, 1H), 8.15 (dt, <i>J</i> = 8.6, 0.9 Hz, 1H), 8.04–7.93 (m, 2H), 7.80 (dd, <i>J</i> = 1.9, 1.1 Hz, 1H), 7.73 (q, <i>J</i> = 1.2 Hz, 1H), 7.39–7.24 (m, 5H), 7.02 (d, <i>J</i> = 7.5 Hz, 1H), 6.89 (dd, <i>J</i> = 2.0, 1.1 Hz, 1H), 2.28 (s, 3H). ESI MS [M-H]<sup>−</sup> for C<sub>23</sub>H<sub>17</sub>N<sub>7</sub>, calcd 390.2, found 390.3.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-Fluoro-1-(1<i>H</i>-indazol-6-yl)-6-(1-(<i>m</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>52</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S2</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 8.03–7.91 (m, 2H), 7.80 (dd, <i>J</i> = 1.9, 0.6 Hz, 1H), 7.44 (d, <i>J</i> = 1.3 Hz, 1H), 7.36–7.25 (m, 4H), 7.23 (dd, <i>J</i> = 8.7, 1.8 Hz, 1H), 7.05 (d, <i>J</i> = 7.5 Hz, 1H), 6.95 (dd, <i>J</i> = 1.9, 0.6 Hz, 1H), 2.28 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>16</sub>FN<sub>7</sub>, calcd 410.2, found 410.2</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-Chloro-1-(1<i>H</i>-indazol-6-yl)-6-(1-(<i>m</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>53</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S4</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (t, <i>J</i> = 1.2 Hz, 1H), 7.99 (dt, <i>J</i> = 8.5, 1.1 Hz, 1H), 7.93 (s, 1H), 7.81 (t, <i>J</i> = 1.6 Hz, 1H), 7.54 (d, <i>J</i> = 1.4 Hz, 2H), 7.36–7.25 (m, 3H), 7.21 (dt, <i>J</i> = 8.6, 1.6 Hz, 1H), 7.05 (d, <i>J</i> = 7.1 Hz, 1H), 6.98 (t, <i>J</i> = 1.6 Hz, 1H), 2.29 (s, 3H). ESI MS [M-H]<sup>−</sup> for C<sub>23</sub>H<sub>16</sub>ClN<sub>7</sub>, calcd 424.1, found 424.1.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-(5-(1-(1<i>H</i>-Indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)benzonitrile (<b>54</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.52 (br. s, 1H), 8.23 (s, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.96 (d, <i>J</i> = 8.5 Hz, 1H), 7.93 (s, 1H), 7.80 (m, 1H), 7.74 (m, 1H), 7.72 (s, 1H), 7.63 (d, <i>J</i> = 7.1 Hz, 1H), 7.51–7.39 (m, 3H), 7.24 (m, 1H), 6.64 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>24</sub>N<sub>8</sub>, calcd. 403.1, found 403.2.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>55</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.26 (s, 1H), 8.21 (s, 1H), 8.12 (d, <i>J</i> = 8.6 Hz, 1H), 7.90 (d, <i>J</i> = 8.6 Hz, 1H), 7.81–7.77 (m, 3H), 7.65–7.61 (m, 2H), 7.46 (dd, <i>J</i> = 7.9, 7.9 Hz, 1H), 7.40–7.31 (m, 2H), 7.25 (m, 1H), 6.66 (m, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>14</sub>F<sub>3</sub>N<sub>7</sub>, calcd. 446.1, found 446.1.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(3-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>56</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.53 (s, 1H), 8.19 (s, 1H), 8.13 (d, <i>J</i> = 9.0 Hz, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 1H), 7.78 (m, 1H), 7.52–7.46 (m, 3H), 7.33 (s, 1H), 7.27 (m, 1H), 7.16 (s, 1H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 6.73 (m, 1H), 6.67 (m, 1H), 3.87 (s, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>17</sub>N<sub>7</sub>O calcd 408.1, found 408.2.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>57</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.39 (s, 1H), 8.25 (s, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 7.99 (d, <i>J</i> = 8.5 Hz, 1H), 7.96 (s, 1H), 7.83 (d, <i>J</i> = 14.3 Hz, 2H), 7.54 (t, <i>J</i> = 8.2 Hz, 1H), 7.39 (m, overlap, 3H), 7.33–7.24 (m, 2H), 6.88 (d, <i>J</i> = 2.0 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>14</sub>F<sub>3</sub>N<sub>7</sub>O calcd 462.4, found 462.3.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 6-(1-(3-Fluorophenyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>58</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.25 (s, 1H), 8.15 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 (d, <i>J</i> = 8.6 Hz, 1H), 7.98 (s, 1H), 7.83 (s, 2H), 7.49–7.37 (m, 2H), 7.32–7.23 (m, 3H), 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 1.9 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>14</sub>FN<sub>7</sub> calcd 396.4, found 396.3.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 6-(1-(3-Chlorophenyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>59</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.25 (s, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 8.04–7.94 (m, 2H), 7.86–7.79 (s, 2H), 7.54–7.45 (m, 2H), 7.45–7.35 (m, 2H), 7.30 (dt, <i>J</i> = 8.7, 1.6 Hz, 1H), 7.24–7.15 (m, 1H), 6.88 (t, J = 1.7 Hz, 1H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>14</sub>ClN<sub>7</sub> calcd 412.9, found 412.2.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 6-(1-Benzyl-1<i>H</i>-pyrazol-5-yl)-4-fluoro-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>60</b>)</h4><div class="NLM_p last">The title compound was prepared in a similar manner to compound <b>41</b> through cross-coupling of 1-benzylpyrazole-5-boronic acid pinacol ester with 6-bromo-4-fluoro-1-(1<i>H</i>-indazol-6-yl)-1,2,3-benzotriazole (<b>S1</b>) <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.27 (s, 1H), 8.03–7.95 (m, 1H), 7.93 (s, 1H), 7.64 (t, <i>J</i> = 2.0 Hz, 1H), 7.53 (s, 1H), 7.48 (d, <i>J</i> = 11.2 Hz, 1H), 7.42 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 7.08 (h, <i>J</i> = 4.4, 3.5 Hz, 3H), 6.94 (dd, <i>J</i> = 7.3, 2.3 Hz, 2H), 6.68 (d, <i>J</i> = 2.0 Hz, 1H), 5.44 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>16</sub>FN<sub>7</sub> calcd 410.1, found 410.1.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 6-(1-Benzyl-1<i>H</i>-pyrazol-5-yl)-4-chloro-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>61</b>)</h4><div class="NLM_p last">The title compound was prepared in a similar manner to compound <b>41</b> through cross-coupling of 1-benzylpyrazole-5-boronic acid pinacol ester with 6-bromo-4-chloro-1-(1<i>H</i>-indazol-6-yl)-1,2,3-benzotriazole (<b>S3</b>) <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.27 (s, 1H), 7.99 (d, <i>J</i> = 8.6 Hz, 1H), 7.93 (s, 1H), 7.71–7.60 (m, 3H), 7.42 (d, <i>J</i> = 8.5 Hz, 1H), 7.12–7.04 (m, 3H), 6.95 (d, <i>J</i> = 7.0 Hz, 2H), 6.69 (s, 1H), 5.43 (s, 2H). ESI MS [M-H]<sup>−</sup> for C<sub>23</sub>H<sub>16</sub>ClN<sub>7</sub> calcd 424.1, found 424.3.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 6-(1-(2-Chlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>62</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.39 (s, 1H), 8.34–8.25 (m, 2H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.96–7.88 (m, 1H), 7.81–7.74 (m, 1H), 7.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.57 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.46 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.27–7.15 (m, 3H), 6.79 (d, <i>J</i> = 7.6 Hz, 1H), 6.69 (d, <i>J</i> = 1.9 Hz, 1H), 5.48 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>17</sub>ClN<sub>7</sub> calcd 426.1, found 426.1.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 6-(1-(3-Chlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>63</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.39 (s, 1H), 8.29–8.23 (m, 2H), 7.99 (d, <i>J</i> = 8.5 Hz, 1H), 7.96–7.93 (m, 1H), 7.76–7.72 (m, 1H), 7.66 (d, <i>J</i> = 1.9 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.47 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.20–7.13 (m, 2H), 7.02–6.97 (m, 1H), 6.92–6.85 (m, 1H), 6.64 (d, <i>J</i> = 1.9 Hz, 1H), 5.43 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>17</sub>ClN<sub>7</sub> calcd 426.1, found 426.3.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 6-(1-(4-Chlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>64</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.34–8.23 (m, 2H), 8.05–7.95 (m, 2H), 7.80–7.70 (m, 1H), 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.58 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.48 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.22 (d, <i>J</i> = 9.1 Hz, 2H), 7.01 (d, <i>J</i> = 8.5 Hz, 2H), 6.66 (d, <i>J</i> = 2.0 Hz, 1H), 5.45 (s, 2H) ppm. ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>17</sub>ClN<sub>7</sub> calcd 426.1, found 426.1.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(2-methylbenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>65</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.38 (s, 1H), 8.27 (t, <i>J</i> = 0.8 Hz, 1H), 8.25 (d, <i>J</i> = 0.8 Hz, 1H), 7.96 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (dt, <i>J</i> = 1.8, 0.9 Hz, 1H), 7.70 (dd, <i>J</i> = 1.4, 0.8 Hz, 1H), 7.67 (d, <i>J</i> = 1.9 Hz, 1H), 7.58 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.38 (ddd, <i>J</i> = 8.6, 1.8, 0.9 Hz, 1H), 7.05–6.99 (m, 2H), 6.95 (dd, <i>J</i> = 5.3, 3.7 Hz, 1H), 6.68 (d, <i>J</i> = 1.9 Hz, 1H), 6.55–6.46 (m, 1H), 5.41 (s, 2H), 2.06 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>20</sub>N<sub>7</sub>, calcd 406.1, found 406.3.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(4-methylbenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>66</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.30–8.26 (m, 2H), 8.00 (d, <i>J</i> = 8.5 Hz, 1H), 7.94 (dt, <i>J</i> = 1.8, 0.9 Hz, 1H), 7.71 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 7.65 (d, <i>J</i> = 1.9 Hz, 1H), 7.58 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.46 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 6.88 (q, <i>J</i> = 8.2 Hz, 4H), 6.63 (d, <i>J</i> = 1.9 Hz, 1H), 5.37 (s, 2H), 2.12 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>20</sub>N<sub>7</sub>, calcd 406.1, found 406.3.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(pyridin-2-ylmethyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>67</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.41 (s, 1H), 8.33 (d, <i>J</i> = 4.7 Hz, 1H), 8.31–8.24 (m, 3H), 8.01 (d, <i>J</i> = 9.1 Hz, 2H), 7.76–7.66 (m, 2H), 7.62 (d, <i>J</i> = 1.8 Hz, 1H), 7.54 (d, <i>J</i> = 8.5 Hz, 1H), 7.18–7.21 (m, 1H), 7.14 (d, <i>J</i> = 7.1 Hz, 1H), 6.64 (d, <i>J</i> = 1.8 Hz, 1H), 5.47 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>17</sub>N<sub>8</sub>, calcd 393.1, found 393.3.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(pyridin-3-ylmethyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>68</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.31 (d, <i>J</i> = 4.9 Hz, 1H), 8.25–8.18 (m, 2H), 8.16 (s, 1H), 8.02 (d, <i>J</i> = 8.2 Hz, 1H), 7.90 (s, 1H), 7.74 (s, 1H), 7.71–7.67 (m, 1H), 7.58 (d, <i>J</i> = 8.6 Hz, 1H), 7.49 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 (d, <i>J</i> = 7.8 Hz, 1H), 7.27–7.20 (m, 1H), 6.64–6.59 (m, 1H), 5.51 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>17</sub>N<sub>8</sub>, calcd 393.1, found 393.3.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(pyridin-4-ylmethyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>69</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.30–8.26 (m, 2H), 8.00 (d, <i>J</i> = 8.5 Hz, 1H), 7.94 (dt, <i>J</i> = 1.8, 0.9 Hz, 1H), 7.71 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 7.65 (d, <i>J</i> = 1.9 Hz, 1H), 7.58 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.46 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 6.88 (q, <i>J</i> = 8.2 Hz, 4H), 6.63 (d, <i>J</i> = 1.9 Hz, 1H), 5.37 (s, 2H), 2.12 (s, 3H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>17</sub>N<sub>8</sub>, calcd 393.1, found 393.3.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(4-(methylsulfonyl)benzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>70</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.30 (d, <i>J</i> = 8.7 Hz, 1H), 8.27–8.22 (m, 1H), 8.04–7.96 (m, 2H), 7.84–7.75 (m, 3H), 7.73–7.68 (m, 1H), 7.60 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.50 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.25 (d, <i>J</i> = 7.9 Hz, 2H), 6.72–6.66 (m, 1H), 5.61 (s, 2H), 3.09 (s, 3H) ppm. ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>20</sub>N<sub>7</sub>O<sub>2</sub>S calcd 470.1, found 470.2.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1-(1<i>H</i>-Indazol-6-yl)-6-(1-(4-isopropylbenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>71</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.29 (dd, <i>J</i> = 8.6, 0.8 Hz, 1H), 8.28–8.26 (m, 1H), 8.02–7.97 (m, 2H), 7.75–7.73 (m, 1H), 7.65 (d, <i>J</i> = 1.9 Hz, 1H), 7.62 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 7.48 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 6.98 (d, <i>J</i> = 7.7 Hz, 2H), 6.92 (d, <i>J</i> = 8.2 Hz, 2H), 6.65 (d, <i>J</i> = 1.9 Hz, 1H), 5.41 (s, 2H), 2.70 (p, <i>J</i> = 6.9 Hz, 1H), 1.04 (d, <i>J</i> = 6.9 Hz, 6H) ppm. ESI MS [M + H]<sup>+</sup> for C<sub>26</sub>H<sub>24</sub>N<sub>7</sub> calcd 434.2, found 434.1.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 4-((5-(1-(1<i>H</i>-Indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)benzonitrile (<b>72</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.39 (s, 1H), 8.30–8.20 (m, 2H), 8.02–7.90 (m, 2H), 7.72 (s, 1H), 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 7.9 Hz, 2H), 7.54 (d, <i>J</i> = 8.6 Hz, 1H), 7.46 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 7.12 (d, <i>J</i> = 8.0 Hz, 2H), 6.66 (d, <i>J</i> = 2.0 Hz, 1H), 5.54 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>17</sub>N<sub>8</sub>, calcd 417.2, found 417.2.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 4-((5-(4-Fluoro-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)benzonitrile (<b>73</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S2</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.46 (s, 1H), 8.28 (s, 1H), 8.01 (dd, <i>J</i> = 8.6, 0.7 Hz, 1H), 7.98 (s, 1H), 7.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.65–7.58 (m, 2H), 7.54 (d, <i>J</i> = 1.2 Hz, 1H), 7.51 (dd, <i>J</i> = 11.1, 1.1 Hz, 1H), 7.46 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.19–7.08 (m, 2H), 6.72 (d, <i>J</i> = 1.9 Hz, 1H), 5.58 (s, 2H). ESI MS [M + H]<sup>+</sup> C<sub>24</sub>H<sub>15</sub>FN<sub>8</sub>, calcd 435.1, found 435.2</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 4-((5-(4-Chloro-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)benzonitrile (<b>74</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S4</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.49–13.42 (m, 1H), 8.28 (q, <i>J</i> = 1.2 Hz, 1H), 8.05–7.95 (m, 2H), 7.70 (dt, <i>J</i> = 3.3, 1.7 Hz, 2H), 7.67–7.61 (m, 2H), 7.49–7.42 (m, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 2H), 6.74 (dd, <i>J</i> = 1.9, 1.0 Hz, 1H), 5.76 (d, <i>J</i> = 1.0 Hz, 1H), 5.57 (d, <i>J</i> = 1.7 Hz, 2H). ESI MS [M + H]<sup>+</sup> C<sub>24</sub>H<sub>15</sub>ClN<sub>8</sub>, calcd 451.1, found 451.1.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 6-(1-((3,5-Dichloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>75</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.38 (s, 1H), 8.45 (d, <i>J</i> = 2.1 Hz), 8.31–8.23 (m, 2H), 8.15 (app. s, overlap, 2H), 7.98 (m, 2H), 7.65 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (m, 2H), 6.58 (s, 1H), 5.59 (s, 2H). ESI-MS [M + H]<sup>+</sup> C<sub>22</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>8</sub>, calcd 461.1, found 461.1.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 6-(1-((5-Chloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>76</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.42 (s, 1H), 8.37 (s, 1H), 8.32–8.25 (m, 2H), 8.17 (s, 1H), 8.04–7.97 (m, 2H), 7.87 (dd, <i>J</i> = 8.4, 2.7 Hz, 1H), 7.67 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 7.63 (t, <i>J</i> = 1.7 Hz, 1H), 7.53 (d, <i>J</i> = 8.7 Hz, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 1H), 6.65 (t, <i>J</i> = 1.7 Hz, 1H), 5.49 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>16</sub>ClN<sub>8</sub>, calcd 427.1, found 427.3.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 6-(1-((3-Chloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>77</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.39 (s, 1H), 8.39 (d, <i>J</i> = 4.7 Hz, 1H), 8.26 (m, 3H), 8.03–7.96 (m, 2H), 7.85 (d, <i>J</i> = 8.6 Hz, 1H), 7.69 (d, <i>J</i> = 8.5 Hz, 1H), 7.58–7.50 (m, 2H), 7.29 (dd, <i>J</i> = 8.0, 4.6 Hz, 1H), 6.60 (d, <i>J</i> = 1.8 Hz, 1H), 5.61 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>16</sub>ClN<sub>8</sub>, calcd 427.1, found 427.2.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 6-((5-(1-(1<i>H</i>-Indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)nicotinonitrile (<b>78</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.80 (s, 1H), 8.25 (m, <i>J</i> = 6.0 Hz, 3H), 8.12 (m, <i>J</i> = 4.9 Hz, 1H), 7.99 (s, 2H), 7.63 (m, 2H), 7.53 (m, 1H), 7.31 (m, 1H), 6.65 (m, 1H), 5.59 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>15</sub>N<sub>9</sub> calcd 418.4, found 418.2.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 6-(1-(4-Chloro-2-fluorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>79</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.35–8.18 (m, 2H), 8.09–7.94 (m, 2H), 7.86 (s, 1H), 7.62 (s, 1H), 7.57 (d, <i>J</i> = 8.6 Hz, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 1H), 7.31–7.13 (m, 2H), 6.94 (t, <i>J</i> = 8.2 Hz, 1H), 6.61 (s, 1H), 5.42 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>15</sub>ClFN<sub>7</sub> calcd 444.1, found 444.2.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 6-(1-(2,4-Dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>80</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>97</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 8.33–8.18 (m, 2H), 7.99 (d, <i>J</i> = 8.6 Hz, 1H), 7.95 (s, 1H), 7.75 (s, 1H), 7.67 (s, 1H), 7.55 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 1H), 7.39–7.36 (m, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 6.82 (d, <i>J</i> = 8.3 Hz, 1H), 6.67 (s, 1H), 5.44 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>7</sub> calcd 460.1, found 460.1.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 6-(1-(2,4-Dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine (<b>81</b>)</h4><div class="NLM_p">To a solution of 6-bromo-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine (<b>101</b>, 5.04 g, 23.6 mmol, 1.0 equiv) in CH<sub>3</sub>CN (118 mL) was added Boc<sub>2</sub>O (25.8 g, 118 mmol, 5.0 equiv), followed by DMAP (144 mg, 1.18 mmol, 5 mol %). The resulting mixture was stirred at reflux for 12 h. Upon completion, the reaction mixture was cooled to 25 °C, concentrated under reduced pressure, and purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/EtOAc), which afforded <i>tert</i>-butyl 3-(bis(<i>tert</i>-butoxycarbonyl)amino)-6-bromo-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine-1-carboxylate (12.0 g, 99% yield) as a white solid.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 3-(bis(<i>tert</i>-butoxycarbonyl)amino)-6-bromo-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine-1-carboxylate (12.0 g, 23.4 mmol, 1.0 equiv) in dioxane (116 mL) was added isopropenylboronate (4.39 mL, 23.4 mmol, 1.0 equiv), followed by 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (35 mL, 70.1 mmol, 3.0 equiv). The mixture was degassed by bubbling nitrogen through the solution for 5 min. To the resulting mixture was added PdCl<sub>2</sub>(dppf) (1.71 g, 2.34 mmol, 10 mol %). The reaction mixture was then stirred under a nitrogen atmosphere at 100 °C for 3 h. Upon completion, the reaction mixture was cooled to 25 °C, diluted with EtOAc (200 mL), filtered over Celite, and concentrated under reduced pressure. Purification by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/EtOAc) provided the desired <i>tert</i>-butyl 3-(di-<i>tert</i>-butoxycarbonylamino)-6-isopropenyl-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate <b>102</b> (3.85 g, 35% yield), as well as a mixture of mono- and bis-Boc-protected products. ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>34</sub>N<sub>4</sub>O<sub>6</sub>, calcd 475.3, found 475.4.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 3-(di-<i>tert</i>-butoxycarbonylamino)-6-isopropenyl-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate (<b>102</b>, 3.85 g, 8.12 mmol, 1.0 equiv) in 2:1 THF/H<sub>2</sub>O (40 mL) was added NaIO<sub>4</sub> (10.4 g, 48.7 mmol, 6.0 equiv), followed by 2,6-lutidine (1.89 mL, 16.2 mmol, 2.0 equiv) and K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O (149 mg, 0.406 mmol, 5 mol %). The resulting suspension was stirred vigorously at 25 °C for 1 h. Upon completion, the reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (15 mL), and the reaction mixture was extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to afford <i>tert</i>-butyl 6-acetyl-3-(di-<i>tert</i>-butoxycarbonylamino)-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate, which was used in step d without further purification.</div><div class="NLM_p">A solution of <i>tert</i>-butyl 6-acetyl-3-(di-<i>tert</i>-butoxycarbonylamino)-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate (3.65 g, 9.76 mmol, 1.0 equiv) in DMF-DMA (19.5 mL) was stirred in a sealed vial at 100 °C for 2 h. Upon completion, the reaction mixture was cooled to 25 °C, concentrated under reduced pressure, and purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH), which provided the mono-Boc-protected product <i>tert</i>-butyl 6-[(<i>E</i>)-3-(dimethylamino)acryloyl]-3-amino-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate <b>103</b> (178 mg, 3% yield). ESI-MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3,</sub> calcd 332.2, found 332.3.</div><div class="NLM_p">A solution of <i>tert</i>-butyl 6-[(<i>E</i>)-3-(dimethylamino)acryloyl]-3-amino-1,2,4-triaza-1<i>H</i>-indene-1-carboxylate (<b>103</b>, 178 mg, 0.536 mmol, 1.0 equiv) and (2,4-dichlorobenzyl)hydrazine HCl salt (146 mg, 0.643 mmol, 1.2 equiv) in EtOH (5.4 mL) was stirred at 80 °C in a sealed vial for 1.5 h. The reaction mixture was then cooled to 25 °C, and a solution of HCl in dioxane (1N, 0.54 mL, 1.0 equiv) was added. The resulting mixture was stirred an additional 1 h at 80 °C. Upon completion, the reaction mixture was cooled to 25 °C, concentrated under reduced pressure, and purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH), which provided 6-(1-(2,4-dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine <b>104</b> (103 mg, 54% yield). ESI-MS [M + H]<sup>+</sup> for C<sub>16</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>6,</sub> calcd 359.1, found 359.1.</div><div class="NLM_p last">A suspension of 6-(1-(2,4-dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine (<b>104</b>, 103 mg, 0.288 mmol, 1.0 equiv), 6-iodo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (104 mg, 0.317 mmol, 1.1 equiv), K<sub>3</sub>PO<sub>4</sub> (122 mg, 0.576 mmol, 2.0 equiv), CuI (55.0 mg, 0.288 mmol, 1.0 equiv), and DMEDA (6.0 uL, 0.576 mmol, 2.0 equiv) in DMF (0.58 mL, 0.5 M) was degassed by bubbling nitrogen through the solution for 5 min. The resulting mixture was then stirred in a sealed vial at 135 °C for 20 h. Upon completion, the reaction mixture was cooled to 25 °C and diluted with water (5 mL). The resulting precipitate was collected by vacuum filtration and rinsed several times with water. The solid was then redissolved in a mixture of MeOH (2 mL) and 1 N HCl/dioxane (3 mL) and stirred at 45 °C for 1 h. Upon completion, the reaction mixture was cooled to 25 °C and concentrated under reduced pressure. The crude product was purified by column chromatography (SiO<sub>2</sub>, gradient 0% to 50% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) followed by reverse phase preparative HPLC (H<sub>2</sub>O/MeCN gradient with 0.1% TFA), which provided the TFA salt of 6-(1-(2,4-dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridin-3-amine <b>81</b> (5 mg, 4% yield), as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.04 (s, 1H), 8.43 (s, 1H), 8.10 (s, 2H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.71 (s, 2H), 7.53 (s, 1H), 7.39 (m, 2H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 6.74 (s, 1H), 6.13 (brs, 2H), 5.49 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>23</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>8</sub>, calcd 475.1, found 475.0.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 4-Chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1-(1<i>H</i>-indazol-6-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole (<b>82</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S4</b> according to General Procedure A. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.41 (s, 1H), 8.29 (d, <i>J</i> = 2.5 Hz, 1H), 8.25 (s, 1H), 8.13 (d, <i>J</i> = 1.2 Hz, 1H), 8.00–7.95 (m, 2H), 7.83 (dd, <i>J</i> = 8.4, 2.5 Hz, 1H), 7.78 (d, <i>J</i> = 1.2 Hz, 1H), 7.59 (d, <i>J</i> = 1.9 Hz, 1H), 7.47 (dd, <i>J</i> = 8.6, 1.7 Hz, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 6.66 (d, <i>J</i> = 1.9 Hz, 1H), 5.46 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>15</sub>C<sub>l2</sub>N<sub>8</sub> calcd 461.1, found 461.0.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Procedures for the Preparation of 4-Halogenated Benzimidazolone Vinylogous Amides. (<i>E</i>)-5-(4-Chloro-6-(3-(dimethylamino)acryloyl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>100a</b>)</h4><div class="NLM_p">To a solution of 5-bromo-1-chloro-3-fluoro-2-nitrobenzene (<b>94a</b>, 18.0 g, 70.7 mmol, 1.0 equiv) and 5-aminobenzimidazolone (12.7 g, 84.9 mmol, 1.2 equiv) in DMSO (71 mL, 1 M) was added Et<sub>3</sub>N (71 mL, 509 mmol). The mixture was stirred at 90 °C for 12 h. Upon completion, the reaction was cooled to 25 °C, and the Et<sub>3</sub>N was removed in vacuo. The resulting solution was diluted with EtOAc (300 mL) and H<sub>2</sub>O (500 mL), which caused the product to precipitate. The resulting precipitate was collected by vacuum filtration, and the cake was washed successively with EtOAc and Et<sub>2</sub>O (2×). The solid was dried under high vacuum for 24 h to afford 5-(5-bromo-3-chloro-2-nitrophenylamino)-1,3-benzimidazol-2-one, which was used without further purification. ESI MS [M + H]<sup>+</sup> for C<sub>13</sub>H<sub>9</sub>BrClN<sub>4</sub>O<sub>3</sub>, calcd 383.0, found 383.0.</div><div class="NLM_p">5-(5-Bromo-3-chloro-2-nitrophenylamino)-1,3-benzimidazol-2-one (∼70.7 mmol) was suspended in EtOAc (589 mL) and EtOH (416 mL) and heated to 80 °C. SnCl<sub>2</sub> (67.1 g, 354 mmol) was added in portions over 1 h and heating continued for 12 h. Upon completion, the reaction mixture was cooled to 0 °C in an ice bath and basified (pH > 7) by addition of 1 M Na<sub>2</sub>CO<sub>3</sub>. The resulting mixture was filtered through Celite. The filter cake was washed with MeOH and THF. The filtrate was evaporated under reduced pressure, and the resulting solids were triturated with water and Et<sub>2</sub>O and then dried <i>in vacuo</i> to provide the desired 5-(2-amino-5-bromo-3-chlorophenylamino)-1,3-benzimidazol-2-one (24.7 g), which was used without purification. ESI MS [M + H]<sup>+</sup> for C<sub>13</sub>H<sub>11</sub>BrClN<sub>4</sub>O, calcd 353.0, found 353.1.</div><div class="NLM_p">To a solution of 5-(2-amino-5-bromo-3-chlorophenylamino)-1,3-benzimidazol-2-one (24.7 g, 70.0 mmol) in CH<sub>3</sub>CN (700 mL, 0.1 M) at 25 °C was added isoamyl nitrite (14.0 mL, 105 mmol, 1.5 equiv). The reaction mixture was then heated to 60 °C and stirred for 3 h at 60 °C. Upon completion, the reaction mixture was cooled to 25 °C, and the product was precipitated from solution. The solid was collected by vacuum filtration and washed with CH<sub>2</sub>Cl<sub>2</sub> (3×). The resulting solid was dried <i>in vacuo</i> at 50 °C to afford the desired 5-(6-bromo-4-chloro-1,2,3-benzotriazol-1-yl)-1,3-benzimidazol-2-one <b>98a</b>, which was used without purification. ESI MS [M + H]<sup>+</sup> for C<sub>13</sub>H<sub>8</sub>BrClN<sub>5</sub>O, calcd 364.0, found 364.1.</div><div class="NLM_p">To a solution of 5-(6-bromo-4-chloro-1,2,3-benzotriazol-1-yl)-1,3-benzimidazol-2-one (<b>98a</b>, ∼70.0 mmol) and methyl dicyclohexylamine (45.4 mL, 212 mmol, 3.0 equiv) in THF (250 mL) was added SEM-Cl (37.5 mL, 212 mmol, 3.0 equiv). The reaction mixture was stirred at 25 °C for 48 h. The reaction mixture was then diluted with EtOAc and filtered through Celite. The filtrate was washed with water, brine, dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The crude product was purified by column chromatography (SiO<sub>2</sub>, 0–50% EtOAc/hexane), which provided the desired 5-(6-bromo-4-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one <b>99a</b> (10.4 g, 24% yield over 4 steps).</div><div class="NLM_p">To a round-bottom flask was added 5-(6-bromo-4-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>99a</b>, 4.81 g, 7.72 mmol, 1.0 equiv), dioxane (38 mL, 0.2 M), and 2 M Na<sub>2</sub>CO<sub>3</sub> (11.6 mL). The resulting mixture was degassed by bubbling N<sub>2</sub> through the solution for 5 min and then PdCl<sub>2</sub>(dppf) (565 mg, 0.77 mmol, 10 mol %) and isopropenylboronic acid pinacol ester (4.35 mL, 23.1 mmol) were added. The mixture was heated to 100 °C and stirred at this temperature for 3 h. After cooling to 25 °C, the reaction was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by column chromatography (SiO<sub>2</sub>, 5–50% EtOAc/hexane), which afforded the desired product, 5-(4-chloro-6-(prop-1-en-2-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (3.92 g, 87% yield). ESI MS [M + H]<sup>+</sup> for C<sub>28</sub>H<sub>41</sub>ClN<sub>5</sub>O<sub>3</sub>Si<sub>2</sub>, calcd 586.2, found 586.4.</div><div class="NLM_p">To a solution of 5-(4-chloro-6-(prop-1-en-2-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (3.92 g, 6.69 mmol) in THF (22 mL) and water (11 mL) was added NaIO<sub>4</sub> (8.58 g, 40.1 mmol), 2,6-lutidine (1.56 mL, 13.4 mmol), and K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O (123 mg, 0.33 mmol). The resulting heavy suspension was stirred for 12 h at 25 °C. The reaction mixture was then partitioned between EtOAc and water. The organic layer was washed with water (2×), brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The crude product, 5-(6-acetyl-4-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one, was used without further purification. ESI MS [M + H]<sup>+</sup> for C<sub>27</sub>H<sub>39</sub>ClN<sub>5</sub>O<sub>4</sub>Si<sub>2</sub>, calcd 588.2, found 588.3.</div><div class="NLM_p last">A solution of 5-(6-acetyl-4-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (3.88 g, 6.6 mmol, 1.0 equiv) in DMF-DMA (12 mL) was stirred in a sealed vial at 100 °C for 12 h. Upon completion, the reaction mixture was cooled to 25 °C, concentrated under reduced pressure, and purified by column chromatography (SiO<sub>2</sub>, 0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>), which provided the product, (<i>E</i>)-5-(4-chloro-6-(3-(dimethylamino)acryloyl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one <b>100a</b> (2.98 g, 70% yield). ESI MS [M + H]<sup>+</sup> for C<sub>30</sub>H<sub>44</sub>ClN<sub>6</sub>O<sub>4</sub>Si<sub>2</sub>, calcd 643.3, found 643.4.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (<i>E</i>)-5-(4-Fluoro-6-(3-(dimethylamino)acryloyl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>100b</b>)</h4><div class="NLM_p last">The title compound was prepared in an identical sequence to the chlorinated vinylogous amide <b>100a</b> beginning from 5-bromo-1,3-difluoro-2-nitrobenzene.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 4-((5-(4-Fluoro-1-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-1H-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)benzonitrile (<b>83</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>100b</b> in a similar manner to compound <b>86</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.03 (s, 1H), 10.98 (s, 1H), 7.69–7.65 (m, 3H), 7.45–7.40 (m, 2H), 7.27–7.23 (m, 2H), 7.14–7.07 (m, 3H), 6.68 (s, 1H), 5.54 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>24</sub>H<sub>15</sub>FN<sub>8</sub>O, calcd 451.1, found 451.1.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 3-Chloro-4-((5-(1-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>c</i>]pyridin-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)benzonitrile (<b>84</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S5</b> in a manner similar to compound <b>86</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (m, 2H), 9.50 (dd, <i>J</i> = 1.2, 2.5 Hz, 1H), 8.19 (dd, <i>J</i> = 1.2, 2.4 Hz, 1H), 8.06 (m, 1H), 7.72–7.64 (m, 2H), 7.44–7.33 (m, 2H), 7.21–7.13 (m, 2H), 6.73 (d, <i>J</i> = 8.2 Hz, 1H), 6.10 (s, 2H). ESI MS [M + H]+ for C<sub>23</sub>H<sub>14</sub>ClN<sub>9</sub>O, calcd 468.1, found 468.3.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 5-(6-(1-(2,4-Dichlorobenzyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>c</i>]pyridin-1-yl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>85</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>S5</b> in a similar manner as compound <b>86</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.11–10.87 (m, 2H), 9.53 (s, 1H), 8.47 (s, 1H), 8.19 (s, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.7 Hz, 1H), 7.66–7.55 (m, 1H), 7.45–7.29 (m, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.06 (s, 1H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.01 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>8</sub>O, calcd 477.1, found 477.2</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 5-(4-Chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>86</b>)</h4><div class="NLM_p last">A solution of (<i>E</i>)-5-(4-chloro-6-(3-(dimethylamino)acryloyl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-bis((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>100a</b>, 103 mg, 0.159 mmol, 1.0 equiv) and 5-chloro-2-(hydrazinylmethyl)pyridine dihydrochloride (44.0 mg, 0.191 mmol, 1.2 equiv) in EtOH (1.6 mL) was stirred at 80 °C in a sealed vial for 2 h. The reaction mixture was then cooled to 25 °C and concentrated under reduced pressure. To the resulting residue was added 90% v/v TFA/H<sub>2</sub>O. The mixture was stirred at 25 °C for 0.5 h, then diluted with toluene and evaporated to dryness. The residue was reconstituted in MeOH and DMEDA (10 equiv) was added. The mixture was heated to 45 °C for 0.5 h. Upon completion, the reaction mixture was cooled to 25 °C and concentrated to dryness. The crude product was purified by column chromatography (SiO<sub>2</sub>, 0–50% MeOH/CH<sub>2</sub>Cl<sub>2</sub>), which provided 5-(4-chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.02 (s, 1H), 10.96 (s, 1H), 8.40 (dd, <i>J</i> = 2.5, 0.7 Hz, 1H), 7.99 (d, <i>J</i> = 1.2 Hz, 1H), 7.88 (dd, <i>J</i> = 8.4, 2.5 Hz, 1H), 7.77 (d, <i>J</i> = 1.2 Hz, 1H), 7.62 (d, <i>J</i> = 1.9 Hz, 1H), 7.32–7.26 (m, 2H), 7.24 (dd, <i>J</i> = 8.4, 0.7 Hz, 1H), 7.10 (dt, <i>J</i> = 7.9, 0.7 Hz, 1H), 6.68 (d, <i>J</i> = 1.9 Hz, 1H), 5.46 (s, 2H). ESI MS [M + H]<sup>+</sup> for C<sub>22</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>8</sub>O calcd 477.1, found 477.2.</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 6-((5-(4-Chloro-1-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-6-yl)-1<i>H</i>-pyrazol-1-yl)methyl)nicotinonitrile (<b>87</b>)</h4><div class="NLM_p last">The title compound was prepared from intermediate <b>100a</b> in a similar manner to compound <b>86</b>. <sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) δ 10.04 (s, 1H), 10.03 (s, 1H), 8.78 (s, 1H), 8.17 (d, <i>J</i> = 8.1 Hz, 1H), 8.07–8.04 (m, 1H), 7.69–7.65 (m, 1H), 7.61–7.56 (m, 1H), 7.49–7.45 (m, 1H), 7.41–7.33 (m, 2H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 6.64–6.59 (m, 1H), 5.60 (s, 2H). ESI MS [M + H]+ for C<sub>23</sub>H<sub>15</sub>ClN<sub>9</sub>O, calcd 468.1, found 468.1.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Cellular Human CD73 Assay</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Generation and Expansion of Human CD73 Stable CHO Cell Line</h4><div class="NLM_p last">Stable cell lines were generated by Lake Pharma (Belmont, CA) using a standard protocol to transform CHO cells with a pcDNA3.1(+) vector carrying the human NT5E (CD73) gene. Antibiotic selection was performed in CD OptiCHO cell media containing 5 μg/mL Puromycin and 200 μg/mL Hygromycin B. Pools of surviving CHO-CD73 were collected and frozen in 7.5% DMSO in CD OptiCHO cell media. Cryopreserved cells were defrosted in a water bath at 37 °C by agitating the vial until the cells were completely thawed. Cells were then transferred to a 15 mL Falcon tube prior to centrifuging at 225<i>g</i> for 5 min to pellet the cells. The cell pellet was resuspended in fresh warm CD OptiCHO Growth Medium supplemented with 2 mM Glutamax and transferred to a T175 flask. After 2 days and on reaching ∼80% confluence (∼20 million cells/flask), cells were split 1:3 into three fresh T175 flasks. After a further 3 days, cells were transferred to a 15 mL Falcon tubes and centrifuged at 250<i>g</i> for 5 min to pellet. Cells were resuspended at a density of 3 million cells per mL in CellBanker2 cryopreservation media and aliquoted into cryogenic vials. Cell aliquots were stored at −80 °C until needed.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> CD73 CHO Cellular Assay</h4><div class="NLM_p last">On the day of the experiment, one vial of CHO-CD73 cells was thawed, and cells were resuspended in 10 mL of assay buffer consisting of 20 mM HEPES, pH 7.4, 137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl<sub>2</sub>, 4.2 mM NaHCO<sub>3</sub> and 0.1% glucose. A 16 point, 1:3 master serial dilution of test compound was prepared in 100% DMSO to span a final concentration range of 100 μM to 0 μM or 0.1 μM to 0 μM. Twenty microliters of assay buffer was added to each well of a 96-well round-bottomed polypropylene plate followed by addition of 10 or 1 μL test compound at 10-fold or 100-fold final concentration. Fifty or 30 microliters of cells were added to each well, and the plate incubated for a further 60 min at 37 °C prior to addition of 20 μL of 125 μM AMP or 49 μL of 51 μM AMP in assay buffer. Final assay conditions comprised 1500 cells per well in 10% or 2% DMSO and 25 μM of AMP substrate. After a further 60 min of incubation at 37 °C and 5% CO<sub>2</sub>, the plate was centrifuged at 225<i>g</i> for 5 min. Eighty microliters of supernatant were transferred to a 96-well Spectra Plate the wells of which had been preloaded with 20 μL of PiColorLock Gold colorimetric assay reagent (Cat. No. 30 300 30, Thermo Fisher). Inorganic phosphate reaction product was assessed as a function of color developed by reaction with PiColorLock Gold reagent and quantitated using an Envision 2102 Multilabel Reader fitted with a 620 nm filter. CD73 enzymatic activity was evaluated as a correlate of phosphate product levels. Percentage maximum activity in each test well was calculated based on DMSO (maximum activity) and wells not containing cells (baseline activity). The IC<sub>50</sub> values of the test compounds were determined from compound dose response curve fitted using a standard four parameter fit equation.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Hepatocyte Stability Procedure</h3><div class="NLM_p last">A 50-donor pool of cryopreserved human hepatocytes was thawed in prewarmed 37 °C thawing medium (BioIVT), centrifuged, and resuspended in incubation medium (BioIVT). The number of viable cells was determined by the Trypan blue exclusion method. The cells were diluted to 2 million viable cells/mL (viability >80%) and seeded into round-bottom 96-well plates (50 μL/well). The test compounds were dissolved in DMSO and further diluted in 50% acetonitrile, with a final concentration of 0.01% DMSO and 0.1% acetonitrile. Incubation was performed at a final concentration of 1 million cells/mL and 0.5 μM test compound, with agitation at a frequency of 1100 rpm in a 37 °C, 5/95% CO<sub>2</sub>/air incubator. At different time points, 100 μL samples were taken and mixed with 300 μL of ice-cold acetonitrile to stop the enzymatic reaction. After centrifugation at 4200 rpm, the supernatant was analyzed by LC-MS/MS.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> CYP Inhibition Procedure</h3><div class="NLM_p last">Test compounds were evaluated <i>in vitro</i> for its potential to inhibit major human drug metabolizing enzymes of the cytochrome P450 family. The test compounds were incubated separately over a concentration range of 0–40 μM with 0.1 mg/mL human liver microsomal protein suspension in 0.1 M potassium phosphate buffer at pH 7.4, 1 mM NADPH, and a probe substrate (Phenacetin for CYP1A2, Diclofenac for CYP2C9, S-mephenytoin for CYP2C19, dextromethorphan for CYP2D6, and midazolam for CYP3A4). Each substrate was incubated at 37 °C for 5–20 min as defined by the previous assay validation. Samples for each substrate were collected and pooled with samples from other substrate incubations for determination of product formation by LC-MS/MS. IC<sub>50</sub> values were calculated using variable slope (4-parameter) model. Furafylline (1A2), sulfaphenazole (2C9), (+)-<i>N</i>-3-Benzylnirvanol (2C19), quinidine (2D6), and ketoconazole (3A4) were used as reference controls.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Assay of NTPDase 2, NTPDase 3, and NTPDase 8 Activity</h3><div class="NLM_p">The ability of compounds of interest to inhibit NTPDase 2, NTPDase 3, and NTPDase 8 activity was tested using CHO cells transiently transfected with NTPDase 2, NTPDase 3, and NTPDase 8. One day prior to the assay, 5 × 10<sup>6</sup> CHO cells were seeded in 11 mL of cell media (Hams F-12 supplemented with 10% FBS and 1% GlutaMax) in T75 flasks. Ten microliters of 100 ng/μL NTPDase 2, NTPDase 3, or NTPDase 8 plasmid DNA were added to 2 mL of serum free Opti-MEM media and combined with 2 mL of serum free Opti-MEM media containing 100 μL of Lipofectamine LTX. The final DNA/LTX mixture was incubated for 30 min at ∼25 °C and added to the T75 flasks containing CHO cells. The cells were incubated at 37 °C and 5% CO<sub>2</sub> overnight.</div><div class="NLM_p">The following day, media was removed by gentle aspiration, and cells were washed twice with 10 mL of PBS. The cells were harvested by addition of 2 mL of Accutase to the flask. The flask was then incubated at 37 °C until the cells could be detached from the flask by a light hand tap. Eight milliliters of PBS were added to the flask to lift the cells, and the resultant suspension was transferred to a 15 mL conical centrifuge and centrifuged at 225<i>g</i> for 5 min. PBS was removed by aspiration, and the cells were resuspended in 5 mL of assay buffer consisting of 20 mM HEPES, pH7.3, 137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl<sub>2</sub>, 4.2 mM NaHCO<sub>3</sub>, and 0.1% glucose. Cell density is determined using Vi-Cell XR.</div><div class="NLM_p last">On the day following transfection, cells were harvested using Accutase and suspended in assay buffer which consisted of 20 mM HEPES, pH 7.3, 137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl<sub>2</sub>, 4.2 mM NaHCO<sub>3</sub>, and 0.1% glucose. A 16 point, 1:3 master serial dilution of test compound was prepared in 100% DMSO to span a final concentration range of 10 μM to 0 μM. Eighteen microliters of assay buffer were added to each well of a 96-well polypropylene plate followed by addition of 2 μL test compound at 50-fold final concentration. Forty microliters of NTPDase 2, 3, or 8/CHO cells in assay buffer were added to each well, and the plate was incubated for 1 h at 37 °C prior to addition of 40 μL of 62.5 μM (NTPDase 2), 37.5 μM (NTPDase 3) or 75 μM (NTPDase 8) of ATP in assay buffer. Final assay conditions comprised 10 000 cells per well in 2% DMSO and 25 μM (NTPDase 2), 15 μM (NTPDase 3) or 30 μM (NTPDase 8) of ATP substrate. After a further 50 min of incubation at 37 °C and 5% CO<sub>2</sub>, the plate was centrifuged at 225<i>g</i> for 5 min. Eighty microliters of supernatant were transferred to a 96-well Spectra Plate, the wells of which had been preloaded with 20 μL of PiColorLock Gold colorimetric assay reagent. Inorganic phosphate reaction product was quantitated as a function of color developed by reaction with PiColorLock Gold reagent and determined using an Envision 2102 Multilabel Reader fitted with a 620 nm filter. NTPDase activity was assessed as a correlate of phosphate product levels. Percentage maximum activity in each of the compound test wells was calculated based on DMSO (maximum activity) and no cell control wells (baseline activity). The IC<sub>50</sub> values of the test compounds were determined from compound dose response curve fitted using a standard four parameter fit equation.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Crystallographic Methods</h3><div class="NLM_p">For cocrystallization experiments, human CD73<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> was recombinantly expressed in HEK293 cells. The expressed gene encodes for the mature human CD73 protein sequence (residues 27–549) (database entry P21589in UniProtKB/Swiss-Prot) and has four asparagine to aspartate mutations at the natural glycosylation sites and a C-terminal His<sub>6</sub> tag (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Figure S2</a>). The supernatant was purified by affinity chromatography using a Nickel excel column and imidazole elution. Following addition of 30 μM ZnCl<sub>2</sub> and 5 mM CaCl<sub>2</sub> to the eluate, the protein was further purified by size exclusion chromatography using a Superdex 200 pg column. The protein in a buffer of 100 mM NaCl, 50 mM Tris-HCl pH 8.0 was concentrated by diafiltration to 5 mg/mL then aliquoted, flash frozen with liquid nitrogen, and stored at −80 °C until further use. For crystallization, vapor diffusion trials were set up at 19 °C. One microliter of the protein solution containing 1 mM of the respective inhibitor and 100 μM of ZnCl<sub>2</sub> was mixed with an equal amount of reservoir buffer solution to give concentrations listed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Table S1</a>. Crystals were stepwise transferred to a cryo buffer composed as reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Table S1</a> and finally flash frozen in liquid nitrogen.</div><div class="NLM_p last">X-ray data collection was carried out at 100 K on beamline 14.1 of the Berlin Synchrotron (BESSY, Berlin, Germany) equipped with a PILATUS 6M detector (Dectris, Baden, Switzerland). The diffraction data were indexed, integrated, and scaled with XDS.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Coordinates of human CD73 in the closed conformation (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H2I">4H2I</a>) were taken as starting models for rigid body refinement. In addition, the pipedream software was used for automatic refinement and ligand placement.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The models were further improved by iterative cycles of TLS refinement using BUSTER-TNT<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and manual rebuilding with COOT.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Restraint dictionaries for inhibitors were generated using the GRADE web server (<a href="http://grade.globalphasing.org" class="extLink">http://grade.globalphasing.org</a>). Relevant crystallographic parameters of the structures are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Table S1</a>. Figures were prepared using PYMOL (<a href="http://pymol.org" class="extLink">http://pymol.org</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01713" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48184" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48184" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01713?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01713</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces of key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Analogous synthetic procedures for the preparation of fluoro- and chloro-5-<i>aza</i>-substituted cores, further cocrystallographic details concerning compounds <b>3b</b>, <b>53</b>, and <b>74</b> DMSO tolerance of the CHO CD73 malachite green assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_001.pdf">jm9b01713_si_001.pdf (151.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf">jm9b01713_si_002.pdf (461.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_003.csv">jm9b01713_si_003.csv (6.23 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates have been deposited in the Protein Data Bank (<a href="https://www.rcsb.org" class="extLink">https://www.rcsb.org</a>) for CD73 complexed with <b>3b</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUQ">6XUQ</a>), <b>53</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>), and <b>74</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE">6XUE</a>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01713" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth V. Lawson</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5094-6337" title="Orcid link">http://orcid.org/0000-0001-5094-6337</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5b30373a2c2834351b3a29382e2839323475383436"><span class="__cf_email__" data-cfemail="6d06010c1a1e02032d0c1f0e181e0f0402430e0200">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel W. Beatty</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erick A. Lindsey</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rhiannon Thomas-Tran</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurent Debien</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debashis Mandal</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenna L. Jeffrey</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anh T. Tran</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy Fournier</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven D. Jacob</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuelei Yan</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel L. Drew</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elaine Ginn</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ada Chen</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amber T. Pham</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon Zhao</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lixia Jin</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen W. Young</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nigel P. Walker</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manmohan Reddy Leleti</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susanne Moschütz</span> - <span class="hlFld-Affiliation affiliation">Institute
of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Norbert Sträter</span> - <span class="hlFld-Affiliation affiliation">Institute
of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay P. Powers</span> - <span class="hlFld-Affiliation affiliation">Arcus
Biosciences, Inc., 3928
Point Eden Way, Hayward, California 94545, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors except S.M and N.S. are employees or former employees of Arcus Biosciences.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8644-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">S.M. and N.S. are grateful to the Joint Berlin MX-Laboratory at BESSY II, Berlin, Germany, for beam time and assistance during synchrotron data collection and to the Helmholtz Zentrum Berlin for traveling support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADO</td><td class="NLM_def"><p class="first last">adenosine monophosphate</p></td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">adenosine monophosphate</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">CD73</td><td class="NLM_def"><p class="first last">cluster of differentiation 73, ecto-5′-nucleotidase</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DMEDA</td><td class="NLM_def"><p class="first last">1,2-dimethylethylendiamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF-DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">NCS</td><td class="NLM_def"><p class="first last"><i>N</i>-chlorosuccinimide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidone</p></td></tr><tr><td class="NLM_term">PIDA</td><td class="NLM_def"><p class="first last">diacetoxyiodobenzene</p></td></tr><tr><td class="NLM_term"><i>p</i>TsOH</td><td class="NLM_def"><p class="first last"><i>para</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1111/imr.12528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1111%2Fimr.12528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=28258700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1eltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2017&pages=121-144&author=B.+Allardauthor=M.+S.+Longhiauthor=S.+C.+Robsonauthor=J.+Stagg&title=The+Ectonucleotidases+CD39+and+CD73%3A+Novel+Checkpoint+Inhibitor+Targets&doi=10.1111%2Fimr.12528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets</span></div><div class="casAuthors">Allard, Bertrand; Longhi, Maria Serena; Robson, Simon C.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-144</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign.  This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state.  Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection-type processes or blocking suppressive pathways.  Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor immune responses.  In this review, we focus on CD39 and CD73 ectoenzymes and encompass aspects of the biochem. of these mols. as well as detailing the distribution and function on immune cells.  Effects of CD39 and CD73 inhibition in preclin. and clin. studies are discussed.  Finally, we provide insights into potential clin. application of adenosinergic and other purinergic-targeting therapies and forecast how these might develop in combination with other anti-cancer modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLKxqHb6HnbVg90H21EOLACvtfcHk0lieZe-R0ikdPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1eltL8%253D&md5=1f2c1bf632b238d6b7d9d7c46cea77c5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fimr.12528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12528%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DLonghi%26aufirst%3DM.%2BS.%26aulast%3DRobson%26aufirst%3DS.%2BC.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DThe%2520Ectonucleotidases%2520CD39%2520and%2520CD73%253A%2520Novel%2520Checkpoint%2520Inhibitor%2520Targets%26jtitle%3DImmunol.%2520Rev.%26date%3D2017%26volume%3D276%26spage%3D121%26epage%3D144%26doi%3D10.1111%2Fimr.12528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">CD39 and CD73 in Immunity and Inflamation</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2013.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.molmed.2013.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23601906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=355-367&author=L.+Antonioliauthor=P.+Pacherauthor=S.+Viziauthor=G.+Hask%C3%B3&title=CD39+and+CD73+in+Immunity+and+Inflamation&doi=10.1016%2Fj.molmed.2013.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">CD39 and CD73 in immunity and inflammation</span></div><div class="casAuthors">Antonioli, Luca; Pacher, Pal; Vizi, E. Sylvester; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The enzymic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chem. nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, resp.  This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine.  The CD39/CD73 pathway changes dynamically with the pathophysiol. context in which it is embedded.  It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiol. events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmWiFFVp_ddbVg90H21EOLACvtfcHk0lieZe-R0ikdPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFamtLg%253D&md5=75d0f7627b3b8a5dd81fd3a76992af2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2013.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2013.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DVizi%26aufirst%3DS.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DCD39%2520and%2520CD73%2520in%2520Immunity%2520and%2520Inflamation%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D355%26epage%3D367%26doi%3D10.1016%2Fj.molmed.2013.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanin, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelweiss, M. I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M. O.</span></span> <span> </span><span class="NLM_article-title">Ectonucleotidases in Tumor Cells and Tumor-Associated Immune Cells: An Overview</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">959848</span>, <span class="refDoi"> DOI: 10.1155/2012/959848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1155%2F2012%2F959848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23118517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BC3s7gtFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=959848&author=L.+S.+Bergaminauthor=E.+Braganholauthor=R.+F.+Zaninauthor=M.+I.+A.+Edelweissauthor=A.+M.+O.+Battastini&title=Ectonucleotidases+in+Tumor+Cells+and+Tumor-Associated+Immune+Cells%3A+An+Overview&doi=10.1155%2F2012%2F959848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview</span></div><div class="casAuthors">Bergamin Leticia Scussel; Braganhol Elizandra; Zanin Rafael Fernandes; Edelweiss Maria Isabel Albano; Battastini Ana Maria Oliveira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">959848</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence points out that genetic alteration does not guarantee the development of a tumor and indicates that complex interactions of tumor cells with the microenvironment are fundamental to tumorigenesis.  Among the pathological alterations that give tumor cells invasive potential, disruption of inflammatory response and the purinergic signaling are emerging as an important component of cancer progression.  Nucleotide/nucleoside receptor-mediated cell communication is orchestrated by ectonucleotidases, which efficiently hydrolyze ATP, ADP, and AMP to adenosine.  ATP can act as danger signaling whereas adenosine, acts as a negative feedback mechanism to limit inflammation.  Many tumors exhibit alterations in ATP-metabolizing enzymes, which may contribute to the pathological events observed in solid cancer.  In this paper, the main changes occurring in the expression and activity of ectonucleotidases in tumor cells as well as in tumor-associated immune cells are discussed.  Furthermore, we focus on the understanding of the purinergic signaling primarily as exemplified by research done by the group on gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGVDLyUgDPhPSAs_PE1QvifW6udTcc2eapLaOi3HpBsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7gtFejtQ%253D%253D&md5=5cce519ac9fc74e5754451e1aebcb5f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1155%2F2012%2F959848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F959848%26sid%3Dliteratum%253Aachs%26aulast%3DBergamin%26aufirst%3DL.%2BS.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DZanin%26aufirst%3DR.%2BF.%26aulast%3DEdelweiss%26aufirst%3DM.%2BI.%2BA.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%2BO.%26atitle%3DEctonucleotidases%2520in%2520Tumor%2520Cells%2520and%2520Tumor-Associated%2520Immune%2520Cells%253A%2520An%2520Overview%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2012%26volume%3D2012%26spage%3D959848%26doi%3D10.1155%2F2012%2F959848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H</span></span> <span> </span><span class="NLM_article-title">5′-Nucleotidase: Molecular Structure and Functional Aspects</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1042/bj2850345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1042%2Fbj2850345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1992&pages=345-365&author=H+Zimmermann&title=5%E2%80%B2-Nucleotidase%3A+Molecular+Structure+and+Functional+Aspects&doi=10.1042%2Fbj2850345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2Fbj2850345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2850345%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DH%26atitle%3D5%25E2%2580%25B2-Nucleotidase%253A%2520Molecular%2520Structure%2520and%2520Functional%2520Aspects%26jtitle%3DBiochem.%2520J.%26date%3D1992%26volume%3D15%26spage%3D345%26epage%3D365%26doi%3D10.1042%2Fbj2850345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-Nucleotidase: Structure Function Relationships</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1007/s11302-006-9000-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2Fs11302-006-9000-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18404474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ktl2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=343-350&author=N.+Str%C3%A4ter&title=Ecto-5%E2%80%B2-Nucleotidase%3A+Structure+Function+Relationships&doi=10.1007%2Fs11302-006-9000-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase: Structure function relationships</span></div><div class="casAuthors">Strater Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic signalling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-50</span>
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT) is attached via a GPI anchor to the extracellular membrane, where it hydrolyses AMP to adenosine and phosphate.  Related 5'-nucleotidases exist in bacteria, where they are exported into the periplasmic space.  X-ray structures of the 5'-nucleotidase from E. coli showed that the enzyme consists of two domains.  The N-terminal domain coordinates two catalytic divalent metal ions, whereas the C-terminal domain provides the substrate specificity pocket for the nucleotides.  Thus, the substrate binds at the interface of the two domains.  Here, the currently available structural information on ecto-5'-NT is reviewed in relation to the catalytic properties and enzyme function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDd9tlAyIrzEC-75aqa5AfW6udTcc2ebEbknAVHnvULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ktl2iug%253D%253D&md5=6b3bf983438fc270d35f8e9cf6d467ed</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11302-006-9000-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-006-9000-8%26sid%3Dliteratum%253Aachs%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DEcto-5%25E2%2580%25B2-Nucleotidase%253A%2520Structure%2520Function%2520Relationships%26jtitle%3DPurinergic%2520Signalling%26date%3D2006%26volume%3D2%26spage%3D343%26epage%3D350%26doi%3D10.1007%2Fs11302-006-9000-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="note"><p class="first last">CD73 in Various Tumor Types:</p></div><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavaresco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockenbach, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azambuja, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliviero
Battastini, A. M.</span></span> <span> </span><span class="NLM_article-title">Differential Extonucleotidase Expression in Human Bladder Cancer Cell Lines</span>. <i>Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2009.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.urolonc.2009.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=19372055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVOmsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=260-267&author=J.+Stellaauthor=L.+Bavarescoauthor=E.+Braganholauthor=L.+Rockenbachauthor=P.+F.+Fariasauthor=M.+R.+Winkauthor=A.+A.+Azambujaauthor=C.+H.+Barriosauthor=F.+B.+Morroneauthor=A.+M.+Oliviero%0ABattastini&title=Differential+Extonucleotidase+Expression+in+Human+Bladder+Cancer+Cell+Lines&doi=10.1016%2Fj.urolonc.2009.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Differential ectonucleotidase expression in human bladder cancer cell lines</span></div><div class="casAuthors">Stella, Joseli; Bavaresco, Luci; Braganhol, Elizandra; Rockenbach, Liliana; Farias, Patricia Fernandes; Wink, Marcia R.; Azambuja, Alan A.; Barrios, Carlos Henrique; Morrone, Fernanda Bueno; Oliveira Battastini, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-267</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Bladder cancer is the most prevalent tumor in the genitourinary tract.  Nucleotides are important mols. that regulate many pathophysiol. functions in the extracellular space.  Studies have revealed evidence of a relationship between purinergic signaling and urothelial malignancies.  Nucleotide-mediated signaling is controlled by a highly efficient enzymic cascade, which includes the members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDases), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPPs), ecto-alk. phosphatases, and ecto-5'-nucleotidase/CD73.  In an attempt to identify possible differential expression of ectonucleotidases during bladder cancer progression, a comparative anal. between RT4 (grade 1) and T24 (grade 3) bladder cancer cell lines was performed.  In RT4 cells, the hydrolysis of tri- and diphosphate nucleosides was higher than monophosphonucleosides.  T24 cells, however, presented the opposite profile, a low level of hydrolysis of tri- and diphosphate nucleosides and a high level of hydrolysis of monophosphates.  Phosphodiesterase activity was negligible in both cell lines at physiol. pH, indicating that these enzymes are not active under our assay conditions, although they are expressed in both cell lines.  The T24 cells expressed NTPDase5 mRNA, while the RT4 cells expressed NTPDase3 and NTPDase5 mRNA.  Both cell lines expressed ecto-5'-nucleotidase/CD73 mRNA.  The present work describes, for the first time, the differential pattern of ectonucleotidases in the more malignant bladder cancer cells compared with cells derived from an early stage of bladder cancer.  Our results open new avenues for research into the physiol. roles of this family of enzymes and their possible therapeutic potential in bladder cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB77YBtzfiLVg90H21EOLACvtfcHk0ljpZM7ZmMAkCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVOmsL4%253D&md5=d3c5ea8b4bbd11ad239ef20872a098dd</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2009.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2009.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DJ.%26aulast%3DBavaresco%26aufirst%3DL.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DRockenbach%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DP.%2BF.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DAzambuja%26aufirst%3DA.%2BA.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DMorrone%26aufirst%3DF.%2BB.%26aulast%3DOliviero%2BBattastini%26aufirst%3DA.%2BM.%26atitle%3DDifferential%2520Extonucleotidase%2520Expression%2520in%2520Human%2520Bladder%2520Cancer%2520Cell%2520Lines%26jtitle%3DUrol.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D260%26epage%3D267%26doi%3D10.1016%2Fj.urolonc.2009.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolovskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amdahl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahesmaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokhin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, J. E.</span></span> <span> </span><span class="NLM_article-title">CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.181.1.464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.4049%2Fjimmunol.181.1.464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18566412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVGisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=464-475&author=A.+Mikhailovauthor=A.+Sokolovskayaauthor=G.+G.+Yegutkinauthor=H.+Amdahlauthor=A.+Westauthor=H.+Yagitaauthor=R.+Lahesmaaauthor=L.+F.+Thompsonauthor=S.+Jalkanenauthor=D.+Blokhinauthor=J.+E.+Eriksson&title=CD73+Participates+in+Cellular+Multiresistance+Program+and+Protects+against+TRAIL-Induced+Apoptosis&doi=10.4049%2Fjimmunol.181.1.464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis</span></div><div class="casAuthors">Mikhailov, Andrey; Sokolovskaya, Alice; Yegutkin, Gennady G.; Amdahl, Hanne; West, Anne; Yagita, Hideo; Lahesmaa, Riitta; Thompson, Linda F.; Jalkanen, Sirpa; Blokhin, Dmitry; Eriksson, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">464-475</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The mol. mechanisms underlying the multiresistant phenotype of leukemic and other cancer cells are incompletely understood.  The authors used expression arrays to reveal differences in the gene expression profiles of an apoptosis-resistant T cell leukemia clone (A4) and normally apoptosis-sensitive parental Jurkat cells.  CD73 (ecto-5'-nucleotidase) was the most up-regulated gene in the resistant A4 cell clone.  A4 cells displayed CD73 surface expression and significant ecto-5'-nucleotidase activity.  The role of CD73 was confirmed by transfection of wild-type CD73 into native Jurkat cells, which led to specific resistance against TRAIL-induced apoptosis, but not other types of apoptosis.  The protective role of CD73 was further confirmed by small interfering RNA-mediated down-regulation of CD73, restoring TRAIL sensitivity.  CD73-mediated resistance was independent of enzymic activity of CD73, but was reliant on the anchoring of the protein to the membrane via GPI.  The authors suggest that the inhibition of TRAIL signaling works via interaction of CD73 with death receptor 5, as CD73 and death receptor 5 could be coimmunopptd. and were shown to be colocalized in the plasma membrane by confocal microscopy.  The authors propose that CD73 is a component of multiresistance machinery, the transcription of which is activated under selective pressure of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_qOj89hIrbVg90H21EOLACvtfcHk0ljpZM7ZmMAkCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVGisrs%253D&md5=dd634ff533a4ac4fe201417c99c57881</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.464%26sid%3Dliteratum%253Aachs%26aulast%3DMikhailov%26aufirst%3DA.%26aulast%3DSokolovskaya%26aufirst%3DA.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DAmdahl%26aufirst%3DH.%26aulast%3DWest%26aufirst%3DA.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DLahesmaa%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DJalkanen%26aufirst%3DS.%26aulast%3DBlokhin%26aufirst%3DD.%26aulast%3DEriksson%26aufirst%3DJ.%2BE.%26atitle%3DCD73%2520Participates%2520in%2520Cellular%2520Multiresistance%2520Program%2520and%2520Protects%2520against%2520TRAIL-Induced%2520Apoptosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D464%26epage%3D475%26doi%3D10.4049%2Fjimmunol.181.1.464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bavaresco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappellari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockenbach, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Cañedo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.</span></span> <span> </span><span class="NLM_article-title">The Role of Ecto-5′-nucleotidase/CD73 in Glioma Cell Line Proliferation</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1007/s11010-008-9877-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2Fs11010-008-9877-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18636315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Krtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2008&pages=61-68&author=L.+Bavarescoauthor=A.+Bernardiauthor=E.+Braganholauthor=A.+R.+Cappellariauthor=L.+Rockenbachauthor=P.+F.+Fariasauthor=M.+R.+Winkauthor=A.+Delgado-Ca%C3%B1edoauthor=A.+M.+Battastini&title=The+Role+of+Ecto-5%E2%80%B2-nucleotidase%2FCD73+in+Glioma+Cell+Line+Proliferation&doi=10.1007%2Fs11010-008-9877-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation</span></div><div class="casAuthors">Bavaresco, Luci; Bernardi, Andressa; Braganhol, Elizandra; Cappellari, Angelica Regina; Rockenbach, Liliana; Farias, Patricia Fernandes; Wink, Marcia Rosangela; Delgado-Canedo, Andres; Battastini, Ana Maria Oliveira</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Malignant gliomas are the most common and devastating primary tumors in the brain and, despite treatment, patients with these tumors have a poor prognosis.  The participation of ecto-5'-NT/CD73 per se as a proliferative factor, being involved in the control of cell growth, differentiation, invasion, migration, and metastasis processes was previously proposed.  In the present study, we evaluated the activity and functions of ecto-5'-NT/CD73 during the proliferation process of rat C6 and human U138MG glioma cell lines.  Increasing confluences and culture times led to an increase in ecto-5'-NT/CD73 activity in both C6 and U138MG glioma cells.  RT-PCR anal. and flow cytometry anal. showed a significant increase in ecto-5'-NT/CD73 mRNA and protein levels, resp., comparing confluent with sub-confluent cultures in human U138MG glioma cells.  Ecto-5'-nucleotidase/CD73 may regulate the extracellular AMP and adenosine levels.  Treatment with 1 μM APCP, a competitive ecto-5'-NT/CD73 inhibitor, caused a significant redn. of 30% in glioma cell proliferation.  In addn., 100 μM adenosine increases cell proliferation by 36%, and the treatment with adenosine plus NBTI and dipyridamole, produced an addnl. and significant increase of on cell proliferation.  The inhibitory effect on cell proliferation caused by APCP was reverted by co-treatment with NBTI and dipyridamole.  AMP (1 and 3 mM) decreased U138MG glioma cell proliferation by 29 and 42%, resp.  Taken together, these results suggest the participation of ecto-5'-NT/CD73 in cell proliferation and that this process is dependent upon the enzyme's prodn. of adenosine, a proliferative factor, and removal of AMP, a toxic mol. for gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolZzz6ix_mBLVg90H21EOLACvtfcHk0lgY0U6b4_V3ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Krtr7I&md5=c803d93aaf616fca668bef9775f16828</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1007%2Fs11010-008-9877-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-008-9877-3%26sid%3Dliteratum%253Aachs%26aulast%3DBavaresco%26aufirst%3DL.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DCappellari%26aufirst%3DA.%2BR.%26aulast%3DRockenbach%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DP.%2BF.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DDelgado-Ca%25C3%25B1edo%26aufirst%3DA.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Role%2520of%2520Ecto-5%25E2%2580%25B2-nucleotidase%252FCD73%2520in%2520Glioma%2520Cell%2520Line%2520Proliferation%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D319%26spage%3D61%26epage%3D68%26doi%3D10.1007%2Fs11010-008-9877-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sadej, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spychala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A. C.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-nucleotidase (eN, CD73) is Coexpressed with Metastasis Promoting Antigens in Human Melanoma Cells</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1080/15257770600894188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1080%2F15257770600894188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=17065075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Wrsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1119-1123&author=R.+Sadejauthor=J.+Spychalaauthor=A.+C.+Skladanowski&title=Ecto-5%E2%80%B2-nucleotidase+%28eN%2C+CD73%29+is+Coexpressed+with+Metastasis+Promoting+Antigens+in+Human+Melanoma+Cells&doi=10.1080%2F15257770600894188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells</span></div><div class="casAuthors">Sadej, R.; Spychala, J.; Skladanowski, A. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9-11</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Upregulated expression of eN has been found in the highly invasive human melanoma cell lines but neither in melanocytes nor in primary tumor cells.  Membrane proteins assocd. with cell adhesion and metastasis: α5-, β1-, β3-integrins, and CD44 were elevated gradually in accordance with increasing metastatic potential.  αν-Integrin was seen mostly in aggressive melanomas.  The expression of eN correlated with a no. of metastasis-related markers and thus may have a function in the process.  EN activity went parallel with its amt. in all cells.  Con A strongly inhibited the enzyme in a noncompetitive way.  Clustering of eN protein in overexpressing cells by ConA-treatment increased the enzyme assocn. with the heavy cytoskeletal complexes.  A similar shift towards cytoskeletal fractions took also place with other membrane proteins coexpressed with eN.  This ConA-induced assocn. may reflect a putative interaction of eN with physiol. ligand, that upon interaction, aggregates protein components of lipid rafts and triggers signaling pathway that may be intrinsically involved in cell-stroma adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0HryZbVEX7Vg90H21EOLACvtfcHk0lgY0U6b4_V3ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Wrsr3O&md5=b09ead652fbb38f1ab9ef4d6270d1690</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1080%2F15257770600894188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15257770600894188%26sid%3Dliteratum%253Aachs%26aulast%3DSadej%26aufirst%3DR.%26aulast%3DSpychala%26aufirst%3DJ.%26aulast%3DSkladanowski%26aufirst%3DA.%2BC.%26atitle%3DEcto-5%25E2%2580%25B2-nucleotidase%2520%2528eN%252C%2520CD73%2529%2520is%2520Coexpressed%2520with%2520Metastasis%2520Promoting%2520Antigens%2520in%2520Human%2520Melanoma%2520Cells%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2006%26volume%3D25%26spage%3D1119%26epage%3D1123%26doi%3D10.1080%2F15257770600894188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, R.</span></span> <span> </span><span class="NLM_article-title">Expression of CD73 and its Ecto-5′-nucleotidase Activity are Elevated in Papillary Thyroid Carcinomas</span>. <i>Histopathology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2559.2005.02277.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1111%2Fj.1365-2559.2005.02277.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=16623792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BD283hslCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2006&pages=612-614&author=T.+Kondoauthor=T.+Nakazawaauthor=S.+I.+Murataauthor=R.+Katoh&title=Expression+of+CD73+and+its+Ecto-5%E2%80%B2-nucleotidase+Activity+are+Elevated+in+Papillary+Thyroid+Carcinomas&doi=10.1111%2Fj.1365-2559.2005.02277.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas</span></div><div class="casAuthors">Kondo T; Nakazawa T; Murata S-I; Katoh R</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">612-4</span>
        ISSN:<span class="NLM_cas:issn">0309-0167</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRntiSnVgZzq-9TkgmBqTqfW6udTcc2eaV3G3zbnhuT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283hslCrsA%253D%253D&md5=b9310174d876d8aa9b6c94bea3788dd8</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2005.02277.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2005.02277.x%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DNakazawa%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DS.%2BI.%26aulast%3DKatoh%26aufirst%3DR.%26atitle%3DExpression%2520of%2520CD73%2520and%2520its%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520Activity%2520are%2520Elevated%2520in%2520Papillary%2520Thyroid%2520Carcinomas%26jtitle%3DHistopathology%26date%3D2006%26volume%3D48%26spage%3D612%26epage%3D614%26doi%3D10.1111%2Fj.1365-2559.2005.02277.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, J. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naaby-Hansen, S.</span></span> <span> </span><span class="NLM_article-title">Combined Affinity Labelling and Mass Spectrometry Analysis of Differential Cell Surface Protein Expression in Normal and Prostate Cancer Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5905</span>– <span class="NLM_lpage">5913</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1038%2Fsj.onc.1208747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=16007208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslakur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=5905-5913&author=C.+Hastieauthor=M.+Saxtonauthor=A.+Akpanauthor=R.+Cramerauthor=J.+R+Mastersauthor=S.+Naaby-Hansen&title=Combined+Affinity+Labelling+and+Mass+Spectrometry+Analysis+of+Differential+Cell+Surface+Protein+Expression+in+Normal+and+Prostate+Cancer+Cells&doi=10.1038%2Fsj.onc.1208747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Combined affinity labeling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells</span></div><div class="casAuthors">Hastie, Claire; Saxton, Malcolm; Akpan, Akunna; Cramer, Rainer; Masters, John R.; Naaby-Hansen, Soren</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5905-5913</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated.  A combination of affinity chromatog. purifn. of biotin-tagged surface proteins with mass spectrometry anal. identified 26 integral membrane proteins and 14 peripheral surface proteins.  The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein.  In addn., several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.  Cell surface protein expression changed both qual. and quant. when the cells were grown in the presence of either or both interferon INFα and INFγ.  Co-stimulation with type I and II interferons had additive or synergistic effects on the membrane d. of several, mainly peripherally attached surface proteins.  Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer.  In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labeling with biotin, and that detailed anal. of extracellular-induced surface changes can be achieved by combining surface-specific labeling with high-resoln. two-dimensional gel electrophoresis and mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0_wJjdIh3bVg90H21EOLACvtfcHk0libsjX6Gyc9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslakur8%253D&md5=2cf858c65e4e20dcd8ae44ded46e12d4</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208747%26sid%3Dliteratum%253Aachs%26aulast%3DHastie%26aufirst%3DC.%26aulast%3DSaxton%26aufirst%3DM.%26aulast%3DAkpan%26aufirst%3DA.%26aulast%3DCramer%26aufirst%3DR.%26aulast%3DMasters%26aufirst%3DJ.%2BR%26aulast%3DNaaby-Hansen%26aufirst%3DS.%26atitle%3DCombined%2520Affinity%2520Labelling%2520and%2520Mass%2520Spectrometry%2520Analysis%2520of%2520Differential%2520Cell%2520Surface%2520Protein%2520Expression%2520in%2520Normal%2520and%2520Prostate%2520Cancer%2520Cells%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D5905%26epage%3D5913%26doi%3D10.1038%2Fsj.onc.1208747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spychala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarowski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapkowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscue, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, B. S.</span></span> <span> </span><span class="NLM_article-title">Role of Estrogen Receptor in the Regulation of Ecto-5′-nucleotidase and Adenosine in Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0811-03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1158%2F1078-0432.CCR-0811-03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=14760094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=708-717&author=J.+Spychalaauthor=E.+Lazarowskiauthor=A.+Ostapkowiczauthor=L.+H.+Ayscueauthor=A.+Jinauthor=B.+S.+Mitchell&title=Role+of+Estrogen+Receptor+in+the+Regulation+of+Ecto-5%E2%80%B2-nucleotidase+and+Adenosine+in+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-0811-03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Estrogen Receptor in the Regulation of Ecto-5'-Nucleotidase and Adenosine in Breast Cancer</span></div><div class="casAuthors">Spychala, Jozef; Lazarowski, Eduardo; Ostapkowicz, Anna; Ayscue, Lanier H.; Jin, Aiwen; Mitchell, Beverly S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose is to understand the expression of ecto-5'-nucleotidase (eN), an adenosine producing enzyme with potential roles in angiogenesis, growth, and immunosuppression, in estrogen receptor (ER)-neg. and -pos. breast cancer.  We investigated the regulation of eN expression at the mRNA and protein levels by ERα in a panel of breast cancer cell lines that differ in ER status and invasive and metastatic potential.  We also detd. rates of adenosine formation in cells with high and low eN expression and in ER+ cells treated with estradiol.  ER-neg. cells express high eN protein and mRNA levels and produce up to 104-fold more adenosine from AMP and ATP.  Estradiol and antiestrogen treatments confirm that eN mRNA and protein expression and adenosine generation are neg. regulated through the ER.  Endogenous expression of eN in ER- cells transfected with ERα and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.  Finally, an examn. of 18 clin. breast cancer samples that were analyzed for both ER status and eN expression by Martin et al. (Cancer Res., 60: 2232-2238, 2000) revealed a significant inverse correlation between ER and eN status.  Our results show for the first time that eN is neg. regulated by ERα in dominant fashion and suggests that eN expression and its generation of adenosine may relate to breast cancer progression.  Addnl., increased expression of eN in a subset of ER-neg. cells may serve as a novel marker for a subset of more aggressive breast carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNbxpxmDuR7bVg90H21EOLACvtfcHk0libsjX6Gyc9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKjtQ%253D%253D&md5=650a16c3bc23292da652c66e1ebac6ff</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0811-03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0811-03%26sid%3Dliteratum%253Aachs%26aulast%3DSpychala%26aufirst%3DJ.%26aulast%3DLazarowski%26aufirst%3DE.%26aulast%3DOstapkowicz%26aufirst%3DA.%26aulast%3DAyscue%26aufirst%3DL.%2BH.%26aulast%3DJin%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DB.%2BS.%26atitle%3DRole%2520of%2520Estrogen%2520Receptor%2520in%2520the%2520Regulation%2520of%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520and%2520Adenosine%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D708%26epage%3D717%26doi%3D10.1158%2F1078-0432.CCR-0811-03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Extracellular Adenosine Triphosphate and Adenosine in Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5346</span>– <span class="NLM_lpage">5358</span>, <span class="refDoi"> DOI: 10.1038/onc.2010.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1038%2Fonc.2010.292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20661219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=5346-5358&author=J.+Staggauthor=M.+J.+Smyth&title=Extracellular+Adenosine+Triphosphate+and+Adenosine+in+Cancer&doi=10.1038%2Fonc.2010.292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular adenosine triphosphate and adenosine in cancer</span></div><div class="casAuthors">Stagg, J.; Smyth, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5346-5358</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ATP is actively released in the extracellular environment in response to tissue damage and cellular stress.  Through the activation of P2X and P2Y receptors, extracellular ATP enhances tissue repair, promotes the recruitment of immune phagocytes and dendritic cells, and acts as a co-activator of NLR family, pyrin domain-contg. 3 (NLRP3) inflammasomes.  The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymic activity of the ecto-nucleotidases CD39 and CD73, acts as a neg.-feedback mechanism to prevent excessive immune responses.  Here we review the effects of extracellular ATP and adenosine on tumorigenesis.  First, we summarize the functions of extracellular ATP and adenosine in the context of tumor immunity.  Second, we present an overview of the immunosuppressive and pro-angiogenic effects of extracellular adenosine.  Third, we present exptl. evidence that extracellular ATP and adenosine receptors are expressed by tumor cells and enhance tumor growth.  Finally, we discuss recent studies, including our own work, which suggest that therapeutic approaches that promote ATP-mediated activation of inflammasomes, or inhibit the accumulation of tumor-derived extracellular adenosine, may constitute effective new means to induce anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3-xCzFIxqLbVg90H21EOLACvtfcHk0libsjX6Gyc9lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtbY%253D&md5=8906a4a1f59f7a66cb183aca41b1f2cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.292%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DExtracellular%2520Adenosine%2520Triphosphate%2520and%2520Adenosine%2520in%2520Cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D5346%26epage%3D5358%26doi%3D10.1038%2Fonc.2010.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Switching off CD73; A Way to Boost the Activity of Conventional and Targeted Antineoplastic Therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.drudis.2017.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=28676406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCmurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1686-1696&author=L.+Antonioliauthor=S.+V.+Novitskiyauthor=K.+F.+Sachsenmeierauthor=M.+Fornaiauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Switching+off+CD73%3B+A+Way+to+Boost+the+Activity+of+Conventional+and+Targeted+Antineoplastic+Therapies&doi=10.1016%2Fj.drudis.2017.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies</span></div><div class="casAuthors">Antonioli, Luca; Novitskiy, Sergey V.; Sachsenmeier, Kris F.; Fornai, Matteo; Blandizzi, Corrado; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1686-1696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past few years, several preclin. studies have highlighted the value of CD73 (ecto-5'-nucleotidase) as a potential therapeutic target for cancer therapy.  Indeed, the pharmacol. blockade of CD73, via monoclonal antibodies or small mols., has promise in counteracting cancer development, growth and spread.  Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential.  In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSgskg4UVAIrVg90H21EOLACvtfcHk0ljXkZQEDEq2AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCmurvN&md5=2110db5523c3c03e82603b6eb37ea2ee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DSwitching%2520off%2520CD73%253B%2520A%2520Way%2520to%2520Boost%2520the%2520Activity%2520of%2520Conventional%2520and%2520Targeted%2520Antineoplastic%2520Therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D1686%26epage%3D1696%26doi%3D10.1016%2Fj.drudis.2017.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.trecan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=27014745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=95-109&author=L.+Antonioliauthor=G.+G.+Yegutkinauthor=P.+Pacherauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Anti-CD73+in+Cancer+Immunotherapy%3A+Awakening+New+Opportunities&doi=10.1016%2Fj.trecan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span></div><div class="casAuthors">Antonioli Luca; Yegutkin Gennady G; Pacher Pal; Blandizzi Corrado; Hasko Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-109</span>
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    </div><div class="casAbstract">In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology.  In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.  Targeting CD73 results in favorable antitumor effects in pre-clinical models and combined treatments of CD73 blockade with other immune-modulating agents (i.e. anti-CTLA-4 mAb or anti-PD1 mAb) is particularly attractive.  Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 monoclonal antibodies, can potentially constitute a new biologic therapy for cancer patients.  In this review, we discuss the link between CD73 and the onset, development and spread of tumors, highlighting the potential value of this molecule as a target and as a novel biomarker in the context of personalized cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJjr-hcquXE36CEoQgWY10fW6udTcc2eb02FkJDxyBerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D&md5=c67d1d1472d80ac9b0f3f0753dc37196</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAnti-CD73%2520in%2520Cancer%2520Immunotherapy%253A%2520Awakening%2520New%2520Opportunities%26jtitle%3DTrends%2520Cancer%26date%3D2016%26volume%3D2%26spage%3D95%26epage%3D109%26doi%3D10.1016%2Fj.trecan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraudon-Paoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jecko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becquart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rispaud-Blanc, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourdin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amigues, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensussan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliaou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narni-Mancinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paturel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoy, N.</span></span> <span> </span><span class="NLM_article-title">Blocking Antibodies Targeting the CD39/CD73 Immunosupressive Pathway Unleash Immune Responses in Combination Cancer Therapies</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.04.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.celrep.2019.04.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=31116985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWksb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2411-2425&author=I.+Perrotauthor=H.-A.+Michaudauthor=M.+Giraudon-Paoliauthor=S.+Augierauthor=A.+Docquierauthor=L.+Grosauthor=R.+Courtoisauthor=C.+Dejouauthor=D.+Jeckoauthor=O.+Becquartauthor=H.+Rispaud-Blancauthor=L.+Gauthierauthor=B.+Rossiauthor=S.+Chanteuxauthor=N.+Gourdinauthor=B.+Amiguesauthor=A.+Rousselauthor=A.+Bensussanauthor=J.-F.+Eliaouauthor=J.+Bastidauthor=F.+Romagneauthor=Y.+Morelauthor=E.+Narni-Mancinelliauthor=E.+Vivierauthor=C.+Paturelauthor=N.+Bonnefoy&title=Blocking+Antibodies+Targeting+the+CD39%2FCD73+Immunosupressive+Pathway+Unleash+Immune+Responses+in+Combination+Cancer+Therapies&doi=10.1016%2Fj.celrep.2019.04.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies</span></div><div class="casAuthors">Perrot, Ivan; Michaud, Henri-Alexandre; Giraudon-Paoli, Marc; Augier, Severine; Docquier, Aurelie; Gros, Laurent; Courtois, Rachel; Dejou, Cecile; Jecko, Diana; Becquart, Ondine; Rispaud-Blanc, Helene; Gauthier, Laurent; Rossi, Benjamin; Chanteux, Stephanie; Gourdin, Nicolas; Amigues, Beatrice; Roussel, Alain; Bensussan, Armand; Eliaou, Jean-Francois; Bastid, Jeremy; Romagne, Francois; Morel, Yannis; Narni-Mancinelli, Emilie; Vivier, Eric; Paturel, Carine; Bonnefoy, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2411-2425.e9</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors have revolutionized cancer treatment.  However, many cancers are resistant to ICIs, and the targeting of addnl. inhibitory signals is crucial for limiting tumor evasion.  The prodn. of adenosine via the sequential activity of CD39 and CD73 ectoenzymes participates to the generation of an immunosuppressive tumor microenvironment.  In order to disrupt the adenosine pathway, we generated two antibodies, IPH5201 and IPH5301, targeting human membrane-assocd. and sol. forms of CD39 and CD73, resp., and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine.  These antibodies promoted antitumor immunity by stimulating dendritic cells and macrophages and by restoring the activation of T cells isolated from cancer patients.  In a human CD39 knockin mouse preclin. model, IPH5201 increased the anti-tumor activity of the ATP-inducing chemotherapeutic drug oxaliplatin.  These results support the use of anti-CD39 and anti-CD73 monoclonal antibodies and their combination with immune checkpoint inhibitors and chemotherapies in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4T46HApEaJbVg90H21EOLACvtfcHk0ljXkZQEDEq2AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWksb7M&md5=b2642873d6ab147a849b16d2866c3ed6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.04.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.04.091%26sid%3Dliteratum%253Aachs%26aulast%3DPerrot%26aufirst%3DI.%26aulast%3DMichaud%26aufirst%3DH.-A.%26aulast%3DGiraudon-Paoli%26aufirst%3DM.%26aulast%3DAugier%26aufirst%3DS.%26aulast%3DDocquier%26aufirst%3DA.%26aulast%3DGros%26aufirst%3DL.%26aulast%3DCourtois%26aufirst%3DR.%26aulast%3DDejou%26aufirst%3DC.%26aulast%3DJecko%26aufirst%3DD.%26aulast%3DBecquart%26aufirst%3DO.%26aulast%3DRispaud-Blanc%26aufirst%3DH.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DRossi%26aufirst%3DB.%26aulast%3DChanteux%26aufirst%3DS.%26aulast%3DGourdin%26aufirst%3DN.%26aulast%3DAmigues%26aufirst%3DB.%26aulast%3DRoussel%26aufirst%3DA.%26aulast%3DBensussan%26aufirst%3DA.%26aulast%3DEliaou%26aufirst%3DJ.-F.%26aulast%3DBastid%26aufirst%3DJ.%26aulast%3DRomagne%26aufirst%3DF.%26aulast%3DMorel%26aufirst%3DY.%26aulast%3DNarni-Mancinelli%26aufirst%3DE.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DPaturel%26aufirst%3DC.%26aulast%3DBonnefoy%26aufirst%3DN.%26atitle%3DBlocking%2520Antibodies%2520Targeting%2520the%2520CD39%252FCD73%2520Immunosupressive%2520Pathway%2520Unleash%2520Immune%2520Responses%2520in%2520Combination%2520Cancer%2520Therapies%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D2411%26epage%3D2425%26doi%3D10.1016%2Fj.celrep.2019.04.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 Antibody Therapy Inhibits Breast Tumor Growth and Metastasis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1073/pnas.0908801107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1073%2Fpnas.0908801107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20080644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1547-1552&author=J.+Staggauthor=U.+Divisekeraauthor=N.+McLaughlinauthor=J.+Sharkeyauthor=S.+Pommeyauthor=D.+Denoyerauthor=K.+M.+Dwyerauthor=M.+J.+Smyth&title=Anti-CD73+Antibody+Therapy+Inhibits+Breast+Tumor+Growth+and+Metastasis&doi=10.1073%2Fpnas.0908801107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; McLaughlin, Nicole; Sharkey, Janelle; Pommey, Sandra; Denoyer, Delphine; Dwyer, Karen M.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1547-1552, S1547/1-S1547/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth.  We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine.  We showed that anti-CD73 mAb therapy significantly delayed primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung metastases.  Notably, anti-CD73 mAb therapy was essentially dependent on the induction of adaptive anti-tumor immune responses.  Knockdown of CD73 in 4T1.2 tumor cells confirmed the tumor-promoting effects of CD73.  In addn. to its immunosuppressive effect, CD73 enhanced tumor cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis.  Accordingly, administration of adenosine-5'-N-ethylcarboxamide to tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung metastasis.  Using selective adenosine-receptor antagonists, we showed that activation of A2B adenosine receptors promoted 4T1.2 tumor cell chemotaxis in vitro and metastasis in vivo.  In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and it also established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2etrhOGG3bVg90H21EOLACvtfcHk0lgqlBzIY1QK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D&md5=7bafdf788526df932910865c2e291959</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0908801107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0908801107%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DMcLaughlin%26aufirst%3DN.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DDwyer%26aufirst%3DK.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-CD73%2520Antibody%2520Therapy%2520Inhibits%2520Breast%2520Tumor%2520Growth%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1547%26epage%3D1552%26doi%3D10.1073%2Fpnas.0908801107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">For a review see:</p></div><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbelini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">das Neves, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira
Battastini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eifler-Lima, V.</span></span> <span> </span><span class="NLM_article-title">Insights into Ecto-5′-nucleotidase as a New Target for Caner Therapy: A Medicinal Chemistry Study</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150408112615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.2174%2F0929867322666150408112615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=25850771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1776-1792&author=P.+Corbeliniauthor=F.+Figueiroauthor=G.+das+Nevesauthor=S.+Andradeauthor=D.+Kawanoauthor=A.+Oliveira%0ABattastiniauthor=V.+Eifler-Lima&title=Insights+into+Ecto-5%E2%80%B2-nucleotidase+as+a+New+Target+for+Caner+Therapy%3A+A+Medicinal+Chemistry+Study&doi=10.2174%2F0929867322666150408112615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Ecto-5'-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study</span></div><div class="casAuthors">Corbelini, Patricia Frasson; Figueiro, Fabricio; Machado das Neves, Gustavo; Andrade, Saulo; Kawano, Daniel Fabio; Oliveira Battastini, Ana Maria; Eifler-Lima, Vera Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1776-1792</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT, 5'-NT, eN, CD73) is a membrane ectoenzyme that is primarily responsible for the extracellular prodn. of adenosine from AMP.  Ecto-5'-NT is overexpressed in various types of cancer cells, leading to elevated concns. of adenosine in the tumor microenvironment.  Adenosine has also been found to be important in cancer pathogenesis, showing strong immunosuppressive effects over antitumor T cells and macrophages and promoting neovascularization and cell adherence.  These actions support tumor growth and development.  It has been suggested that the inhibition of ecto-5'-NT results in lower extracellular concns. of adenosine within the tumor microenvironment, which would directly affect cancer cells and render malignant cells more susceptible to host defense systems.  Such mechanisms are proposed to represent promising new targets for cancer therapy.  The aim of this review is to explore the biochem. and structural features of ecto-5'-NT, including a brief anal. of its active site by mol. modeling, as a means of evaluating whether the inhibition of this enzyme does indeed represent a feasible strategy for treating cancer.  Known inhibitors and possible prototypes that could be used to target ecto-5'-NT during cancer therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxGNC2_iGAn7Vg90H21EOLACvtfcHk0lgqlBzIY1QK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGnuro%253D&md5=29a35d2e469dc2e69823eb0f8a428e28</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150408112615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150408112615%26sid%3Dliteratum%253Aachs%26aulast%3DCorbelini%26aufirst%3DP.%26aulast%3DFigueiro%26aufirst%3DF.%26aulast%3Ddas%2BNeves%26aufirst%3DG.%26aulast%3DAndrade%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DD.%26aulast%3DOliveira%2BBattastini%26aufirst%3DA.%26aulast%3DEifler-Lima%26aufirst%3DV.%26atitle%3DInsights%2520into%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520as%2520a%2520New%2520Target%2520for%2520Caner%2520Therapy%253A%2520A%2520Medicinal%2520Chemistry%2520Study%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1776%26epage%3D1792%26doi%3D10.2174%2F0929867322666150408112615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, J. M.</span></span> <span> </span><span class="NLM_article-title">Preparation an Properties of 5′-Nucleotidase from Smooth Muscle of Small Intestine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>245</i></span>,  <span class="NLM_fpage">6274</span>– <span class="NLM_lpage">6280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=4320834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADyaE3MXjvVGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1970&pages=6274-6280&author=R.+M.+Burgerauthor=J.+M.+Lowenstein&title=Preparation+an+Properties+of+5%E2%80%B2-Nucleotidase+from+Smooth+Muscle+of+Small+Intestine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and properties of 5'-nucleotidase from smooth muscle of small intestine</span></div><div class="casAuthors">Burger, Richard; Lowenstein, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">245</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6274-80</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">ADP strongly inhibited a 5' -nucleotidase prepd. from pig smooth muscle.  This inhibition was much stronger than the previously described inhibition of 5' -nucleotidase by ATP.  Α,β-Methylene adenosine 5' -diphosphate (I) was an exceptionally powerful inhibitor of the enzyme.  The enzyme had 3 pH optima.  The lowest of these optima was seen only when the enzyme was not inhibited by buffer anions; the highest was seen only in the presence of Mg2+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkMkr4_XWRbVg90H21EOLACvtfcHk0lgqlBzIY1QK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXjvVGgsQ%253D%253D&md5=a60b798fa2da1eb9dd34eb446040301a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DR.%2BM.%26aulast%3DLowenstein%26aufirst%3DJ.%2BM.%26atitle%3DPreparation%2520an%2520Properties%2520of%25205%25E2%2580%25B2-Nucleotidase%2520from%2520Smooth%2520Muscle%2520of%2520Small%2520Intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1970%26volume%3D245%26spage%3D6274%26epage%3D6280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strater, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title"><i>α,β</i>-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective <i>ecto</i>-5′-Nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6248-6263&author=S.+Bhattaraiauthor=M.+Freundliebauthor=J.+Pippelauthor=A.+Meyerauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=N.+Straterauthor=A.+El-Tayebauthor=C.+E.+Muller&title=%CE%B1%2C%CE%B2-Methylene-ADP+%28AOPCP%29+Derivatives+and+Analogues%3A+Development+of+Potent+and+Selective+ecto-5%E2%80%B2-Nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Bhattarai, Sanjay; Freundlieb, Marianne; Pippel, Jan; Meyer, Anne; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; Yegutkin, Gennady G.; Straeter, Norbert; El-Tayeb, Ali; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics.  The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivs. modified in various positions were prepd.  Products were tested at rat recombinant eN.  6-(Ar)alkylamino substitution led to the largest improvement in potency.  N6-Monosubstitution was superior to sym. N6,N6-disubstitution.  The most potent inhibitors were N6-(4-chlorobenzyl)- (PSB-12441, Ki 7.23 nM), N6-phenylethyl- (PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] I (PSB-12379, Ki 9.03 nM).  Replacement of the 6-NH group in I by O (PSB-12431) or S (PSB-12553) yielded equally potent inhibitors (9.20 nM and 9.50 nM, resp.).  Selected compds. investigated at the human enzyme did not show species differences; they displayed high selectivity vs. other ecto-nucleotidases and ADP-activated P2Y receptors.  Moreover, high metabolic stability was obsd.  These compds. represent the most potent eN inhibitors described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmxberqVtKLVg90H21EOLACvtfcHk0lh1BJJ-0gnQBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF&md5=5f1231a662dd86345b9d3803f1c4e716</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00802%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStrater%26aufirst%3DN.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D%25CE%25B1%252C%25CE%25B2-Methylene-ADP%2520%2528AOPCP%2529%2520Derivatives%2520and%2520Analogues%253A%2520Development%2520of%2520Potent%2520and%2520Selective%2520ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6248%26epage%3D6263%26doi%3D10.1021%2Facs.jmedchem.5b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobelmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losenkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irjala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5′-Nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3677-3695&author=A.+Junkerauthor=C.+Rennauthor=C.+Dobelmannauthor=V.+Namasivayamauthor=S.+Jainauthor=K.+Losenkovaauthor=H.+Irjalaauthor=S.+Ducaauthor=R.+Balasubramanianauthor=S.+Chakrabortyauthor=F.+Borgelauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=C.+E.+Mullerauthor=K.+A.+Jacobson&title=Structure%E2%80%93Activity+Relationship+of+Purine+and+Pyrimidine+Nucleotides+as+Ecto-5%E2%80%B2-Nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Junker, Anna; Renn, Christian; Dobelmann, Clemens; Namasivayam, Vigneshwaran; Jain, Shanu; Losenkova, Karolina; Irjala, Heikki; Duca, Sierra; Balasubramanian, Ramachandran; Chakraborty, Saibal; Borgel, Frederik; Zimmermann, Herbert; Yegutkin, Gennady G.; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3677-3695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cluster of differentiation 73 (CD73) converts AMP to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment.  We synthesized 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogs, and compared their CD73 inhibitory potencies.  In the adenine series, most ribose modifications and 1-deaza and 3-deaza were detrimental, but 7-deaza was tolerated.  Uracil substitution with N3-Me, but not larger groups, or 2-thio, was tolerated. 1,2-Diphosphono-Et modifications were not tolerated.  N4-(Aryl)alkyloxy-cytosine derivs., esp. with bulky benzyloxy substituents, showed increased potency.  Among the most potent inhibitors were the 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of 5-fluorouridine, N4-benzoyl-cytidine, N4-[O-(4-benzyloxy)]-cytidine, and N4-[O-(4-naphth-2-ylmethyloxy)]-cytidine (Ki values 5-10 nM at human CD73).  Selected compds. tested at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, esp. those with large nucleobase substituents.  These nucleotide analogs are among the most potent CD73 inhibitors reported and may be considered for development as parenteral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmqsc2IyljbVg90H21EOLACvtfcHk0lh1BJJ-0gnQBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D&md5=374b1862da172f31363dc74a4545661a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00164%26sid%3Dliteratum%253Aachs%26aulast%3DJunker%26aufirst%3DA.%26aulast%3DRenn%26aufirst%3DC.%26aulast%3DDobelmann%26aufirst%3DC.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DLosenkova%26aufirst%3DK.%26aulast%3DIrjala%26aufirst%3DH.%26aulast%3DDuca%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520of%2520Purine%2520and%2520Pyrimidine%2520Nucleotides%2520as%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3677%26epage%3D3695%26doi%3D10.1021%2Facs.jmedchem.9b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. W.</span></span> <span> </span><span class="NLM_article-title">An Exceptionally Potent Inhibitor of Human CD73</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3331</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=3331&author=C.+E.+Bowmanauthor=R.+G.+da+Silvaauthor=A.+Phamauthor=S.+W.+Young&title=An+Exceptionally+Potent+Inhibitor+of+Human+CD73&doi=10.1021%2Facs.biochem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">An Exceptionally Potent Inhibitor of Human CD73</span></div><div class="casAuthors">Bowman, Christine E.; da Silva, Rafael G.; Pham, Amber; Young, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3331-3334</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported the initiation of a Phase I clin. trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973).  We undertook a detailed kinetic anal. of the interaction between human CD73 and AB680 to det. the mode of inhibition.  We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a Ki of 5 pM.  Clin. candidates of this potency are uncommon and deserve special consideration during lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGag3hdjGb7Vg90H21EOLACvtfcHk0lh9AYzUZZKm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O&md5=ad600cb74b603c4daa3c5f002e1c5f4a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DC.%2BE.%26aulast%3Dda%2BSilva%26aufirst%3DR.%2BG.%26aulast%3DPham%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BW.%26atitle%3DAn%2520Exceptionally%2520Potent%2520Inhibitor%2520of%2520Human%2520CD73%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D3331%26doi%3D10.1021%2Facs.biochem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">Development of Potent and Selective Inhibitors of <i>Ecto</i>-5′-Nucleotidase Based on an Anthraquinone Scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1021/jm901851t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901851t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2076-2086&author=Y.+Baqiauthor=S.-Y.+Leeauthor=J.+Iqbalauthor=P.+Ripphausenauthor=A.+Lehrauthor=A.+B.+Scheiffauthor=H.+Zimmermannauthor=J.+Bajorathauthor=C.+E.+Muller&title=Development+of+Potent+and+Selective+Inhibitors+of+Ecto-5%E2%80%B2-Nucleotidase+Based+on+an+Anthraquinone+Scaffold&doi=10.1021%2Fjm901851t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Inhibitors of ecto-5'-Nucleotidase Based on an Anthraquinone Scaffold</span></div><div class="casAuthors">Baqi, Younis; Lee, Sang-Yong; Iqbal, Jamshed; Ripphausen, Peter; Lehr, Anne; Scheiff, Anja B.; Zimmermann, Herbert; Bajorath, Jurgen; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2076-2086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels.  EN inhibitors have potential as novel drugs, for example, for the treatment of cancer.  In the present study, we synthesized and investigated a series of 55 anthraquinone derivs. as potential inhibitors of eN, 11 of which are novel compds. and another 11 of which had previously been described but have now been synthesized by an improved method.  We identified several potent inhibitors of rat eN.  The most potent compds. were 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0952, Ki = 260 nM) and 1-amino-4-[2-anthracenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0963, 150 nM), with the latter being the most potent eN inhibitor described to date.  Selected compds. were further characterized and found to exhibit a competitive mechanism of inhibition.  Investigations of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compd. PSB-0952 exhibited the highest degree of selectivity (>150-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJKU5mUcJOrVg90H21EOLACvtfcHk0lh9AYzUZZKm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D&md5=b9e4c62d6423478d5cd4d95f702f689e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901851t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901851t%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DLehr%26aufirst%3DA.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3DDevelopment%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520Based%2520on%2520an%2520Anthraquinone%2520Scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2076%26epage%3D2086%26doi%3D10.1021%2Fjm901851t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening Identifies Novel Sulfonamide Inhibitors of <i>exto</i>-5′-Nucleotidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6576</span>– <span class="NLM_lpage">6581</span>, <span class="refDoi"> DOI: 10.1021/jm300658n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300658n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6576-6581&author=P.+Ripphausenauthor=M.+Freundliebauthor=A.+Brunschweigerauthor=H.+Zimmermannauthor=C.+E.+Mullerauthor=J.+Bajorath&title=Virtual+Screening+Identifies+Novel+Sulfonamide+Inhibitors+of+exto-5%E2%80%B2-Nucleotidase&doi=10.1021%2Fjm300658n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto-5'-Nucleotidase</span></div><div class="casAuthors">Ripphausen, Peter; Freundlieb, Marianne; Brunschweiger, Andreas; Zimmermann, Herbert; Mueller, Christa E.; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6576-6581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metallophosphoesterase that is implicated in the control of purinergic receptor signaling and a no. of assocd. therapeutically relevant effects.  Currently, only very few compds., including ADP, its more stable analog α,β-methylene-ADP, ATP, and anthraquinone derivs. are known to inhibit this enzyme.  In the search for inhibitors with more drug-like properties, we applied a model structure-based virtual screening approach augmented by chem. similarity searching.  On the basis of this anal., 51 candidate compds. were finally selected for exptl. evaluation.  A total of 13 of these mols. were confirmed to have competitive inhibitory activity.  The most potent inhibitor, 6-chloro-2-oxo-N-(4-sulfamoylphenyl)-2H-chromene-3-carboxylic acid amide (17), showed an IC50 value of 1.90 μM.  In contrast to the nucleotide- and anthraquinone-derived antagonists, the newly identified competitive inhibitors are uncharged at physiol. pH values, possess a drug-like structure, and are structurally distinct from known active compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0goFQAkEQe7Vg90H21EOLACvtfcHk0lh9AYzUZZKm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D&md5=106abecfd7469af4be3acfb516d237f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300658n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300658n%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DVirtual%2520Screening%2520Identifies%2520Novel%2520Sulfonamide%2520Inhibitors%2520of%2520exto-5%25E2%2580%25B2-Nucleotidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6576%26epage%3D6581%26doi%3D10.1021%2Fjm300658n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamajusuku, A. S.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.O.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-Nucleotidase/CD73 Inhibition by Quercetin in the Human U138MG Glioma Cell Line</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">1352</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.bbagen.2007.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=17643826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1CmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=1352-1359&author=E.+Braganholauthor=A.+S.K.+Tamajusukuauthor=A.+Bernardiauthor=M.+R.+Winkauthor=A.+M.O.+Battastini&title=Ecto-5%E2%80%B2-Nucleotidase%2FCD73+Inhibition+by+Quercetin+in+the+Human+U138MG+Glioma+Cell+Line&doi=10.1016%2Fj.bbagen.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line</span></div><div class="casAuthors">Braganhol, Elizandra; Tamajusuku, Alessandra S. K.; Bernardi, Andressa; Wink, Marcia R.; Battastini, Ana M. O.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1352-1359</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gliomas are the most malignant of the primary brain tumors.  Nucleotides represent an important class of extracellular mols. that are crucial for the normal function of the nervous system.  ATP and adenosine can stimulate cell proliferation in different glioma cell lines; the events induced by extracellular adenine nucleotides are controlled by the action of ecto-nucleotidases, which hydrolyze ATP into adenosine in the extracellular space.  Recent studies have shown that quercetin has an anti-proliferative effect on the U138MG glioma cell line.  Since evidence suggests that purinergic signaling is involved in the growth and progression of glioma and, taking into consideration the anti-proliferative effect elicited by quercetin in this tumor type, the aim of the present study was to better investigate the extracellular metab. of AMP and evaluate the effect of quercetin on this system in the human U138MG glioma cell line.  The adenine products secreted by glioma cells were first characterized; extracellular AMP was efficiently metabolized by the glioma culture, demonstrating a very active ecto-5'-NT/CD73.  Quercetin was able to inhibit the ecto-5'-NT/CD73 activity and modulate its expression.  In addn., the cell treatment with APCP (α,β-methyleneadenosine-5'-diphosphate), an ecto-5'-NT/CD73 inhibitor, led to a significant redn. in glioma cell proliferation.  We suggest that the inhibition of ecto-5'-NT/CD73 may result in a decrease in extracellular adenosine prodn. with a consequent redn. in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76-vFDbju7rVg90H21EOLACvtfcHk0lh9AYzUZZKm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1CmsL8%253D&md5=120b4326e880c0780fa7efe48f50fd90</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DTamajusuku%26aufirst%3DA.%2BS.K.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DBattastini%26aufirst%3DA.%2BM.O.%26atitle%3DEcto-5%25E2%2580%25B2-Nucleotidase%252FCD73%2520Inhibition%2520by%2520Quercetin%2520in%2520the%2520Human%2520U138MG%2520Glioma%2520Cell%2520Line%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D1352%26epage%3D1359%26doi%3D10.1016%2Fj.bbagen.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weimer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimer, D. F.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of Phosphonates and Phosphates: Crossing the Membrane Barrier</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2F128_2014_561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=25391982" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2015&pages=115-160&author=A.+J.+Weimerauthor=D.+F.+Weimer&title=Prodrugs+of+Phosphonates+and+Phosphates%3A+Crossing+the+Membrane+Barrier"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2F128_2014_561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F128_2014_561%26sid%3Dliteratum%253Aachs%26aulast%3DWeimer%26aufirst%3DA.%2BJ.%26aulast%3DWeimer%26aufirst%3DD.%2BF.%26atitle%3DProdrugs%2520of%2520Phosphonates%2520and%2520Phosphates%253A%2520Crossing%2520the%2520Membrane%2520Barrier%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2015%26volume%3D360%26spage%3D115%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Sulfation and Glucoronidation of Phenolics: Insights into the Structural Basis of Conjugation</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.2174/138920011797470100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.2174%2F138920011797470100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=21933112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOkurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=900-916&author=B.+Wuauthor=S.+Basuauthor=S.+Mengauthor=X.+Wangauthor=S.+Zhangauthor=M.+Hu&title=Regioselective+Sulfation+and+Glucoronidation+of+Phenolics%3A+Insights+into+the+Structural+Basis+of+Conjugation&doi=10.2174%2F138920011797470100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective sulfation and glucuronidation of phenolics: Insights into the structural basis</span></div><div class="casAuthors">Wu, Baojian; Basu, Sumit; Meng, Shengnan; Wang, Xiaoqiang; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">900-916</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phase II metab. sulfation and glucuronidation, mediated by sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs), resp., are significant metabolic pathways for numerous endobiotics and xenobiotics.  An understanding of SULT/UGT substrate specificity including regioselectivity (i.e., position preference) is of great importance in predicting the contribution of sulfation/glucuronidation to drug and metabolite disposition in vivo.  Here, the authors summarize regioselective sulfation and glucuronidation of phenolic compds. with multiple OH groups as potential conjugation sites.  The strict regioselective patterns are highlighted for several SULT and UGT isoforms toward flavonoids, a large class of natural polyphenols.  To seek for a mol.-level explanation, the enzyme structures (i.e., SULT crystal structures and a homol.-modeled UGT structure) combined with mol. docking are employed.  In particular, the structural basis for regioselective metab. of flavonoids by SULT1A3 and UGT1A1 is discussed.  It is concluded that the regioselective nature of these phase II enzymes is detd. by the size and shape of the binding pocket.  While the mol. structures of the enzymes can be used to explain regioselective metab. regarding the binding property, predicting the turnover at different positions remains a particularly difficult task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRk_w2p8hrAbVg90H21EOLACvtfcHk0lgq7JlHmVtZNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOkurrJ&md5=e23988c2cc5d176fe297228f8acc849f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F138920011797470100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011797470100%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DRegioselective%2520Sulfation%2520and%2520Glucoronidation%2520of%2520Phenolics%253A%2520Insights%2520into%2520the%2520Structural%2520Basis%2520of%2520Conjugation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26spage%3D900%26epage%3D916%26doi%3D10.2174%2F138920011797470100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. A.</span></span> <span> </span><span class="NLM_article-title">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/tx3003824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=6-25&author=L.+A.+Peterson&title=Reactive+Metabolites+in+the+Biotransformation+of+Molecules+Containing+a+Furan+Ring&doi=10.1021%2Ftx3003824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span></div><div class="casAuthors">Peterson, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-25</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many xenobiotics contg. a furan ring are toxic and/or carcinogenic.  The harmful effects of these compds. require furan ring oxidn.  This reaction generates an electrophilic intermediate.  Depending on the furan ring substituents, the intermediate is either an epoxide or a cis-enedione with more ring substitution favoring epoxide formation.  Either intermediate reacts with cellular nucleophiles such as protein or DNA to trigger toxicities.  The reactivity of the metabolite dets. which cellular nucleophiles are targeted.  The toxicity of a particular furan is also influenced by the presence of competing metabolic pathways or efficient detoxification routes.  GSH plays an important role in modulating the harmful effects of this class of compd. by reacting with the reactive metabolite.  However, this may not represent a detoxification step in all cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp4Dr5stLUSrVg90H21EOLACvtfcHk0lgq7JlHmVtZNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN&md5=fe3a280d0b7a99a436ec619abc1e1fa0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Ftx3003824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003824%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DReactive%2520Metabolites%2520in%2520the%2520Biotransformation%2520of%2520Molecules%2520Containing%2520a%2520Furan%2520Ring%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D6%26epage%3D25%26doi%3D10.1021%2Ftx3003824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>In
addition to the improved
potency of the benzotriazole core, moderate instability had been observed
upon handling of the 1,2,4-triazolopyridine analogues. Because of
the known propensity of similar electron-poor 1,2,4-triazolopyridines
to undergo Dimroth-type rearrangement, we opted to further pursue
the benzotriazole moiety.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=In%0Aaddition+to+the+improved%0Apotency+of+the+benzotriazole+core%2C+moderate+instability+had+been+observed%0Aupon+handling+of+the+1%2C2%2C4-triazolopyridine+analogues.+Because+of%0Athe+known+propensity+of+similar+electron-poor+1%2C2%2C4-triazolopyridines%0Ato+undergo+Dimroth-type+rearrangement%2C+we+opted+to+further+pursue%0Athe+benzotriazole+moiety."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into Regulation of Purinergic Signalling</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2161</span>– <span class="NLM_lpage">2173</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.str.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23142347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2161-2173&author=K.+Knappauthor=M.+Zebischauthor=J.+Pippelauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCllerauthor=N.+Str%C3%A4ter&title=Crystal+Structure+of+the+Human+Ecto-5%E2%80%B2-Nucleotidase+%28CD73%29%3A+Insights+into+Regulation+of+Purinergic+Signalling&doi=10.1016%2Fj.str.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling</span></div><div class="casAuthors">Knapp, Karen; Zebisch, Matthias; Pippel, Jan; El-Tayeb, Ali; Mueller, Christa E.; Straeter, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2161-2173</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In vertebrates ecto-5'-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.  Due to its pivotal role for activation of P1 adenosine receptors, e5NT has emerged as an appealing drug target for treatment of inflammation, chronic pain, hypoxia, and cancer.  Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme.  The dimerization interface is formed by the C-terminal domains and exhibits interchain motions of up to 13°.  Complex structures with adenosine and AMPCP indicate that structural control of the domain movement dets. the selectivity for monophosphate nucleotides.  Binding modes of nucleotide-derived and flavonoid-based compds. complexed to the C-terminal domain in the open form reveal an addnl. binding pocket of ∼210 Å3 that might be explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MOj4dwx2J7Vg90H21EOLACvtfcHk0lgq7JlHmVtZNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK&md5=e108171e8079cca4dd11483dfacb909e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DK.%26aulast%3DZebisch%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%253A%2520Insights%2520into%2520Regulation%2520of%2520Purinergic%2520Signalling%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D2161%26epage%3D2173%26doi%3D10.1016%2Fj.str.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0li5sYtB4b6yNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roversi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Refinement of Severely Incomplete Structures with Maximum Likelihood in BUSTER-TNT</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span>,  <span class="NLM_fpage">2210</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1107/S0907444904016427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444904016427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2210-2221&author=E.+Blancauthor=P.+Roversiauthor=C.+Vonrheinauthor=C.+Flensburgauthor=S.+M.+Leaauthor=G.+Bricogne&title=Refinement+of+Severely+Incomplete+Structures+with+Maximum+Likelihood+in+BUSTER-TNT&doi=10.1107%2FS0907444904016427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT</span></div><div class="casAuthors">Blanc, E.; Roversi, P.; Vonrhein, C.; Flensburg, C.; Lea, S. M.; Bricogne, G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2210-2221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">BUSTER-TNT is a max.-likelihood macromol. refinement package.  BUSTER assembles the structural model, scales obsd. and calcd. structure-factor amplitudes and computes the model likelihood, while TNT handles the stereochem. and NCS restraints/constraints and shifts the at. coordinates, B factors and occupancies.  In real space, in addn. to the traditional at. and bulk-solvent models, BUSTER models the parts of the structure for which an at. model is not yet available ('missing structure') as low-resoln. probability distributions for the random positions of the missing atoms.  In reciprocal space, the BUSTER structure-factor distribution in the complex plane is a two-dimensional Gaussian centered around the structure factor calcd. from the at., bulk-solvent and missing-structure models.  The errors assocd. with these three structural components are added to compute the overall spread of the Gaussian.  When the at. model is very incomplete, modeling of the missing structure and the consistency of the BUSTER statistical model help structure building and completion because (i) the accuracy of the overall scale factors is increased, (ii) the bias affecting at. model refinement is reduced by accounting for some of the scattering from the missing structure, (iii) the addn. of a spatial definition to the source of incompleteness improves on traditional Luzzati and σA-based error models and (iv) the program can perform selective d. modification in the regions of unbuilt structure alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0psykpyEUoLVg90H21EOLACvtfcHk0li5sYtB4b6yNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO&md5=6ea77dcafccd3e87facac18928469bfa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1107%2FS0907444904016427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904016427%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DE.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DLea%26aufirst%3DS.%2BM.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DRefinement%2520of%2520Severely%2520Incomplete%2520Structures%2520with%2520Maximum%2520Likelihood%2520in%2520BUSTER-TNT%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2210%26epage%3D2221%26doi%3D10.1107%2FS0907444904016427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roversi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Refinement of Severely Incomplete Structures with Maximum Likelihood in BUSTER-TNT</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span>,  <span class="NLM_fpage">2210</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1107/S0907444904016427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444904016427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2210-2221&author=E.+Blancauthor=P.+Roversiauthor=C.+Vonrheinauthor=C.+Flensburgauthor=S.+M.+Leaauthor=G.+Bricogne&title=Refinement+of+Severely+Incomplete+Structures+with+Maximum+Likelihood+in+BUSTER-TNT&doi=10.1107%2FS0907444904016427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT</span></div><div class="casAuthors">Blanc, E.; Roversi, P.; Vonrhein, C.; Flensburg, C.; Lea, S. M.; Bricogne, G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2210-2221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">BUSTER-TNT is a max.-likelihood macromol. refinement package.  BUSTER assembles the structural model, scales obsd. and calcd. structure-factor amplitudes and computes the model likelihood, while TNT handles the stereochem. and NCS restraints/constraints and shifts the at. coordinates, B factors and occupancies.  In real space, in addn. to the traditional at. and bulk-solvent models, BUSTER models the parts of the structure for which an at. model is not yet available ('missing structure') as low-resoln. probability distributions for the random positions of the missing atoms.  In reciprocal space, the BUSTER structure-factor distribution in the complex plane is a two-dimensional Gaussian centered around the structure factor calcd. from the at., bulk-solvent and missing-structure models.  The errors assocd. with these three structural components are added to compute the overall spread of the Gaussian.  When the at. model is very incomplete, modeling of the missing structure and the consistency of the BUSTER statistical model help structure building and completion because (i) the accuracy of the overall scale factors is increased, (ii) the bias affecting at. model refinement is reduced by accounting for some of the scattering from the missing structure, (iii) the addn. of a spatial definition to the source of incompleteness improves on traditional Luzzati and σA-based error models and (iv) the program can perform selective d. modification in the regions of unbuilt structure alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0psykpyEUoLVg90H21EOLACvtfcHk0li5sYtB4b6yNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO&md5=6ea77dcafccd3e87facac18928469bfa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1107%2FS0907444904016427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904016427%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DE.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DLea%26aufirst%3DS.%2BM.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DRefinement%2520of%2520Severely%2520Incomplete%2520Structures%2520with%2520Maximum%2520Likelihood%2520in%2520BUSTER-TNT%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2210%26epage%3D2221%26doi%3D10.1107%2FS0907444904016427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgeJRpA-SGg5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ehesan U. Sharif, Jaroslaw Kalisiak, Kenneth V. Lawson, Dillon H. Miles, Eric Newcomb, Erick A. Lindsey, Brandon R. Rosen, Laurent P. P. Debien, Ada Chen, Xiaoning Zhao, Stephen W. Young, Nigel P. Walker, Norbert Sträter, Emma R. Scaletti, Lixia Jin, Guifen Xu, Manmohan R. Leleti, <span class="NLM_string-name hlFld-ContribAuthor">Jay P. Powers</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 845-860. <a href="https://doi.org/10.1021/acs.jmedchem.0c01835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01835%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BMethylenephosphonic%252BAcid%252BCD73%252BInhibitors%26aulast%3DSharif%26aufirst%3DEhesan%2BU.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D20102020%26date%3D05012021%26volume%3D64%26issue%3D1%26spage%3D845%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Abida Ashraf, Zahid Shafiq, Muhammad Siraj Khan Jadoon, Muhammad Nawaz Tahir, Julie Pelletier, Jean Sevigny, Muhammad Yaqub, <span class="NLM_string-name hlFld-ContribAuthor">Jamshed Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Characterization, and In Silico Studies of Novel Spirooxindole Derivatives as Ecto-5′-Nucleotidase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2397-2405. <a href="https://doi.org/10.1021/acsmedchemlett.0c00343" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00343%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%25252C%252BCharacterization%25252C%252Band%252BIn%252BSilico%252BStudies%252Bof%252BNovel%252BSpirooxindole%252BDerivatives%252Bas%252BEcto-5%2525E2%252580%2525B2-Nucleotidase%252BInhibitors%26aulast%3DAshraf%26aufirst%3DAbida%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D23102020%26date%3D29102020%26volume%3D11%26issue%3D12%26spage%3D2397%26epage%3D2405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jenna L. Jeffrey, Kenneth V. Lawson, <span class="NLM_string-name hlFld-ContribAuthor">Jay P. Powers</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13444-13465. <a href="https://doi.org/10.1021/acs.jmedchem.0c01044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01044%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BMetabolism%252Bof%252BExtracellular%252BNucleotides%252Bvia%252BInhibition%252Bof%252BEctonucleotidases%252BCD73%252Band%252BCD39%26aulast%3DJeffrey%26aufirst%3DJenna%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17062020%26date%3D15092020%26date%3D13082020%26volume%3D63%26issue%3D22%26spage%3D13444%26epage%3D13465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Constanze C. Schmies, Georg Rolshoven, Riham M. Idris, Karolina Losenkova, Christian Renn, Laura Schäkel, Haneen Al-Hroub, Yulu Wang, Francesca Garofano, Ingo G. H. Schmidt-Wolf, Herbert Zimmermann, Gennady G. Yegutkin, <span class="NLM_string-name hlFld-ContribAuthor">Christa E. Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorescent Probes for Ecto-5′-nucleotidase (CD73). </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2253-2260. <a href="https://doi.org/10.1021/acsmedchemlett.0c00391" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00391%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFluorescent%252BProbes%252Bfor%252BEcto-5%2525E2%252580%2525B2-nucleotidase%252B%252528CD73%252529%26aulast%3DSchmies%26aufirst%3DConstanze%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13072020%26date%3D03092020%26date%3D09092020%26date%3D03092020%26volume%3D11%26issue%3D11%26spage%3D2253%26epage%3D2260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karel P.  Alcedo</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Bowser</span>, <span class="hlFld-ContribAuthor ">Natasha T.  Snider</span>. </span><span class="cited-content_cbyCitation_article-title">The elegant complexity of mammalian ecto-5′-nucleotidase (CD73). </span><span class="cited-content_cbyCitation_journal-name">Trends in Cell Biology</span><span> <strong>2021,</strong> <em>187 </em><a href="https://doi.org/10.1016/j.tcb.2021.05.008" title="DOI URL">https://doi.org/10.1016/j.tcb.2021.05.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tcb.2021.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tcb.2021.05.008%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cell%2520Biology%26atitle%3DThe%252Belegant%252Bcomplexity%252Bof%252Bmammalian%252Becto-5%2525E2%252580%2525B2-nucleotidase%252B%252528CD73%252529%26aulast%3DAlcedo%26aufirst%3DKarel%2BP.%26date%3D2021%26volume%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Nocentini</span>, <span class="hlFld-ContribAuthor ">Clemente  Capasso</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>22 </em>, 1-10. <a href="https://doi.org/10.1080/13543776.2021.1923694" title="DOI URL">https://doi.org/10.1080/13543776.2021.1923694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1923694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1923694%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252BCD73%252Binhibitors%252Bfor%252Bthe%252Bimmunotherapy%252Bof%252Bcancer%25253A%252Ba%252Bpatent%252Band%252Bliterature%252Breview%252B%2525282017%2525E2%252580%252593present%252529%26aulast%3DNocentini%26aufirst%3DAlessio%26date%3D2021%26date%3D2021%26volume%3D22%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Chuanhao  Wang</span>, <span class="hlFld-ContribAuthor ">Yazhao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yanming  Zhang</span>, <span class="hlFld-ContribAuthor ">Baobao  Chen</span>, <span class="hlFld-ContribAuthor ">Yuelin  Wu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Yao</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>34 </em>, 127758. <a href="https://doi.org/10.1016/j.bmcl.2020.127758" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127758</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127758%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnatural%252Bproduct%252Bellagic%252Bacid%252Bas%252Ba%252Bpotent%252BCD73%252Band%252BCD39%252Bdual%252Binhibitor%26aulast%3DWang%26aufirst%3DYuan%26date%3D2021%26volume%3D34%26spage%3D127758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rayane  Ghoteimi</span>, <span class="hlFld-ContribAuthor ">Abdennour  Braka</span>, <span class="hlFld-ContribAuthor ">Céline  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Emeline  Cros-Perrial</span>, <span class="hlFld-ContribAuthor ">Van  Tai Nguyen</span>, <span class="hlFld-ContribAuthor ">Jean-Pierre  Uttaro</span>, <span class="hlFld-ContribAuthor ">Christophe  Mathé</span>, <span class="hlFld-ContribAuthor ">Laurent  Chaloin</span>, <span class="hlFld-ContribAuthor ">Christine  Ménétrier-Caux</span>, <span class="hlFld-ContribAuthor ">Lars Petter  Jordheim</span>, <span class="hlFld-ContribAuthor ">Suzanne  Peyrottes</span>. </span><span class="cited-content_cbyCitation_article-title">4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104577. <a href="https://doi.org/10.1016/j.bioorg.2020.104577" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104577%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D4-Substituted-1%25252C2%25252C3-triazolo%252Bnucleotide%252Banalogues%252Bas%252BCD73%252Binhibitors%25252C%252Btheir%252Bsynthesis%25252C%252Bin%252Bvitro%252Bscreening%25252C%252Bkinetic%252Band%252Bin%252Bsilico%252Bstudies%26aulast%3DGhoteimi%26aufirst%3DRayane%26date%3D2021%26volume%3D107%26spage%3D104577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Veronica  Salmaso</span>, <span class="hlFld-ContribAuthor ">R. Rama  Suresh</span>, <span class="hlFld-ContribAuthor ">Dilip K.  Tosh</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1039/D1MD00167A" title="DOI URL">https://doi.org/10.1039/D1MD00167A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00167A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00167A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DExpanding%252Bthe%252Brepertoire%252Bof%252Bmethanocarba%252Bnucleosides%252Bfrom%252Bpurinergic%252Bsignaling%252Bto%252Bdiverse%252Btargets%26aulast%3DJacobson%26aufirst%3DKenneth%2BA.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Potent nucleotide inhibitors of CD73 and the initial HTS hit A0001999.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>N</i>-Phenyl and <i>N</i>-benzyl pyrazoles identified as promising starting points for further optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structures of inhibitors bound to recombinant human CD73. (A) Cocrystal structure of compound <b>73</b> (green, 1.94 Å resolution, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE">6XUE</a>). (B) Overlay of <b>74</b> (green) with the cocrystal structure of compound <b>53</b> (2.09 Å resolution, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>). (C) Published cocrystal structure of AMPCP <b>1</b> (cyan, 2 Å resolution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H2I">4H2I</a>). (D) Overlay of the two cocrystal structures of <b>74</b> (green) and AMPCP <b>1</b> (cyan, superimposed based on the C-terminal domain) shows close alignment of hydrogen bonding motifs. See the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a> for further details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of A0001999 Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) two steps (i) 3-hydroxybenzaldehyde, EtOH, reflux. (ii) PIDA, CH<sub>2</sub>Cl<sub>2</sub>, 21%, 2 steps. (b) for compounds <b>4</b>, <b>25</b>–<b>27</b>, <b>30</b>–<b>31</b>, <b>33</b>–<b>35</b>, aryl boronate, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF or dioxane, 75–100 °C. (c) for compound <b>28</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2-(tri-<i>n</i>-butyl stannyl)oxazole, toluene, 90 °C. (d) for compound <b>29</b>, (i) trimethylsilylacetylene, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Et<sub>3</sub>N, DMF, 80 °C, 35%. (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, 36%. (iii) NaN<sub>3</sub>, HCHO, AcOH, CuSO<sub>4</sub>, Na Ascorbate, THF. (e) For compound <b>32</b>, CuI, pyrazole, <i>N</i>,<i>N</i>′-dimethylethylenediamine, K<sub>2</sub>CO<sub>3</sub>, DMF (f) two steps (i) triethyl orthoformate, <i>p</i>TsOH, 80 °C, 79%. (ii) NCS, DMF, 50 °C, 60%. (g) furan-3-boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, 75 °C, 61%. (h) for compounds <b>14</b>–<b>24</b>, aryl boronate, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, or dioxane, 75–100 °C. (i) 3-Aminophenol, <i>N,N</i>-diisopropylethylamine, NMP, 100 °C, 60%. (j) AcOH, EtOH, Fe powder, 60 °C. (k) AcOH, 5 N HCl, NaNO<sub>2</sub>, 0 °C, 9%. (l) Furan-3-boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), THF, 75 °C, 71%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Early C4-Substituted Analogues<sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-aminophenol, <i>N,N</i>-diisopropylethylamine, NMP, 100 °C. (b) SnCl<sub>2</sub>, EtOH, EtOAc, 70 °C. (c) Isoamyl nitrite, acetonitrile. (d) 1-Methylpyrazole-5-boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 68%. (aq.), THF, 75 °C. (e) For compounds <b>37</b>–<b>39</b>, Pd-BrettPhos-G3, BrettPhos, amine, LiHMDS, THF, 70 °C. (f) For compound <b>40</b>, Pd-BrettPhos-G3, BrettPhos, NaOMe, MeOH, THF, 70 °C, 33%. (g) For compound <b>42</b>, Zn(CN)<sub>2</sub>, Pd-BrettPhos-G3, BrettPhos, THF, 70 °C, 58%. (h) For compounds <b>44</b> and <b>45</b>: (i) Vinylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), dioxane, 110 °C, 82%. (ii) For compound <b>45</b>, Pd/C, H<sub>2</sub> (1 atm), MeOH, 68%.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compounds <b>36</b> and <b>43</b> were synthesized in an analogous fashion from 4-bromo-2-fluoro-1-nitro benzene and 5-bromo-1-fluoro-3-methyl-2-nitrobenzene, respectively.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Vinylogous Amide Synthesis and Pyrazole Formation in the Indazole Series<sup>a</sup><sup>,</sup><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 6-aminoindazole, Et<sub>3</sub>N, DMSO, 65 °C, 75%. (b) SnCl<sub>2</sub>, EtOAc, EtOH, 70 °C; (c) isoamyl nitrite, MeCN, 65 °C, 60%, 2 steps. (d) butyl vinyl ether, Pd(OAc)<sub>2</sub>, dppf, ethylene glycol, Et<sub>3</sub>N; then HCl, 82%. (e) DMF-DMA, 100 °C, 45%. (f) Aryl or benzyl hydrazine hydrochloride, EtOH, 80 °C.</p><p class="last"><span class="fn-label"><sup>b</sup></span>C4-halogenated compounds were derived through a similar sequence. See the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf" class="ext-link">Supporting Information</a>.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Vinylogous Amide Synthesis and Pyrazole Formation in the Benzimidazolone Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-aminobenzimidazolone, Et<sub>3</sub>N, DMSO, 90 °C. (b) SnCl<sub>2</sub>, EtOAc, EtOH, 80 °C. (c) isoamyl nitrite, MeCN, 60 °C. (d) SEM-Cl, methyl dicyclohexylamine, THF, 24%, 4 steps (X = Cl). (e) PdCl<sub>2</sub>(dppf), isopropenyl boronic acid pinacol ester, 100 °C, 87% (X = Cl). (f) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, 2,6-lutidine, THF, H<sub>2</sub>O. (g) DMF-DMA, 100 °C, 70%, 2 steps (X = Cl). (h) benzyl hydrazine dihydrochloride, EtOH, 80 °C (i) TFA, H<sub>2</sub>O, then DMEDA, MeOH, 45 °C.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/medium/jm9b01713_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0008.jpeg" id="rightTab-GRAPHIC-d7e1857-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Indazole <b>81</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01713/20200416/images/large/jm9b01713_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01713&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, MeCN, 60 °C, 99%. (b) Isopropenylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq.), dioxane, 100 °C, 35%. (c) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 2,6-lutidine, THF, H<sub>2</sub>O. (d) DMF-DMA, 100 °C, 3%, 2 steps. (e) [(2,4-Dichlorophenyl)methyl]-hydrazine hydrochloride, EtOH, 80 °C, 54%. (f) CuI, DMEDA, 6-iodo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole, DMF, 110 °C, 4%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1111/imr.12528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1111%2Fimr.12528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=28258700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1eltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2017&pages=121-144&author=B.+Allardauthor=M.+S.+Longhiauthor=S.+C.+Robsonauthor=J.+Stagg&title=The+Ectonucleotidases+CD39+and+CD73%3A+Novel+Checkpoint+Inhibitor+Targets&doi=10.1111%2Fimr.12528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets</span></div><div class="casAuthors">Allard, Bertrand; Longhi, Maria Serena; Robson, Simon C.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-144</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign.  This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state.  Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection-type processes or blocking suppressive pathways.  Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor immune responses.  In this review, we focus on CD39 and CD73 ectoenzymes and encompass aspects of the biochem. of these mols. as well as detailing the distribution and function on immune cells.  Effects of CD39 and CD73 inhibition in preclin. and clin. studies are discussed.  Finally, we provide insights into potential clin. application of adenosinergic and other purinergic-targeting therapies and forecast how these might develop in combination with other anti-cancer modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLKxqHb6HnbVg90H21EOLACvtfcHk0li6wXQpM0SkDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1eltL8%253D&md5=1f2c1bf632b238d6b7d9d7c46cea77c5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fimr.12528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12528%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DLonghi%26aufirst%3DM.%2BS.%26aulast%3DRobson%26aufirst%3DS.%2BC.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DThe%2520Ectonucleotidases%2520CD39%2520and%2520CD73%253A%2520Novel%2520Checkpoint%2520Inhibitor%2520Targets%26jtitle%3DImmunol.%2520Rev.%26date%3D2017%26volume%3D276%26spage%3D121%26epage%3D144%26doi%3D10.1111%2Fimr.12528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">CD39 and CD73 in Immunity and Inflamation</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2013.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.molmed.2013.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23601906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=355-367&author=L.+Antonioliauthor=P.+Pacherauthor=S.+Viziauthor=G.+Hask%C3%B3&title=CD39+and+CD73+in+Immunity+and+Inflamation&doi=10.1016%2Fj.molmed.2013.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">CD39 and CD73 in immunity and inflammation</span></div><div class="casAuthors">Antonioli, Luca; Pacher, Pal; Vizi, E. Sylvester; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The enzymic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chem. nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, resp.  This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine.  The CD39/CD73 pathway changes dynamically with the pathophysiol. context in which it is embedded.  It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiol. events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmWiFFVp_ddbVg90H21EOLACvtfcHk0li6wXQpM0SkDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFamtLg%253D&md5=75d0f7627b3b8a5dd81fd3a76992af2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2013.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2013.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DVizi%26aufirst%3DS.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DCD39%2520and%2520CD73%2520in%2520Immunity%2520and%2520Inflamation%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D355%26epage%3D367%26doi%3D10.1016%2Fj.molmed.2013.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanin, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelweiss, M. I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M. O.</span></span> <span> </span><span class="NLM_article-title">Ectonucleotidases in Tumor Cells and Tumor-Associated Immune Cells: An Overview</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">959848</span>, <span class="refDoi"> DOI: 10.1155/2012/959848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1155%2F2012%2F959848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23118517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BC3s7gtFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=959848&author=L.+S.+Bergaminauthor=E.+Braganholauthor=R.+F.+Zaninauthor=M.+I.+A.+Edelweissauthor=A.+M.+O.+Battastini&title=Ectonucleotidases+in+Tumor+Cells+and+Tumor-Associated+Immune+Cells%3A+An+Overview&doi=10.1155%2F2012%2F959848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview</span></div><div class="casAuthors">Bergamin Leticia Scussel; Braganhol Elizandra; Zanin Rafael Fernandes; Edelweiss Maria Isabel Albano; Battastini Ana Maria Oliveira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">959848</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence points out that genetic alteration does not guarantee the development of a tumor and indicates that complex interactions of tumor cells with the microenvironment are fundamental to tumorigenesis.  Among the pathological alterations that give tumor cells invasive potential, disruption of inflammatory response and the purinergic signaling are emerging as an important component of cancer progression.  Nucleotide/nucleoside receptor-mediated cell communication is orchestrated by ectonucleotidases, which efficiently hydrolyze ATP, ADP, and AMP to adenosine.  ATP can act as danger signaling whereas adenosine, acts as a negative feedback mechanism to limit inflammation.  Many tumors exhibit alterations in ATP-metabolizing enzymes, which may contribute to the pathological events observed in solid cancer.  In this paper, the main changes occurring in the expression and activity of ectonucleotidases in tumor cells as well as in tumor-associated immune cells are discussed.  Furthermore, we focus on the understanding of the purinergic signaling primarily as exemplified by research done by the group on gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGVDLyUgDPhPSAs_PE1QvifW6udTcc2eZxjJaipi-0QLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7gtFejtQ%253D%253D&md5=5cce519ac9fc74e5754451e1aebcb5f9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1155%2F2012%2F959848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F959848%26sid%3Dliteratum%253Aachs%26aulast%3DBergamin%26aufirst%3DL.%2BS.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DZanin%26aufirst%3DR.%2BF.%26aulast%3DEdelweiss%26aufirst%3DM.%2BI.%2BA.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%2BO.%26atitle%3DEctonucleotidases%2520in%2520Tumor%2520Cells%2520and%2520Tumor-Associated%2520Immune%2520Cells%253A%2520An%2520Overview%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2012%26volume%3D2012%26spage%3D959848%26doi%3D10.1155%2F2012%2F959848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H</span></span> <span> </span><span class="NLM_article-title">5′-Nucleotidase: Molecular Structure and Functional Aspects</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1042/bj2850345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1042%2Fbj2850345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1992&pages=345-365&author=H+Zimmermann&title=5%E2%80%B2-Nucleotidase%3A+Molecular+Structure+and+Functional+Aspects&doi=10.1042%2Fbj2850345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2Fbj2850345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2850345%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DH%26atitle%3D5%25E2%2580%25B2-Nucleotidase%253A%2520Molecular%2520Structure%2520and%2520Functional%2520Aspects%26jtitle%3DBiochem.%2520J.%26date%3D1992%26volume%3D15%26spage%3D345%26epage%3D365%26doi%3D10.1042%2Fbj2850345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-Nucleotidase: Structure Function Relationships</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1007/s11302-006-9000-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2Fs11302-006-9000-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18404474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ktl2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=343-350&author=N.+Str%C3%A4ter&title=Ecto-5%E2%80%B2-Nucleotidase%3A+Structure+Function+Relationships&doi=10.1007%2Fs11302-006-9000-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase: Structure function relationships</span></div><div class="casAuthors">Strater Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic signalling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-50</span>
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT) is attached via a GPI anchor to the extracellular membrane, where it hydrolyses AMP to adenosine and phosphate.  Related 5'-nucleotidases exist in bacteria, where they are exported into the periplasmic space.  X-ray structures of the 5'-nucleotidase from E. coli showed that the enzyme consists of two domains.  The N-terminal domain coordinates two catalytic divalent metal ions, whereas the C-terminal domain provides the substrate specificity pocket for the nucleotides.  Thus, the substrate binds at the interface of the two domains.  Here, the currently available structural information on ecto-5'-NT is reviewed in relation to the catalytic properties and enzyme function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDd9tlAyIrzEC-75aqa5AfW6udTcc2eYpTMVrUF6k4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ktl2iug%253D%253D&md5=6b3bf983438fc270d35f8e9cf6d467ed</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11302-006-9000-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-006-9000-8%26sid%3Dliteratum%253Aachs%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DEcto-5%25E2%2580%25B2-Nucleotidase%253A%2520Structure%2520Function%2520Relationships%26jtitle%3DPurinergic%2520Signalling%26date%3D2006%26volume%3D2%26spage%3D343%26epage%3D350%26doi%3D10.1007%2Fs11302-006-9000-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="note"><p class="first last">CD73 in Various Tumor Types:</p></div><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavaresco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockenbach, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azambuja, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliviero
Battastini, A. M.</span></span> <span> </span><span class="NLM_article-title">Differential Extonucleotidase Expression in Human Bladder Cancer Cell Lines</span>. <i>Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2009.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.urolonc.2009.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=19372055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVOmsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=260-267&author=J.+Stellaauthor=L.+Bavarescoauthor=E.+Braganholauthor=L.+Rockenbachauthor=P.+F.+Fariasauthor=M.+R.+Winkauthor=A.+A.+Azambujaauthor=C.+H.+Barriosauthor=F.+B.+Morroneauthor=A.+M.+Oliviero%0ABattastini&title=Differential+Extonucleotidase+Expression+in+Human+Bladder+Cancer+Cell+Lines&doi=10.1016%2Fj.urolonc.2009.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Differential ectonucleotidase expression in human bladder cancer cell lines</span></div><div class="casAuthors">Stella, Joseli; Bavaresco, Luci; Braganhol, Elizandra; Rockenbach, Liliana; Farias, Patricia Fernandes; Wink, Marcia R.; Azambuja, Alan A.; Barrios, Carlos Henrique; Morrone, Fernanda Bueno; Oliveira Battastini, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-267</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Bladder cancer is the most prevalent tumor in the genitourinary tract.  Nucleotides are important mols. that regulate many pathophysiol. functions in the extracellular space.  Studies have revealed evidence of a relationship between purinergic signaling and urothelial malignancies.  Nucleotide-mediated signaling is controlled by a highly efficient enzymic cascade, which includes the members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDases), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPPs), ecto-alk. phosphatases, and ecto-5'-nucleotidase/CD73.  In an attempt to identify possible differential expression of ectonucleotidases during bladder cancer progression, a comparative anal. between RT4 (grade 1) and T24 (grade 3) bladder cancer cell lines was performed.  In RT4 cells, the hydrolysis of tri- and diphosphate nucleosides was higher than monophosphonucleosides.  T24 cells, however, presented the opposite profile, a low level of hydrolysis of tri- and diphosphate nucleosides and a high level of hydrolysis of monophosphates.  Phosphodiesterase activity was negligible in both cell lines at physiol. pH, indicating that these enzymes are not active under our assay conditions, although they are expressed in both cell lines.  The T24 cells expressed NTPDase5 mRNA, while the RT4 cells expressed NTPDase3 and NTPDase5 mRNA.  Both cell lines expressed ecto-5'-nucleotidase/CD73 mRNA.  The present work describes, for the first time, the differential pattern of ectonucleotidases in the more malignant bladder cancer cells compared with cells derived from an early stage of bladder cancer.  Our results open new avenues for research into the physiol. roles of this family of enzymes and their possible therapeutic potential in bladder cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB77YBtzfiLVg90H21EOLACvtfcHk0ljujVKQcpqPRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVOmsL4%253D&md5=d3c5ea8b4bbd11ad239ef20872a098dd</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2009.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2009.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DJ.%26aulast%3DBavaresco%26aufirst%3DL.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DRockenbach%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DP.%2BF.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DAzambuja%26aufirst%3DA.%2BA.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DMorrone%26aufirst%3DF.%2BB.%26aulast%3DOliviero%2BBattastini%26aufirst%3DA.%2BM.%26atitle%3DDifferential%2520Extonucleotidase%2520Expression%2520in%2520Human%2520Bladder%2520Cancer%2520Cell%2520Lines%26jtitle%3DUrol.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D260%26epage%3D267%26doi%3D10.1016%2Fj.urolonc.2009.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolovskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amdahl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahesmaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokhin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, J. E.</span></span> <span> </span><span class="NLM_article-title">CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.181.1.464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.4049%2Fjimmunol.181.1.464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18566412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVGisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=464-475&author=A.+Mikhailovauthor=A.+Sokolovskayaauthor=G.+G.+Yegutkinauthor=H.+Amdahlauthor=A.+Westauthor=H.+Yagitaauthor=R.+Lahesmaaauthor=L.+F.+Thompsonauthor=S.+Jalkanenauthor=D.+Blokhinauthor=J.+E.+Eriksson&title=CD73+Participates+in+Cellular+Multiresistance+Program+and+Protects+against+TRAIL-Induced+Apoptosis&doi=10.4049%2Fjimmunol.181.1.464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis</span></div><div class="casAuthors">Mikhailov, Andrey; Sokolovskaya, Alice; Yegutkin, Gennady G.; Amdahl, Hanne; West, Anne; Yagita, Hideo; Lahesmaa, Riitta; Thompson, Linda F.; Jalkanen, Sirpa; Blokhin, Dmitry; Eriksson, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">464-475</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The mol. mechanisms underlying the multiresistant phenotype of leukemic and other cancer cells are incompletely understood.  The authors used expression arrays to reveal differences in the gene expression profiles of an apoptosis-resistant T cell leukemia clone (A4) and normally apoptosis-sensitive parental Jurkat cells.  CD73 (ecto-5'-nucleotidase) was the most up-regulated gene in the resistant A4 cell clone.  A4 cells displayed CD73 surface expression and significant ecto-5'-nucleotidase activity.  The role of CD73 was confirmed by transfection of wild-type CD73 into native Jurkat cells, which led to specific resistance against TRAIL-induced apoptosis, but not other types of apoptosis.  The protective role of CD73 was further confirmed by small interfering RNA-mediated down-regulation of CD73, restoring TRAIL sensitivity.  CD73-mediated resistance was independent of enzymic activity of CD73, but was reliant on the anchoring of the protein to the membrane via GPI.  The authors suggest that the inhibition of TRAIL signaling works via interaction of CD73 with death receptor 5, as CD73 and death receptor 5 could be coimmunopptd. and were shown to be colocalized in the plasma membrane by confocal microscopy.  The authors propose that CD73 is a component of multiresistance machinery, the transcription of which is activated under selective pressure of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_qOj89hIrbVg90H21EOLACvtfcHk0ljujVKQcpqPRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVGisrs%253D&md5=dd634ff533a4ac4fe201417c99c57881</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.464%26sid%3Dliteratum%253Aachs%26aulast%3DMikhailov%26aufirst%3DA.%26aulast%3DSokolovskaya%26aufirst%3DA.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DAmdahl%26aufirst%3DH.%26aulast%3DWest%26aufirst%3DA.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DLahesmaa%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DJalkanen%26aufirst%3DS.%26aulast%3DBlokhin%26aufirst%3DD.%26aulast%3DEriksson%26aufirst%3DJ.%2BE.%26atitle%3DCD73%2520Participates%2520in%2520Cellular%2520Multiresistance%2520Program%2520and%2520Protects%2520against%2520TRAIL-Induced%2520Apoptosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D464%26epage%3D475%26doi%3D10.4049%2Fjimmunol.181.1.464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bavaresco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappellari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockenbach, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Cañedo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.</span></span> <span> </span><span class="NLM_article-title">The Role of Ecto-5′-nucleotidase/CD73 in Glioma Cell Line Proliferation</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1007/s11010-008-9877-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2Fs11010-008-9877-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=18636315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Krtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2008&pages=61-68&author=L.+Bavarescoauthor=A.+Bernardiauthor=E.+Braganholauthor=A.+R.+Cappellariauthor=L.+Rockenbachauthor=P.+F.+Fariasauthor=M.+R.+Winkauthor=A.+Delgado-Ca%C3%B1edoauthor=A.+M.+Battastini&title=The+Role+of+Ecto-5%E2%80%B2-nucleotidase%2FCD73+in+Glioma+Cell+Line+Proliferation&doi=10.1007%2Fs11010-008-9877-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation</span></div><div class="casAuthors">Bavaresco, Luci; Bernardi, Andressa; Braganhol, Elizandra; Cappellari, Angelica Regina; Rockenbach, Liliana; Farias, Patricia Fernandes; Wink, Marcia Rosangela; Delgado-Canedo, Andres; Battastini, Ana Maria Oliveira</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Malignant gliomas are the most common and devastating primary tumors in the brain and, despite treatment, patients with these tumors have a poor prognosis.  The participation of ecto-5'-NT/CD73 per se as a proliferative factor, being involved in the control of cell growth, differentiation, invasion, migration, and metastasis processes was previously proposed.  In the present study, we evaluated the activity and functions of ecto-5'-NT/CD73 during the proliferation process of rat C6 and human U138MG glioma cell lines.  Increasing confluences and culture times led to an increase in ecto-5'-NT/CD73 activity in both C6 and U138MG glioma cells.  RT-PCR anal. and flow cytometry anal. showed a significant increase in ecto-5'-NT/CD73 mRNA and protein levels, resp., comparing confluent with sub-confluent cultures in human U138MG glioma cells.  Ecto-5'-nucleotidase/CD73 may regulate the extracellular AMP and adenosine levels.  Treatment with 1 μM APCP, a competitive ecto-5'-NT/CD73 inhibitor, caused a significant redn. of 30% in glioma cell proliferation.  In addn., 100 μM adenosine increases cell proliferation by 36%, and the treatment with adenosine plus NBTI and dipyridamole, produced an addnl. and significant increase of on cell proliferation.  The inhibitory effect on cell proliferation caused by APCP was reverted by co-treatment with NBTI and dipyridamole.  AMP (1 and 3 mM) decreased U138MG glioma cell proliferation by 29 and 42%, resp.  Taken together, these results suggest the participation of ecto-5'-NT/CD73 in cell proliferation and that this process is dependent upon the enzyme's prodn. of adenosine, a proliferative factor, and removal of AMP, a toxic mol. for gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolZzz6ix_mBLVg90H21EOLACvtfcHk0li2jRBaaYl23w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Krtr7I&md5=c803d93aaf616fca668bef9775f16828</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1007%2Fs11010-008-9877-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-008-9877-3%26sid%3Dliteratum%253Aachs%26aulast%3DBavaresco%26aufirst%3DL.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DCappellari%26aufirst%3DA.%2BR.%26aulast%3DRockenbach%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DP.%2BF.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DDelgado-Ca%25C3%25B1edo%26aufirst%3DA.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Role%2520of%2520Ecto-5%25E2%2580%25B2-nucleotidase%252FCD73%2520in%2520Glioma%2520Cell%2520Line%2520Proliferation%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D319%26spage%3D61%26epage%3D68%26doi%3D10.1007%2Fs11010-008-9877-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sadej, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spychala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A. C.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-nucleotidase (eN, CD73) is Coexpressed with Metastasis Promoting Antigens in Human Melanoma Cells</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1080/15257770600894188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1080%2F15257770600894188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=17065075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Wrsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1119-1123&author=R.+Sadejauthor=J.+Spychalaauthor=A.+C.+Skladanowski&title=Ecto-5%E2%80%B2-nucleotidase+%28eN%2C+CD73%29+is+Coexpressed+with+Metastasis+Promoting+Antigens+in+Human+Melanoma+Cells&doi=10.1080%2F15257770600894188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells</span></div><div class="casAuthors">Sadej, R.; Spychala, J.; Skladanowski, A. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9-11</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Upregulated expression of eN has been found in the highly invasive human melanoma cell lines but neither in melanocytes nor in primary tumor cells.  Membrane proteins assocd. with cell adhesion and metastasis: α5-, β1-, β3-integrins, and CD44 were elevated gradually in accordance with increasing metastatic potential.  αν-Integrin was seen mostly in aggressive melanomas.  The expression of eN correlated with a no. of metastasis-related markers and thus may have a function in the process.  EN activity went parallel with its amt. in all cells.  Con A strongly inhibited the enzyme in a noncompetitive way.  Clustering of eN protein in overexpressing cells by ConA-treatment increased the enzyme assocn. with the heavy cytoskeletal complexes.  A similar shift towards cytoskeletal fractions took also place with other membrane proteins coexpressed with eN.  This ConA-induced assocn. may reflect a putative interaction of eN with physiol. ligand, that upon interaction, aggregates protein components of lipid rafts and triggers signaling pathway that may be intrinsically involved in cell-stroma adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0HryZbVEX7Vg90H21EOLACvtfcHk0li2jRBaaYl23w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Wrsr3O&md5=b09ead652fbb38f1ab9ef4d6270d1690</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1080%2F15257770600894188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15257770600894188%26sid%3Dliteratum%253Aachs%26aulast%3DSadej%26aufirst%3DR.%26aulast%3DSpychala%26aufirst%3DJ.%26aulast%3DSkladanowski%26aufirst%3DA.%2BC.%26atitle%3DEcto-5%25E2%2580%25B2-nucleotidase%2520%2528eN%252C%2520CD73%2529%2520is%2520Coexpressed%2520with%2520Metastasis%2520Promoting%2520Antigens%2520in%2520Human%2520Melanoma%2520Cells%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2006%26volume%3D25%26spage%3D1119%26epage%3D1123%26doi%3D10.1080%2F15257770600894188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, R.</span></span> <span> </span><span class="NLM_article-title">Expression of CD73 and its Ecto-5′-nucleotidase Activity are Elevated in Papillary Thyroid Carcinomas</span>. <i>Histopathology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2559.2005.02277.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1111%2Fj.1365-2559.2005.02277.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=16623792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BD283hslCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2006&pages=612-614&author=T.+Kondoauthor=T.+Nakazawaauthor=S.+I.+Murataauthor=R.+Katoh&title=Expression+of+CD73+and+its+Ecto-5%E2%80%B2-nucleotidase+Activity+are+Elevated+in+Papillary+Thyroid+Carcinomas&doi=10.1111%2Fj.1365-2559.2005.02277.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas</span></div><div class="casAuthors">Kondo T; Nakazawa T; Murata S-I; Katoh R</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">612-4</span>
        ISSN:<span class="NLM_cas:issn">0309-0167</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRntiSnVgZzq-9TkgmBqTqfW6udTcc2ead7rFfX41vD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283hslCrsA%253D%253D&md5=b9310174d876d8aa9b6c94bea3788dd8</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2005.02277.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2005.02277.x%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DNakazawa%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DS.%2BI.%26aulast%3DKatoh%26aufirst%3DR.%26atitle%3DExpression%2520of%2520CD73%2520and%2520its%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520Activity%2520are%2520Elevated%2520in%2520Papillary%2520Thyroid%2520Carcinomas%26jtitle%3DHistopathology%26date%3D2006%26volume%3D48%26spage%3D612%26epage%3D614%26doi%3D10.1111%2Fj.1365-2559.2005.02277.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, J. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naaby-Hansen, S.</span></span> <span> </span><span class="NLM_article-title">Combined Affinity Labelling and Mass Spectrometry Analysis of Differential Cell Surface Protein Expression in Normal and Prostate Cancer Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5905</span>– <span class="NLM_lpage">5913</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1038%2Fsj.onc.1208747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=16007208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslakur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=5905-5913&author=C.+Hastieauthor=M.+Saxtonauthor=A.+Akpanauthor=R.+Cramerauthor=J.+R+Mastersauthor=S.+Naaby-Hansen&title=Combined+Affinity+Labelling+and+Mass+Spectrometry+Analysis+of+Differential+Cell+Surface+Protein+Expression+in+Normal+and+Prostate+Cancer+Cells&doi=10.1038%2Fsj.onc.1208747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Combined affinity labeling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells</span></div><div class="casAuthors">Hastie, Claire; Saxton, Malcolm; Akpan, Akunna; Cramer, Rainer; Masters, John R.; Naaby-Hansen, Soren</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5905-5913</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated.  A combination of affinity chromatog. purifn. of biotin-tagged surface proteins with mass spectrometry anal. identified 26 integral membrane proteins and 14 peripheral surface proteins.  The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein.  In addn., several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.  Cell surface protein expression changed both qual. and quant. when the cells were grown in the presence of either or both interferon INFα and INFγ.  Co-stimulation with type I and II interferons had additive or synergistic effects on the membrane d. of several, mainly peripherally attached surface proteins.  Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer.  In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labeling with biotin, and that detailed anal. of extracellular-induced surface changes can be achieved by combining surface-specific labeling with high-resoln. two-dimensional gel electrophoresis and mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0_wJjdIh3bVg90H21EOLACvtfcHk0ljae_-cYNEfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslakur8%253D&md5=2cf858c65e4e20dcd8ae44ded46e12d4</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208747%26sid%3Dliteratum%253Aachs%26aulast%3DHastie%26aufirst%3DC.%26aulast%3DSaxton%26aufirst%3DM.%26aulast%3DAkpan%26aufirst%3DA.%26aulast%3DCramer%26aufirst%3DR.%26aulast%3DMasters%26aufirst%3DJ.%2BR%26aulast%3DNaaby-Hansen%26aufirst%3DS.%26atitle%3DCombined%2520Affinity%2520Labelling%2520and%2520Mass%2520Spectrometry%2520Analysis%2520of%2520Differential%2520Cell%2520Surface%2520Protein%2520Expression%2520in%2520Normal%2520and%2520Prostate%2520Cancer%2520Cells%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D5905%26epage%3D5913%26doi%3D10.1038%2Fsj.onc.1208747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spychala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarowski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapkowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscue, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, B. S.</span></span> <span> </span><span class="NLM_article-title">Role of Estrogen Receptor in the Regulation of Ecto-5′-nucleotidase and Adenosine in Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0811-03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1158%2F1078-0432.CCR-0811-03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=14760094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=708-717&author=J.+Spychalaauthor=E.+Lazarowskiauthor=A.+Ostapkowiczauthor=L.+H.+Ayscueauthor=A.+Jinauthor=B.+S.+Mitchell&title=Role+of+Estrogen+Receptor+in+the+Regulation+of+Ecto-5%E2%80%B2-nucleotidase+and+Adenosine+in+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-0811-03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Estrogen Receptor in the Regulation of Ecto-5'-Nucleotidase and Adenosine in Breast Cancer</span></div><div class="casAuthors">Spychala, Jozef; Lazarowski, Eduardo; Ostapkowicz, Anna; Ayscue, Lanier H.; Jin, Aiwen; Mitchell, Beverly S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose is to understand the expression of ecto-5'-nucleotidase (eN), an adenosine producing enzyme with potential roles in angiogenesis, growth, and immunosuppression, in estrogen receptor (ER)-neg. and -pos. breast cancer.  We investigated the regulation of eN expression at the mRNA and protein levels by ERα in a panel of breast cancer cell lines that differ in ER status and invasive and metastatic potential.  We also detd. rates of adenosine formation in cells with high and low eN expression and in ER+ cells treated with estradiol.  ER-neg. cells express high eN protein and mRNA levels and produce up to 104-fold more adenosine from AMP and ATP.  Estradiol and antiestrogen treatments confirm that eN mRNA and protein expression and adenosine generation are neg. regulated through the ER.  Endogenous expression of eN in ER- cells transfected with ERα and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.  Finally, an examn. of 18 clin. breast cancer samples that were analyzed for both ER status and eN expression by Martin et al. (Cancer Res., 60: 2232-2238, 2000) revealed a significant inverse correlation between ER and eN status.  Our results show for the first time that eN is neg. regulated by ERα in dominant fashion and suggests that eN expression and its generation of adenosine may relate to breast cancer progression.  Addnl., increased expression of eN in a subset of ER-neg. cells may serve as a novel marker for a subset of more aggressive breast carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNbxpxmDuR7bVg90H21EOLACvtfcHk0ljae_-cYNEfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKjtQ%253D%253D&md5=650a16c3bc23292da652c66e1ebac6ff</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0811-03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0811-03%26sid%3Dliteratum%253Aachs%26aulast%3DSpychala%26aufirst%3DJ.%26aulast%3DLazarowski%26aufirst%3DE.%26aulast%3DOstapkowicz%26aufirst%3DA.%26aulast%3DAyscue%26aufirst%3DL.%2BH.%26aulast%3DJin%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DB.%2BS.%26atitle%3DRole%2520of%2520Estrogen%2520Receptor%2520in%2520the%2520Regulation%2520of%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520and%2520Adenosine%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D708%26epage%3D717%26doi%3D10.1158%2F1078-0432.CCR-0811-03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Extracellular Adenosine Triphosphate and Adenosine in Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5346</span>– <span class="NLM_lpage">5358</span>, <span class="refDoi"> DOI: 10.1038/onc.2010.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1038%2Fonc.2010.292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20661219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=5346-5358&author=J.+Staggauthor=M.+J.+Smyth&title=Extracellular+Adenosine+Triphosphate+and+Adenosine+in+Cancer&doi=10.1038%2Fonc.2010.292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular adenosine triphosphate and adenosine in cancer</span></div><div class="casAuthors">Stagg, J.; Smyth, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5346-5358</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ATP is actively released in the extracellular environment in response to tissue damage and cellular stress.  Through the activation of P2X and P2Y receptors, extracellular ATP enhances tissue repair, promotes the recruitment of immune phagocytes and dendritic cells, and acts as a co-activator of NLR family, pyrin domain-contg. 3 (NLRP3) inflammasomes.  The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymic activity of the ecto-nucleotidases CD39 and CD73, acts as a neg.-feedback mechanism to prevent excessive immune responses.  Here we review the effects of extracellular ATP and adenosine on tumorigenesis.  First, we summarize the functions of extracellular ATP and adenosine in the context of tumor immunity.  Second, we present an overview of the immunosuppressive and pro-angiogenic effects of extracellular adenosine.  Third, we present exptl. evidence that extracellular ATP and adenosine receptors are expressed by tumor cells and enhance tumor growth.  Finally, we discuss recent studies, including our own work, which suggest that therapeutic approaches that promote ATP-mediated activation of inflammasomes, or inhibit the accumulation of tumor-derived extracellular adenosine, may constitute effective new means to induce anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3-xCzFIxqLbVg90H21EOLACvtfcHk0ljae_-cYNEfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtbY%253D&md5=8906a4a1f59f7a66cb183aca41b1f2cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.292%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DExtracellular%2520Adenosine%2520Triphosphate%2520and%2520Adenosine%2520in%2520Cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D5346%26epage%3D5358%26doi%3D10.1038%2Fonc.2010.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Switching off CD73; A Way to Boost the Activity of Conventional and Targeted Antineoplastic Therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.drudis.2017.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=28676406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCmurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1686-1696&author=L.+Antonioliauthor=S.+V.+Novitskiyauthor=K.+F.+Sachsenmeierauthor=M.+Fornaiauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Switching+off+CD73%3B+A+Way+to+Boost+the+Activity+of+Conventional+and+Targeted+Antineoplastic+Therapies&doi=10.1016%2Fj.drudis.2017.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies</span></div><div class="casAuthors">Antonioli, Luca; Novitskiy, Sergey V.; Sachsenmeier, Kris F.; Fornai, Matteo; Blandizzi, Corrado; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1686-1696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past few years, several preclin. studies have highlighted the value of CD73 (ecto-5'-nucleotidase) as a potential therapeutic target for cancer therapy.  Indeed, the pharmacol. blockade of CD73, via monoclonal antibodies or small mols., has promise in counteracting cancer development, growth and spread.  Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential.  In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSgskg4UVAIrVg90H21EOLACvtfcHk0ljae_-cYNEfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCmurvN&md5=2110db5523c3c03e82603b6eb37ea2ee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DSwitching%2520off%2520CD73%253B%2520A%2520Way%2520to%2520Boost%2520the%2520Activity%2520of%2520Conventional%2520and%2520Targeted%2520Antineoplastic%2520Therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D1686%26epage%3D1696%26doi%3D10.1016%2Fj.drudis.2017.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.trecan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=27014745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=95-109&author=L.+Antonioliauthor=G.+G.+Yegutkinauthor=P.+Pacherauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Anti-CD73+in+Cancer+Immunotherapy%3A+Awakening+New+Opportunities&doi=10.1016%2Fj.trecan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span></div><div class="casAuthors">Antonioli Luca; Yegutkin Gennady G; Pacher Pal; Blandizzi Corrado; Hasko Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-109</span>
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    </div><div class="casAbstract">In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology.  In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.  Targeting CD73 results in favorable antitumor effects in pre-clinical models and combined treatments of CD73 blockade with other immune-modulating agents (i.e. anti-CTLA-4 mAb or anti-PD1 mAb) is particularly attractive.  Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 monoclonal antibodies, can potentially constitute a new biologic therapy for cancer patients.  In this review, we discuss the link between CD73 and the onset, development and spread of tumors, highlighting the potential value of this molecule as a target and as a novel biomarker in the context of personalized cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJjr-hcquXE36CEoQgWY10fW6udTcc2eYfRzUoTSbwuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D&md5=c67d1d1472d80ac9b0f3f0753dc37196</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAnti-CD73%2520in%2520Cancer%2520Immunotherapy%253A%2520Awakening%2520New%2520Opportunities%26jtitle%3DTrends%2520Cancer%26date%3D2016%26volume%3D2%26spage%3D95%26epage%3D109%26doi%3D10.1016%2Fj.trecan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraudon-Paoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jecko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becquart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rispaud-Blanc, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourdin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amigues, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensussan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliaou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narni-Mancinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paturel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoy, N.</span></span> <span> </span><span class="NLM_article-title">Blocking Antibodies Targeting the CD39/CD73 Immunosupressive Pathway Unleash Immune Responses in Combination Cancer Therapies</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.04.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.celrep.2019.04.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=31116985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWksb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2411-2425&author=I.+Perrotauthor=H.-A.+Michaudauthor=M.+Giraudon-Paoliauthor=S.+Augierauthor=A.+Docquierauthor=L.+Grosauthor=R.+Courtoisauthor=C.+Dejouauthor=D.+Jeckoauthor=O.+Becquartauthor=H.+Rispaud-Blancauthor=L.+Gauthierauthor=B.+Rossiauthor=S.+Chanteuxauthor=N.+Gourdinauthor=B.+Amiguesauthor=A.+Rousselauthor=A.+Bensussanauthor=J.-F.+Eliaouauthor=J.+Bastidauthor=F.+Romagneauthor=Y.+Morelauthor=E.+Narni-Mancinelliauthor=E.+Vivierauthor=C.+Paturelauthor=N.+Bonnefoy&title=Blocking+Antibodies+Targeting+the+CD39%2FCD73+Immunosupressive+Pathway+Unleash+Immune+Responses+in+Combination+Cancer+Therapies&doi=10.1016%2Fj.celrep.2019.04.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies</span></div><div class="casAuthors">Perrot, Ivan; Michaud, Henri-Alexandre; Giraudon-Paoli, Marc; Augier, Severine; Docquier, Aurelie; Gros, Laurent; Courtois, Rachel; Dejou, Cecile; Jecko, Diana; Becquart, Ondine; Rispaud-Blanc, Helene; Gauthier, Laurent; Rossi, Benjamin; Chanteux, Stephanie; Gourdin, Nicolas; Amigues, Beatrice; Roussel, Alain; Bensussan, Armand; Eliaou, Jean-Francois; Bastid, Jeremy; Romagne, Francois; Morel, Yannis; Narni-Mancinelli, Emilie; Vivier, Eric; Paturel, Carine; Bonnefoy, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2411-2425.e9</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors have revolutionized cancer treatment.  However, many cancers are resistant to ICIs, and the targeting of addnl. inhibitory signals is crucial for limiting tumor evasion.  The prodn. of adenosine via the sequential activity of CD39 and CD73 ectoenzymes participates to the generation of an immunosuppressive tumor microenvironment.  In order to disrupt the adenosine pathway, we generated two antibodies, IPH5201 and IPH5301, targeting human membrane-assocd. and sol. forms of CD39 and CD73, resp., and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine.  These antibodies promoted antitumor immunity by stimulating dendritic cells and macrophages and by restoring the activation of T cells isolated from cancer patients.  In a human CD39 knockin mouse preclin. model, IPH5201 increased the anti-tumor activity of the ATP-inducing chemotherapeutic drug oxaliplatin.  These results support the use of anti-CD39 and anti-CD73 monoclonal antibodies and their combination with immune checkpoint inhibitors and chemotherapies in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4T46HApEaJbVg90H21EOLACvtfcHk0lggG8laAXSECw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWksb7M&md5=b2642873d6ab147a849b16d2866c3ed6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.04.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.04.091%26sid%3Dliteratum%253Aachs%26aulast%3DPerrot%26aufirst%3DI.%26aulast%3DMichaud%26aufirst%3DH.-A.%26aulast%3DGiraudon-Paoli%26aufirst%3DM.%26aulast%3DAugier%26aufirst%3DS.%26aulast%3DDocquier%26aufirst%3DA.%26aulast%3DGros%26aufirst%3DL.%26aulast%3DCourtois%26aufirst%3DR.%26aulast%3DDejou%26aufirst%3DC.%26aulast%3DJecko%26aufirst%3DD.%26aulast%3DBecquart%26aufirst%3DO.%26aulast%3DRispaud-Blanc%26aufirst%3DH.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DRossi%26aufirst%3DB.%26aulast%3DChanteux%26aufirst%3DS.%26aulast%3DGourdin%26aufirst%3DN.%26aulast%3DAmigues%26aufirst%3DB.%26aulast%3DRoussel%26aufirst%3DA.%26aulast%3DBensussan%26aufirst%3DA.%26aulast%3DEliaou%26aufirst%3DJ.-F.%26aulast%3DBastid%26aufirst%3DJ.%26aulast%3DRomagne%26aufirst%3DF.%26aulast%3DMorel%26aufirst%3DY.%26aulast%3DNarni-Mancinelli%26aufirst%3DE.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DPaturel%26aufirst%3DC.%26aulast%3DBonnefoy%26aufirst%3DN.%26atitle%3DBlocking%2520Antibodies%2520Targeting%2520the%2520CD39%252FCD73%2520Immunosupressive%2520Pathway%2520Unleash%2520Immune%2520Responses%2520in%2520Combination%2520Cancer%2520Therapies%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D2411%26epage%3D2425%26doi%3D10.1016%2Fj.celrep.2019.04.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 Antibody Therapy Inhibits Breast Tumor Growth and Metastasis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1073/pnas.0908801107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1073%2Fpnas.0908801107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20080644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1547-1552&author=J.+Staggauthor=U.+Divisekeraauthor=N.+McLaughlinauthor=J.+Sharkeyauthor=S.+Pommeyauthor=D.+Denoyerauthor=K.+M.+Dwyerauthor=M.+J.+Smyth&title=Anti-CD73+Antibody+Therapy+Inhibits+Breast+Tumor+Growth+and+Metastasis&doi=10.1073%2Fpnas.0908801107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; McLaughlin, Nicole; Sharkey, Janelle; Pommey, Sandra; Denoyer, Delphine; Dwyer, Karen M.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1547-1552, S1547/1-S1547/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth.  We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine.  We showed that anti-CD73 mAb therapy significantly delayed primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung metastases.  Notably, anti-CD73 mAb therapy was essentially dependent on the induction of adaptive anti-tumor immune responses.  Knockdown of CD73 in 4T1.2 tumor cells confirmed the tumor-promoting effects of CD73.  In addn. to its immunosuppressive effect, CD73 enhanced tumor cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis.  Accordingly, administration of adenosine-5'-N-ethylcarboxamide to tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung metastasis.  Using selective adenosine-receptor antagonists, we showed that activation of A2B adenosine receptors promoted 4T1.2 tumor cell chemotaxis in vitro and metastasis in vivo.  In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and it also established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2etrhOGG3bVg90H21EOLACvtfcHk0lggG8laAXSECw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D&md5=7bafdf788526df932910865c2e291959</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0908801107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0908801107%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DMcLaughlin%26aufirst%3DN.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DDwyer%26aufirst%3DK.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-CD73%2520Antibody%2520Therapy%2520Inhibits%2520Breast%2520Tumor%2520Growth%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1547%26epage%3D1552%26doi%3D10.1073%2Fpnas.0908801107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">For a review see:</p></div><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbelini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">das Neves, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira
Battastini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eifler-Lima, V.</span></span> <span> </span><span class="NLM_article-title">Insights into Ecto-5′-nucleotidase as a New Target for Caner Therapy: A Medicinal Chemistry Study</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150408112615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.2174%2F0929867322666150408112615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=25850771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1776-1792&author=P.+Corbeliniauthor=F.+Figueiroauthor=G.+das+Nevesauthor=S.+Andradeauthor=D.+Kawanoauthor=A.+Oliveira%0ABattastiniauthor=V.+Eifler-Lima&title=Insights+into+Ecto-5%E2%80%B2-nucleotidase+as+a+New+Target+for+Caner+Therapy%3A+A+Medicinal+Chemistry+Study&doi=10.2174%2F0929867322666150408112615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Ecto-5'-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study</span></div><div class="casAuthors">Corbelini, Patricia Frasson; Figueiro, Fabricio; Machado das Neves, Gustavo; Andrade, Saulo; Kawano, Daniel Fabio; Oliveira Battastini, Ana Maria; Eifler-Lima, Vera Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1776-1792</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT, 5'-NT, eN, CD73) is a membrane ectoenzyme that is primarily responsible for the extracellular prodn. of adenosine from AMP.  Ecto-5'-NT is overexpressed in various types of cancer cells, leading to elevated concns. of adenosine in the tumor microenvironment.  Adenosine has also been found to be important in cancer pathogenesis, showing strong immunosuppressive effects over antitumor T cells and macrophages and promoting neovascularization and cell adherence.  These actions support tumor growth and development.  It has been suggested that the inhibition of ecto-5'-NT results in lower extracellular concns. of adenosine within the tumor microenvironment, which would directly affect cancer cells and render malignant cells more susceptible to host defense systems.  Such mechanisms are proposed to represent promising new targets for cancer therapy.  The aim of this review is to explore the biochem. and structural features of ecto-5'-NT, including a brief anal. of its active site by mol. modeling, as a means of evaluating whether the inhibition of this enzyme does indeed represent a feasible strategy for treating cancer.  Known inhibitors and possible prototypes that could be used to target ecto-5'-NT during cancer therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxGNC2_iGAn7Vg90H21EOLACvtfcHk0liBwdIUE5taQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGnuro%253D&md5=29a35d2e469dc2e69823eb0f8a428e28</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150408112615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150408112615%26sid%3Dliteratum%253Aachs%26aulast%3DCorbelini%26aufirst%3DP.%26aulast%3DFigueiro%26aufirst%3DF.%26aulast%3Ddas%2BNeves%26aufirst%3DG.%26aulast%3DAndrade%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DD.%26aulast%3DOliveira%2BBattastini%26aufirst%3DA.%26aulast%3DEifler-Lima%26aufirst%3DV.%26atitle%3DInsights%2520into%2520Ecto-5%25E2%2580%25B2-nucleotidase%2520as%2520a%2520New%2520Target%2520for%2520Caner%2520Therapy%253A%2520A%2520Medicinal%2520Chemistry%2520Study%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1776%26epage%3D1792%26doi%3D10.2174%2F0929867322666150408112615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, J. M.</span></span> <span> </span><span class="NLM_article-title">Preparation an Properties of 5′-Nucleotidase from Smooth Muscle of Small Intestine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>245</i></span>,  <span class="NLM_fpage">6274</span>– <span class="NLM_lpage">6280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=4320834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADyaE3MXjvVGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1970&pages=6274-6280&author=R.+M.+Burgerauthor=J.+M.+Lowenstein&title=Preparation+an+Properties+of+5%E2%80%B2-Nucleotidase+from+Smooth+Muscle+of+Small+Intestine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and properties of 5'-nucleotidase from smooth muscle of small intestine</span></div><div class="casAuthors">Burger, Richard; Lowenstein, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">245</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6274-80</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">ADP strongly inhibited a 5' -nucleotidase prepd. from pig smooth muscle.  This inhibition was much stronger than the previously described inhibition of 5' -nucleotidase by ATP.  Α,β-Methylene adenosine 5' -diphosphate (I) was an exceptionally powerful inhibitor of the enzyme.  The enzyme had 3 pH optima.  The lowest of these optima was seen only when the enzyme was not inhibited by buffer anions; the highest was seen only in the presence of Mg2+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkMkr4_XWRbVg90H21EOLACvtfcHk0liBwdIUE5taQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXjvVGgsQ%253D%253D&md5=a60b798fa2da1eb9dd34eb446040301a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DR.%2BM.%26aulast%3DLowenstein%26aufirst%3DJ.%2BM.%26atitle%3DPreparation%2520an%2520Properties%2520of%25205%25E2%2580%25B2-Nucleotidase%2520from%2520Smooth%2520Muscle%2520of%2520Small%2520Intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1970%26volume%3D245%26spage%3D6274%26epage%3D6280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strater, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title"><i>α,β</i>-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective <i>ecto</i>-5′-Nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6248-6263&author=S.+Bhattaraiauthor=M.+Freundliebauthor=J.+Pippelauthor=A.+Meyerauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=N.+Straterauthor=A.+El-Tayebauthor=C.+E.+Muller&title=%CE%B1%2C%CE%B2-Methylene-ADP+%28AOPCP%29+Derivatives+and+Analogues%3A+Development+of+Potent+and+Selective+ecto-5%E2%80%B2-Nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Bhattarai, Sanjay; Freundlieb, Marianne; Pippel, Jan; Meyer, Anne; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; Yegutkin, Gennady G.; Straeter, Norbert; El-Tayeb, Ali; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics.  The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivs. modified in various positions were prepd.  Products were tested at rat recombinant eN.  6-(Ar)alkylamino substitution led to the largest improvement in potency.  N6-Monosubstitution was superior to sym. N6,N6-disubstitution.  The most potent inhibitors were N6-(4-chlorobenzyl)- (PSB-12441, Ki 7.23 nM), N6-phenylethyl- (PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] I (PSB-12379, Ki 9.03 nM).  Replacement of the 6-NH group in I by O (PSB-12431) or S (PSB-12553) yielded equally potent inhibitors (9.20 nM and 9.50 nM, resp.).  Selected compds. investigated at the human enzyme did not show species differences; they displayed high selectivity vs. other ecto-nucleotidases and ADP-activated P2Y receptors.  Moreover, high metabolic stability was obsd.  These compds. represent the most potent eN inhibitors described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmxberqVtKLVg90H21EOLACvtfcHk0liBwdIUE5taQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF&md5=5f1231a662dd86345b9d3803f1c4e716</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00802%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStrater%26aufirst%3DN.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D%25CE%25B1%252C%25CE%25B2-Methylene-ADP%2520%2528AOPCP%2529%2520Derivatives%2520and%2520Analogues%253A%2520Development%2520of%2520Potent%2520and%2520Selective%2520ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6248%26epage%3D6263%26doi%3D10.1021%2Facs.jmedchem.5b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobelmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losenkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irjala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5′-Nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3677-3695&author=A.+Junkerauthor=C.+Rennauthor=C.+Dobelmannauthor=V.+Namasivayamauthor=S.+Jainauthor=K.+Losenkovaauthor=H.+Irjalaauthor=S.+Ducaauthor=R.+Balasubramanianauthor=S.+Chakrabortyauthor=F.+Borgelauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=C.+E.+Mullerauthor=K.+A.+Jacobson&title=Structure%E2%80%93Activity+Relationship+of+Purine+and+Pyrimidine+Nucleotides+as+Ecto-5%E2%80%B2-Nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Junker, Anna; Renn, Christian; Dobelmann, Clemens; Namasivayam, Vigneshwaran; Jain, Shanu; Losenkova, Karolina; Irjala, Heikki; Duca, Sierra; Balasubramanian, Ramachandran; Chakraborty, Saibal; Borgel, Frederik; Zimmermann, Herbert; Yegutkin, Gennady G.; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3677-3695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cluster of differentiation 73 (CD73) converts AMP to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment.  We synthesized 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogs, and compared their CD73 inhibitory potencies.  In the adenine series, most ribose modifications and 1-deaza and 3-deaza were detrimental, but 7-deaza was tolerated.  Uracil substitution with N3-Me, but not larger groups, or 2-thio, was tolerated. 1,2-Diphosphono-Et modifications were not tolerated.  N4-(Aryl)alkyloxy-cytosine derivs., esp. with bulky benzyloxy substituents, showed increased potency.  Among the most potent inhibitors were the 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of 5-fluorouridine, N4-benzoyl-cytidine, N4-[O-(4-benzyloxy)]-cytidine, and N4-[O-(4-naphth-2-ylmethyloxy)]-cytidine (Ki values 5-10 nM at human CD73).  Selected compds. tested at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, esp. those with large nucleobase substituents.  These nucleotide analogs are among the most potent CD73 inhibitors reported and may be considered for development as parenteral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmqsc2IyljbVg90H21EOLACvtfcHk0lgpVaTPyi_DiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D&md5=374b1862da172f31363dc74a4545661a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00164%26sid%3Dliteratum%253Aachs%26aulast%3DJunker%26aufirst%3DA.%26aulast%3DRenn%26aufirst%3DC.%26aulast%3DDobelmann%26aufirst%3DC.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DLosenkova%26aufirst%3DK.%26aulast%3DIrjala%26aufirst%3DH.%26aulast%3DDuca%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520of%2520Purine%2520and%2520Pyrimidine%2520Nucleotides%2520as%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3677%26epage%3D3695%26doi%3D10.1021%2Facs.jmedchem.9b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. W.</span></span> <span> </span><span class="NLM_article-title">An Exceptionally Potent Inhibitor of Human CD73</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3331</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=3331&author=C.+E.+Bowmanauthor=R.+G.+da+Silvaauthor=A.+Phamauthor=S.+W.+Young&title=An+Exceptionally+Potent+Inhibitor+of+Human+CD73&doi=10.1021%2Facs.biochem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">An Exceptionally Potent Inhibitor of Human CD73</span></div><div class="casAuthors">Bowman, Christine E.; da Silva, Rafael G.; Pham, Amber; Young, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3331-3334</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported the initiation of a Phase I clin. trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973).  We undertook a detailed kinetic anal. of the interaction between human CD73 and AB680 to det. the mode of inhibition.  We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a Ki of 5 pM.  Clin. candidates of this potency are uncommon and deserve special consideration during lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGag3hdjGb7Vg90H21EOLACvtfcHk0lgpVaTPyi_DiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O&md5=ad600cb74b603c4daa3c5f002e1c5f4a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DC.%2BE.%26aulast%3Dda%2BSilva%26aufirst%3DR.%2BG.%26aulast%3DPham%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BW.%26atitle%3DAn%2520Exceptionally%2520Potent%2520Inhibitor%2520of%2520Human%2520CD73%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D3331%26doi%3D10.1021%2Facs.biochem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">Development of Potent and Selective Inhibitors of <i>Ecto</i>-5′-Nucleotidase Based on an Anthraquinone Scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1021/jm901851t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901851t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2076-2086&author=Y.+Baqiauthor=S.-Y.+Leeauthor=J.+Iqbalauthor=P.+Ripphausenauthor=A.+Lehrauthor=A.+B.+Scheiffauthor=H.+Zimmermannauthor=J.+Bajorathauthor=C.+E.+Muller&title=Development+of+Potent+and+Selective+Inhibitors+of+Ecto-5%E2%80%B2-Nucleotidase+Based+on+an+Anthraquinone+Scaffold&doi=10.1021%2Fjm901851t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Inhibitors of ecto-5'-Nucleotidase Based on an Anthraquinone Scaffold</span></div><div class="casAuthors">Baqi, Younis; Lee, Sang-Yong; Iqbal, Jamshed; Ripphausen, Peter; Lehr, Anne; Scheiff, Anja B.; Zimmermann, Herbert; Bajorath, Jurgen; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2076-2086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels.  EN inhibitors have potential as novel drugs, for example, for the treatment of cancer.  In the present study, we synthesized and investigated a series of 55 anthraquinone derivs. as potential inhibitors of eN, 11 of which are novel compds. and another 11 of which had previously been described but have now been synthesized by an improved method.  We identified several potent inhibitors of rat eN.  The most potent compds. were 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0952, Ki = 260 nM) and 1-amino-4-[2-anthracenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0963, 150 nM), with the latter being the most potent eN inhibitor described to date.  Selected compds. were further characterized and found to exhibit a competitive mechanism of inhibition.  Investigations of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compd. PSB-0952 exhibited the highest degree of selectivity (>150-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJKU5mUcJOrVg90H21EOLACvtfcHk0lgpVaTPyi_DiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D&md5=b9e4c62d6423478d5cd4d95f702f689e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901851t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901851t%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DLehr%26aufirst%3DA.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3DDevelopment%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520Based%2520on%2520an%2520Anthraquinone%2520Scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2076%26epage%3D2086%26doi%3D10.1021%2Fjm901851t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening Identifies Novel Sulfonamide Inhibitors of <i>exto</i>-5′-Nucleotidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6576</span>– <span class="NLM_lpage">6581</span>, <span class="refDoi"> DOI: 10.1021/jm300658n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300658n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6576-6581&author=P.+Ripphausenauthor=M.+Freundliebauthor=A.+Brunschweigerauthor=H.+Zimmermannauthor=C.+E.+Mullerauthor=J.+Bajorath&title=Virtual+Screening+Identifies+Novel+Sulfonamide+Inhibitors+of+exto-5%E2%80%B2-Nucleotidase&doi=10.1021%2Fjm300658n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto-5'-Nucleotidase</span></div><div class="casAuthors">Ripphausen, Peter; Freundlieb, Marianne; Brunschweiger, Andreas; Zimmermann, Herbert; Mueller, Christa E.; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6576-6581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metallophosphoesterase that is implicated in the control of purinergic receptor signaling and a no. of assocd. therapeutically relevant effects.  Currently, only very few compds., including ADP, its more stable analog α,β-methylene-ADP, ATP, and anthraquinone derivs. are known to inhibit this enzyme.  In the search for inhibitors with more drug-like properties, we applied a model structure-based virtual screening approach augmented by chem. similarity searching.  On the basis of this anal., 51 candidate compds. were finally selected for exptl. evaluation.  A total of 13 of these mols. were confirmed to have competitive inhibitory activity.  The most potent inhibitor, 6-chloro-2-oxo-N-(4-sulfamoylphenyl)-2H-chromene-3-carboxylic acid amide (17), showed an IC50 value of 1.90 μM.  In contrast to the nucleotide- and anthraquinone-derived antagonists, the newly identified competitive inhibitors are uncharged at physiol. pH values, possess a drug-like structure, and are structurally distinct from known active compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0goFQAkEQe7Vg90H21EOLACvtfcHk0lgA-tn7W7n_gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D&md5=106abecfd7469af4be3acfb516d237f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300658n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300658n%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DVirtual%2520Screening%2520Identifies%2520Novel%2520Sulfonamide%2520Inhibitors%2520of%2520exto-5%25E2%2580%25B2-Nucleotidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6576%26epage%3D6581%26doi%3D10.1021%2Fjm300658n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamajusuku, A. S.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.O.</span></span> <span> </span><span class="NLM_article-title">Ecto-5′-Nucleotidase/CD73 Inhibition by Quercetin in the Human U138MG Glioma Cell Line</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">1352</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.bbagen.2007.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=17643826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1CmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=1352-1359&author=E.+Braganholauthor=A.+S.K.+Tamajusukuauthor=A.+Bernardiauthor=M.+R.+Winkauthor=A.+M.O.+Battastini&title=Ecto-5%E2%80%B2-Nucleotidase%2FCD73+Inhibition+by+Quercetin+in+the+Human+U138MG+Glioma+Cell+Line&doi=10.1016%2Fj.bbagen.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line</span></div><div class="casAuthors">Braganhol, Elizandra; Tamajusuku, Alessandra S. K.; Bernardi, Andressa; Wink, Marcia R.; Battastini, Ana M. O.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1352-1359</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gliomas are the most malignant of the primary brain tumors.  Nucleotides represent an important class of extracellular mols. that are crucial for the normal function of the nervous system.  ATP and adenosine can stimulate cell proliferation in different glioma cell lines; the events induced by extracellular adenine nucleotides are controlled by the action of ecto-nucleotidases, which hydrolyze ATP into adenosine in the extracellular space.  Recent studies have shown that quercetin has an anti-proliferative effect on the U138MG glioma cell line.  Since evidence suggests that purinergic signaling is involved in the growth and progression of glioma and, taking into consideration the anti-proliferative effect elicited by quercetin in this tumor type, the aim of the present study was to better investigate the extracellular metab. of AMP and evaluate the effect of quercetin on this system in the human U138MG glioma cell line.  The adenine products secreted by glioma cells were first characterized; extracellular AMP was efficiently metabolized by the glioma culture, demonstrating a very active ecto-5'-NT/CD73.  Quercetin was able to inhibit the ecto-5'-NT/CD73 activity and modulate its expression.  In addn., the cell treatment with APCP (α,β-methyleneadenosine-5'-diphosphate), an ecto-5'-NT/CD73 inhibitor, led to a significant redn. in glioma cell proliferation.  We suggest that the inhibition of ecto-5'-NT/CD73 may result in a decrease in extracellular adenosine prodn. with a consequent redn. in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76-vFDbju7rVg90H21EOLACvtfcHk0lhu8hUGsERWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1CmsL8%253D&md5=120b4326e880c0780fa7efe48f50fd90</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DTamajusuku%26aufirst%3DA.%2BS.K.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DWink%26aufirst%3DM.%2BR.%26aulast%3DBattastini%26aufirst%3DA.%2BM.O.%26atitle%3DEcto-5%25E2%2580%25B2-Nucleotidase%252FCD73%2520Inhibition%2520by%2520Quercetin%2520in%2520the%2520Human%2520U138MG%2520Glioma%2520Cell%2520Line%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D1352%26epage%3D1359%26doi%3D10.1016%2Fj.bbagen.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weimer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimer, D. F.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of Phosphonates and Phosphates: Crossing the Membrane Barrier</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1007%2F128_2014_561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=25391982" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2015&pages=115-160&author=A.+J.+Weimerauthor=D.+F.+Weimer&title=Prodrugs+of+Phosphonates+and+Phosphates%3A+Crossing+the+Membrane+Barrier"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2F128_2014_561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F128_2014_561%26sid%3Dliteratum%253Aachs%26aulast%3DWeimer%26aufirst%3DA.%2BJ.%26aulast%3DWeimer%26aufirst%3DD.%2BF.%26atitle%3DProdrugs%2520of%2520Phosphonates%2520and%2520Phosphates%253A%2520Crossing%2520the%2520Membrane%2520Barrier%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2015%26volume%3D360%26spage%3D115%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Sulfation and Glucoronidation of Phenolics: Insights into the Structural Basis of Conjugation</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.2174/138920011797470100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.2174%2F138920011797470100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=21933112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOkurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=900-916&author=B.+Wuauthor=S.+Basuauthor=S.+Mengauthor=X.+Wangauthor=S.+Zhangauthor=M.+Hu&title=Regioselective+Sulfation+and+Glucoronidation+of+Phenolics%3A+Insights+into+the+Structural+Basis+of+Conjugation&doi=10.2174%2F138920011797470100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective sulfation and glucuronidation of phenolics: Insights into the structural basis</span></div><div class="casAuthors">Wu, Baojian; Basu, Sumit; Meng, Shengnan; Wang, Xiaoqiang; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">900-916</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phase II metab. sulfation and glucuronidation, mediated by sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs), resp., are significant metabolic pathways for numerous endobiotics and xenobiotics.  An understanding of SULT/UGT substrate specificity including regioselectivity (i.e., position preference) is of great importance in predicting the contribution of sulfation/glucuronidation to drug and metabolite disposition in vivo.  Here, the authors summarize regioselective sulfation and glucuronidation of phenolic compds. with multiple OH groups as potential conjugation sites.  The strict regioselective patterns are highlighted for several SULT and UGT isoforms toward flavonoids, a large class of natural polyphenols.  To seek for a mol.-level explanation, the enzyme structures (i.e., SULT crystal structures and a homol.-modeled UGT structure) combined with mol. docking are employed.  In particular, the structural basis for regioselective metab. of flavonoids by SULT1A3 and UGT1A1 is discussed.  It is concluded that the regioselective nature of these phase II enzymes is detd. by the size and shape of the binding pocket.  While the mol. structures of the enzymes can be used to explain regioselective metab. regarding the binding property, predicting the turnover at different positions remains a particularly difficult task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRk_w2p8hrAbVg90H21EOLACvtfcHk0lhu8hUGsERWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOkurrJ&md5=e23988c2cc5d176fe297228f8acc849f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F138920011797470100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011797470100%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DRegioselective%2520Sulfation%2520and%2520Glucoronidation%2520of%2520Phenolics%253A%2520Insights%2520into%2520the%2520Structural%2520Basis%2520of%2520Conjugation%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26spage%3D900%26epage%3D916%26doi%3D10.2174%2F138920011797470100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. A.</span></span> <span> </span><span class="NLM_article-title">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/tx3003824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=6-25&author=L.+A.+Peterson&title=Reactive+Metabolites+in+the+Biotransformation+of+Molecules+Containing+a+Furan+Ring&doi=10.1021%2Ftx3003824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span></div><div class="casAuthors">Peterson, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-25</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many xenobiotics contg. a furan ring are toxic and/or carcinogenic.  The harmful effects of these compds. require furan ring oxidn.  This reaction generates an electrophilic intermediate.  Depending on the furan ring substituents, the intermediate is either an epoxide or a cis-enedione with more ring substitution favoring epoxide formation.  Either intermediate reacts with cellular nucleophiles such as protein or DNA to trigger toxicities.  The reactivity of the metabolite dets. which cellular nucleophiles are targeted.  The toxicity of a particular furan is also influenced by the presence of competing metabolic pathways or efficient detoxification routes.  GSH plays an important role in modulating the harmful effects of this class of compd. by reacting with the reactive metabolite.  However, this may not represent a detoxification step in all cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp4Dr5stLUSrVg90H21EOLACvtfcHk0lhu8hUGsERWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN&md5=fe3a280d0b7a99a436ec619abc1e1fa0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Ftx3003824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003824%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DReactive%2520Metabolites%2520in%2520the%2520Biotransformation%2520of%2520Molecules%2520Containing%2520a%2520Furan%2520Ring%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D6%26epage%3D25%26doi%3D10.1021%2Ftx3003824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>In
addition to the improved
potency of the benzotriazole core, moderate instability had been observed
upon handling of the 1,2,4-triazolopyridine analogues. Because of
the known propensity of similar electron-poor 1,2,4-triazolopyridines
to undergo Dimroth-type rearrangement, we opted to further pursue
the benzotriazole moiety.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=In%0Aaddition+to+the+improved%0Apotency+of+the+benzotriazole+core%2C+moderate+instability+had+been+observed%0Aupon+handling+of+the+1%2C2%2C4-triazolopyridine+analogues.+Because+of%0Athe+known+propensity+of+similar+electron-poor+1%2C2%2C4-triazolopyridines%0Ato+undergo+Dimroth-type+rearrangement%2C+we+opted+to+further+pursue%0Athe+benzotriazole+moiety."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into Regulation of Purinergic Signalling</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2161</span>– <span class="NLM_lpage">2173</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1016%2Fj.str.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=23142347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2161-2173&author=K.+Knappauthor=M.+Zebischauthor=J.+Pippelauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCllerauthor=N.+Str%C3%A4ter&title=Crystal+Structure+of+the+Human+Ecto-5%E2%80%B2-Nucleotidase+%28CD73%29%3A+Insights+into+Regulation+of+Purinergic+Signalling&doi=10.1016%2Fj.str.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling</span></div><div class="casAuthors">Knapp, Karen; Zebisch, Matthias; Pippel, Jan; El-Tayeb, Ali; Mueller, Christa E.; Straeter, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2161-2173</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In vertebrates ecto-5'-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.  Due to its pivotal role for activation of P1 adenosine receptors, e5NT has emerged as an appealing drug target for treatment of inflammation, chronic pain, hypoxia, and cancer.  Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme.  The dimerization interface is formed by the C-terminal domains and exhibits interchain motions of up to 13°.  Complex structures with adenosine and AMPCP indicate that structural control of the domain movement dets. the selectivity for monophosphate nucleotides.  Binding modes of nucleotide-derived and flavonoid-based compds. complexed to the C-terminal domain in the open form reveal an addnl. binding pocket of ∼210 Å3 that might be explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MOj4dwx2J7Vg90H21EOLACvtfcHk0ljaQqMmEcnRrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK&md5=e108171e8079cca4dd11483dfacb909e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DK.%26aulast%3DZebisch%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Ecto-5%25E2%2580%25B2-Nucleotidase%2520%2528CD73%2529%253A%2520Insights%2520into%2520Regulation%2520of%2520Purinergic%2520Signalling%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D2161%26epage%3D2173%26doi%3D10.1016%2Fj.str.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0ljaQqMmEcnRrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roversi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Refinement of Severely Incomplete Structures with Maximum Likelihood in BUSTER-TNT</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span>,  <span class="NLM_fpage">2210</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1107/S0907444904016427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444904016427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2210-2221&author=E.+Blancauthor=P.+Roversiauthor=C.+Vonrheinauthor=C.+Flensburgauthor=S.+M.+Leaauthor=G.+Bricogne&title=Refinement+of+Severely+Incomplete+Structures+with+Maximum+Likelihood+in+BUSTER-TNT&doi=10.1107%2FS0907444904016427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT</span></div><div class="casAuthors">Blanc, E.; Roversi, P.; Vonrhein, C.; Flensburg, C.; Lea, S. M.; Bricogne, G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2210-2221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">BUSTER-TNT is a max.-likelihood macromol. refinement package.  BUSTER assembles the structural model, scales obsd. and calcd. structure-factor amplitudes and computes the model likelihood, while TNT handles the stereochem. and NCS restraints/constraints and shifts the at. coordinates, B factors and occupancies.  In real space, in addn. to the traditional at. and bulk-solvent models, BUSTER models the parts of the structure for which an at. model is not yet available ('missing structure') as low-resoln. probability distributions for the random positions of the missing atoms.  In reciprocal space, the BUSTER structure-factor distribution in the complex plane is a two-dimensional Gaussian centered around the structure factor calcd. from the at., bulk-solvent and missing-structure models.  The errors assocd. with these three structural components are added to compute the overall spread of the Gaussian.  When the at. model is very incomplete, modeling of the missing structure and the consistency of the BUSTER statistical model help structure building and completion because (i) the accuracy of the overall scale factors is increased, (ii) the bias affecting at. model refinement is reduced by accounting for some of the scattering from the missing structure, (iii) the addn. of a spatial definition to the source of incompleteness improves on traditional Luzzati and σA-based error models and (iv) the program can perform selective d. modification in the regions of unbuilt structure alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0psykpyEUoLVg90H21EOLACvtfcHk0ljaQqMmEcnRrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO&md5=6ea77dcafccd3e87facac18928469bfa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1107%2FS0907444904016427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904016427%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DE.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DLea%26aufirst%3DS.%2BM.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DRefinement%2520of%2520Severely%2520Incomplete%2520Structures%2520with%2520Maximum%2520Likelihood%2520in%2520BUSTER-TNT%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2210%26epage%3D2221%26doi%3D10.1107%2FS0907444904016427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roversi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Refinement of Severely Incomplete Structures with Maximum Likelihood in BUSTER-TNT</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span>,  <span class="NLM_fpage">2210</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1107/S0907444904016427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444904016427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2210-2221&author=E.+Blancauthor=P.+Roversiauthor=C.+Vonrheinauthor=C.+Flensburgauthor=S.+M.+Leaauthor=G.+Bricogne&title=Refinement+of+Severely+Incomplete+Structures+with+Maximum+Likelihood+in+BUSTER-TNT&doi=10.1107%2FS0907444904016427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT</span></div><div class="casAuthors">Blanc, E.; Roversi, P.; Vonrhein, C.; Flensburg, C.; Lea, S. M.; Bricogne, G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2210-2221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">BUSTER-TNT is a max.-likelihood macromol. refinement package.  BUSTER assembles the structural model, scales obsd. and calcd. structure-factor amplitudes and computes the model likelihood, while TNT handles the stereochem. and NCS restraints/constraints and shifts the at. coordinates, B factors and occupancies.  In real space, in addn. to the traditional at. and bulk-solvent models, BUSTER models the parts of the structure for which an at. model is not yet available ('missing structure') as low-resoln. probability distributions for the random positions of the missing atoms.  In reciprocal space, the BUSTER structure-factor distribution in the complex plane is a two-dimensional Gaussian centered around the structure factor calcd. from the at., bulk-solvent and missing-structure models.  The errors assocd. with these three structural components are added to compute the overall spread of the Gaussian.  When the at. model is very incomplete, modeling of the missing structure and the consistency of the BUSTER statistical model help structure building and completion because (i) the accuracy of the overall scale factors is increased, (ii) the bias affecting at. model refinement is reduced by accounting for some of the scattering from the missing structure, (iii) the addn. of a spatial definition to the source of incompleteness improves on traditional Luzzati and σA-based error models and (iv) the program can perform selective d. modification in the regions of unbuilt structure alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0psykpyEUoLVg90H21EOLACvtfcHk0ljxCOfly1wmuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars7rO&md5=6ea77dcafccd3e87facac18928469bfa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1107%2FS0907444904016427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904016427%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DE.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DLea%26aufirst%3DS.%2BM.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DRefinement%2520of%2520Severely%2520Incomplete%2520Structures%2520with%2520Maximum%2520Likelihood%2520in%2520BUSTER-TNT%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2210%26epage%3D2221%26doi%3D10.1107%2FS0907444904016427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0ljxCOfly1wmuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE','PDB','6XUE'); return false;">PDB: 6XUE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG','PDB','6XUG'); return false;">PDB: 6XUG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H2I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H2I','PDB','4H2I'); return false;">PDB: 4H2I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUQ','PDB','6XUQ'); return false;">PDB: 6XUQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i117"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01713">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88120"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01713?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01713</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Analogous synthetic procedures for the preparation of fluoro- and chloro-5-<i>aza</i>-substituted cores, further cocrystallographic details concerning compounds <b>3b</b>, <b>53</b>, and <b>74</b> DMSO tolerance of the CHO CD73 malachite green assay (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_001.pdf">jm9b01713_si_001.pdf (151.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_002.pdf">jm9b01713_si_002.pdf (461.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01713/suppl_file/jm9b01713_si_003.csv">jm9b01713_si_003.csv (6.23 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates have been deposited in the Protein Data Bank (<a href="https://www.rcsb.org" class="extLink">https://www.rcsb.org</a>) for CD73 complexed with <b>3b</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUQ">6XUQ</a>), <b>53</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUG">6XUG</a>), and <b>74</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XUE">6XUE</a>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01713&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01713" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01713" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d1961de53cdc","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
